{"links": [{"source": 0, "target": "t8765", "value": "None"}, {"source": 0, "target": "t8651", "value": "None"}, {"source": 0, "target": "t8720", "value": "None"}, {"source": 0, "target": "t8734", "value": "None"}, {"source": 0, "target": "t8754", "value": "None"}, {"source": 0, "target": "t8690", "value": "None"}, {"source": 0, "target": "t8772", "value": "None"}, {"source": 0, "target": "t8680", "value": "None"}, {"source": 0, "target": "t8701", "value": "None"}, {"source": 0, "target": "t8664", "value": "None"}, {"source": 0, "target": "t8743", "value": "None"}, {"source": 0, "target": "t8709", "value": "None"}, {"source": 0, "target": "t6277", "value": "None"}, {"source": 0, "target": "t6266", "value": "None"}, {"source": 0, "target": "t6163", "value": "None"}, {"source": 0, "target": "t6284", "value": "None"}, {"source": 0, "target": "t6213", "value": "None"}, {"source": 0, "target": "t6202", "value": "None"}, {"source": 0, "target": "t6246", "value": "None"}, {"source": 0, "target": "t6255", "value": "None"}, {"source": 0, "target": "t6176", "value": "None"}, {"source": 0, "target": "t6192", "value": "None"}, {"source": 0, "target": "t6232", "value": "None"}, {"source": 0, "target": "t6221", "value": "None"}, {"source": "t8765", "target": "t8766", "value": "None"}, {"source": "t8651", "target": "t8653", "value": "None"}, {"source": "t8651", "target": "t8656", "value": "None"}, {"source": "t8651", "target": "t8652", "value": "None"}, {"source": "t8651", "target": "t8655", "value": "None"}, {"source": "t8651", "target": "t8654", "value": "None"}, {"source": "t8720", "target": "t8732", "value": "None"}, {"source": "t8720", "target": "t8731", "value": "None"}, {"source": "t8720", "target": "t8721", "value": "None"}, {"source": "t8734", "target": "t8742", "value": "None"}, {"source": "t8734", "target": "t8736", "value": "None"}, {"source": "t8734", "target": "t8735", "value": "None"}, {"source": "t8754", "target": "t8762", "value": "None"}, {"source": "t8754", "target": "t8755", "value": "None"}, {"source": "t8690", "target": "t8698", "value": "None"}, {"source": "t8690", "target": "t8691", "value": "None"}, {"source": "t8772", "target": "t8773", "value": "None"}, {"source": "t8680", "target": "t8681", "value": "None"}, {"source": "t8680", "target": "t8689", "value": "None"}, {"source": "t8701", "target": "t8702", "value": "None"}, {"source": "t8701", "target": "t8707", "value": "None"}, {"source": "t8664", "target": "t8665", "value": "None"}, {"source": "t8664", "target": "t8679", "value": "None"}, {"source": "t8743", "target": "t8744", "value": "None"}, {"source": "t8743", "target": "t8752", "value": "None"}, {"source": "t8743", "target": "t8751", "value": "None"}, {"source": "t8709", "target": "t8710", "value": "None"}, {"source": "t6277", "target": "t6278", "value": "None"}, {"source": "t6266", "target": "t6267", "value": "None"}, {"source": "t6266", "target": "t6274", "value": "None"}, {"source": "t6163", "target": "t6168", "value": "None"}, {"source": "t6163", "target": "t6167", "value": "None"}, {"source": "t6163", "target": "t6166", "value": "None"}, {"source": "t6163", "target": "t6164", "value": "None"}, {"source": "t6163", "target": "t6165", "value": "None"}, {"source": "t6284", "target": "t6285", "value": "None"}, {"source": "t6213", "target": "t6214", "value": "None"}, {"source": "t6213", "target": "t6219", "value": "None"}, {"source": "t6202", "target": "t6210", "value": "None"}, {"source": "t6202", "target": "t6203", "value": "None"}, {"source": "t6246", "target": "t6254", "value": "None"}, {"source": "t6246", "target": "t6248", "value": "None"}, {"source": "t6246", "target": "t6247", "value": "None"}, {"source": "t6255", "target": "t6263", "value": "None"}, {"source": "t6255", "target": "t6256", "value": "None"}, {"source": "t6255", "target": "t6264", "value": "None"}, {"source": "t6176", "target": "t6191", "value": "None"}, {"source": "t6176", "target": "t6177", "value": "None"}, {"source": "t6192", "target": "t6201", "value": "None"}, {"source": "t6192", "target": "t6193", "value": "None"}, {"source": "t6232", "target": "t6244", "value": "None"}, {"source": "t6232", "target": "t6243", "value": "None"}, {"source": "t6232", "target": "t6233", "value": "None"}, {"source": "t6221", "target": "t6222", "value": "None"}, {"source": "t8766", "target": "t8767", "value": "None"}, {"source": "t8653", "target": "t8657", "value": "None"}, {"source": "t8656", "target": "t8657", "value": "None"}, {"source": "t8652", "target": "t8657", "value": "None"}, {"source": "t8652", "target": "d25", "value": "None"}, {"source": "t8655", "target": "t8657", "value": "None"}, {"source": "t8654", "target": "t8657", "value": "None"}, {"source": "t8721", "target": "t8722", "value": "None"}, {"source": "t8736", "target": "t8737", "value": "None"}, {"source": "t8736", "target": "t8738", "value": "None"}, {"source": "t8735", "target": "t8736", "value": "None"}, {"source": "t8762", "target": "t8763", "value": "None"}, {"source": "t8755", "target": "t8761", "value": "None"}, {"source": "t8755", "target": "t8756", "value": "None"}, {"source": "t8691", "target": "t8692", "value": "None"}, {"source": "t8691", "target": "t8699", "value": "None"}, {"source": "t8773", "target": "t8774", "value": "None"}, {"source": "t8681", "target": "t8682", "value": "None"}, {"source": "t8681", "target": "d25", "value": "None"}, {"source": "t8681", "target": "d181", "value": "None"}, {"source": "t8702", "target": "t8706", "value": "None"}, {"source": "t8702", "target": "t8703", "value": "None"}, {"source": "t8702", "target": "t8705", "value": "None"}, {"source": "t8702", "target": "t8704", "value": "None"}, {"source": "t8665", "target": "t8666", "value": "None"}, {"source": "t8744", "target": "t8745", "value": "None"}, {"source": "t8710", "target": "t8711", "value": "None"}, {"source": "t6278", "target": "t6279", "value": "None"}, {"source": "t6267", "target": "t6268", "value": "None"}, {"source": "t6267", "target": "t6273", "value": "None"}, {"source": "t6274", "target": "t6275", "value": "None"}, {"source": "t6168", "target": "t6169", "value": "None"}, {"source": "t6167", "target": "t6169", "value": "None"}, {"source": "t6166", "target": "t6169", "value": "None"}, {"source": "t6164", "target": "t6169", "value": "None"}, {"source": "t6164", "target": "d25", "value": "None"}, {"source": "t6165", "target": "t6169", "value": "None"}, {"source": "t6285", "target": "t6286", "value": "None"}, {"source": "t6214", "target": "t6215", "value": "None"}, {"source": "t6214", "target": "t6216", "value": "None"}, {"source": "t6214", "target": "t6217", "value": "None"}, {"source": "t6214", "target": "t6218", "value": "None"}, {"source": "t6203", "target": "t6211", "value": "None"}, {"source": "t6203", "target": "t6204", "value": "None"}, {"source": "t6248", "target": "t6250", "value": "None"}, {"source": "t6248", "target": "t6249", "value": "None"}, {"source": "t6247", "target": "t6248", "value": "None"}, {"source": "t6256", "target": "t6257", "value": "None"}, {"source": "t6177", "target": "t6178", "value": "None"}, {"source": "t6193", "target": "t6194", "value": "None"}, {"source": "t6193", "target": "d181", "value": "None"}, {"source": "t6193", "target": "d25", "value": "None"}, {"source": "t6233", "target": "t6234", "value": "None"}, {"source": "t6222", "target": "t6223", "value": "None"}, {"source": "t8767", "target": "t8768", "value": "None"}, {"source": "t8767", "target": "d25", "value": "None"}, {"source": "t8657", "target": "t8661", "value": "None"}, {"source": "t8657", "target": "t8658", "value": "None"}, {"source": "t8722", "target": "t8727", "value": "None"}, {"source": "t8722", "target": "t8723", "value": "None"}, {"source": "t8737", "target": "t8739", "value": "None"}, {"source": "t8738", "target": "t8740", "value": "None"}, {"source": "t8763", "target": "t8764", "value": "None"}, {"source": "t8761", "target": "t8764", "value": "None"}, {"source": "t8756", "target": "t8757", "value": "None"}, {"source": "t8692", "target": "t8694", "value": "None"}, {"source": "t8692", "target": "t8696", "value": "None"}, {"source": "t8692", "target": "t8693", "value": "None"}, {"source": "t8692", "target": "t8695", "value": "None"}, {"source": "t8774", "target": "t8775", "value": "None"}, {"source": "t8682", "target": "t8683", "value": "None"}, {"source": "t8703", "target": "t8708", "value": "None"}, {"source": "t8704", "target": "t8708", "value": "None"}, {"source": "t8666", "target": "t8667", "value": "None"}, {"source": "t8666", "target": "t8670", "value": "None"}, {"source": "t8666", "target": "t8669", "value": "None"}, {"source": "t8666", "target": "t8668", "value": "None"}, {"source": "t8666", "target": "d25", "value": "None"}, {"source": "t8666", "target": "d181", "value": "None"}, {"source": "t8745", "target": "t8746", "value": "None"}, {"source": "t8711", "target": "t8712", "value": "None"}, {"source": "t6279", "target": "t6280", "value": "None"}, {"source": "t6279", "target": "d25", "value": "None"}, {"source": "t6268", "target": "t6269", "value": "None"}, {"source": "t6273", "target": "t6276", "value": "None"}, {"source": "t6275", "target": "t6276", "value": "None"}, {"source": "t6169", "target": "t6170", "value": "None"}, {"source": "t6169", "target": "t6173", "value": "None"}, {"source": "t6286", "target": "t6287", "value": "None"}, {"source": "t6215", "target": "t6220", "value": "None"}, {"source": "t6216", "target": "t6220", "value": "None"}, {"source": "t6204", "target": "t6207", "value": "None"}, {"source": "t6204", "target": "t6206", "value": "None"}, {"source": "t6204", "target": "t6208", "value": "None"}, {"source": "t6204", "target": "t6205", "value": "None"}, {"source": "t6250", "target": "t6252", "value": "None"}, {"source": "t6249", "target": "t6251", "value": "None"}, {"source": "t6257", "target": "t6258", "value": "None"}, {"source": "t6178", "target": "t6181", "value": "None"}, {"source": "t6178", "target": "t6179", "value": "None"}, {"source": "t6178", "target": "t6182", "value": "None"}, {"source": "t6178", "target": "t6180", "value": "None"}, {"source": "t6178", "target": "d181", "value": "None"}, {"source": "t6178", "target": "d25", "value": "None"}, {"source": "t6194", "target": "t6195", "value": "None"}, {"source": "t6234", "target": "t6235", "value": "None"}, {"source": "t6234", "target": "t6239", "value": "None"}, {"source": "t6223", "target": "t6224", "value": "None"}, {"source": "t8768", "target": "t8769", "value": "None"}, {"source": "t8658", "target": "t8659", "value": "None"}, {"source": "t8658", "target": "t8660", "value": "None"}, {"source": "t8727", "target": "t8728", "value": "None"}, {"source": "t8723", "target": "t8724", "value": "None"}, {"source": "t8740", "target": "t8741", "value": "None"}, {"source": "t8757", "target": "t8758", "value": "None"}, {"source": "t8694", "target": "t8697", "value": "None"}, {"source": "t8696", "target": "t8697", "value": "None"}, {"source": "t8693", "target": "t8697", "value": "None"}, {"source": "t8693", "target": "d375", "value": "None"}, {"source": "t8695", "target": "t8697", "value": "None"}, {"source": "t8775", "target": "t8776", "value": "None"}, {"source": "t8775", "target": "t8777", "value": "None"}, {"source": "t8683", "target": "t8684", "value": "None"}, {"source": "t8683", "target": "t8685", "value": "None"}, {"source": "t8667", "target": "t8671", "value": "None"}, {"source": "t8667", "target": "d375", "value": "None"}, {"source": "t8667", "target": "d271", "value": "None"}, {"source": "t8670", "target": "t8671", "value": "None"}, {"source": "t8670", "target": "d213", "value": "None"}, {"source": "t8669", "target": "t8671", "value": "None"}, {"source": "t8668", "target": "t8671", "value": "None"}, {"source": "t8746", "target": "t8747", "value": "None"}, {"source": "t8712", "target": "t8718", "value": "None"}, {"source": "t8712", "target": "t8714", "value": "None"}, {"source": "t8712", "target": "t8713", "value": "None"}, {"source": "t6280", "target": "t6281", "value": "None"}, {"source": "t6269", "target": "t6270", "value": "None"}, {"source": "t6170", "target": "t6172", "value": "None"}, {"source": "t6170", "target": "t6171", "value": "None"}, {"source": "t6287", "target": "t6288", "value": "None"}, {"source": "t6287", "target": "t6289", "value": "None"}, {"source": "t6207", "target": "t6209", "value": "None"}, {"source": "t6206", "target": "t6209", "value": "None"}, {"source": "t6208", "target": "t6209", "value": "None"}, {"source": "t6205", "target": "t6209", "value": "None"}, {"source": "t6205", "target": "d375", "value": "None"}, {"source": "t6252", "target": "t6253", "value": "None"}, {"source": "t6258", "target": "t6259", "value": "None"}, {"source": "t6181", "target": "t6183", "value": "None"}, {"source": "t6179", "target": "t6183", "value": "None"}, {"source": "t6179", "target": "d375", "value": "None"}, {"source": "t6179", "target": "d271", "value": "None"}, {"source": "t6182", "target": "t6183", "value": "None"}, {"source": "t6182", "target": "d213", "value": "None"}, {"source": "t6180", "target": "t6183", "value": "None"}, {"source": "t6195", "target": "t6197", "value": "None"}, {"source": "t6195", "target": "t6196", "value": "None"}, {"source": "t6235", "target": "t6236", "value": "None"}, {"source": "t6239", "target": "t6240", "value": "None"}, {"source": "t6224", "target": "t6226", "value": "None"}, {"source": "t6224", "target": "t6230", "value": "None"}, {"source": "t6224", "target": "t6225", "value": "None"}, {"source": "t8769", "target": "t8770", "value": "None"}, {"source": "t8659", "target": "t8662", "value": "None"}, {"source": "t8660", "target": "t8662", "value": "None"}, {"source": "t8728", "target": "t8729", "value": "None"}, {"source": "t8724", "target": "t8725", "value": "None"}, {"source": "t8758", "target": "t8759", "value": "None"}, {"source": "t8697", "target": "t8700", "value": "None"}, {"source": "t8776", "target": "t8778", "value": "None"}, {"source": "t8777", "target": "t8778", "value": "None"}, {"source": "t8684", "target": "t8686", "value": "None"}, {"source": "t8684", "target": "d375", "value": "None"}, {"source": "t8685", "target": "t8684", "value": "None"}, {"source": "t8671", "target": "t8672", "value": "None"}, {"source": "t8747", "target": "t8749", "value": "None"}, {"source": "t8747", "target": "t8748", "value": "None"}, {"source": "t8714", "target": "t8715", "value": "None"}, {"source": "t8713", "target": "t8719", "value": "None"}, {"source": "t6281", "target": "t6282", "value": "None"}, {"source": "t6270", "target": "t6271", "value": "None"}, {"source": "t6172", "target": "t6174", "value": "None"}, {"source": "t6171", "target": "t6174", "value": "None"}, {"source": "t6288", "target": "t6290", "value": "None"}, {"source": "t6289", "target": "t6290", "value": "None"}, {"source": "t6209", "target": "t6212", "value": "None"}, {"source": "t6259", "target": "t6261", "value": "None"}, {"source": "t6259", "target": "t6260", "value": "None"}, {"source": "t6183", "target": "t6184", "value": "None"}, {"source": "t6197", "target": "t6196", "value": "None"}, {"source": "t6196", "target": "t6198", "value": "None"}, {"source": "t6196", "target": "d375", "value": "None"}, {"source": "t6236", "target": "t6237", "value": "None"}, {"source": "t6240", "target": "t6241", "value": "None"}, {"source": "t6226", "target": "t6227", "value": "None"}, {"source": "t6225", "target": "t6231", "value": "None"}, {"source": "t8770", "target": "t8771", "value": "None"}, {"source": "t8770", "target": "d25", "value": "None"}, {"source": "t8662", "target": "t8663", "value": "None"}, {"source": "t8729", "target": "t8730", "value": "None"}, {"source": "t8725", "target": "t8726", "value": "None"}, {"source": "t8759", "target": "t8760", "value": "None"}, {"source": "t8686", "target": "t8687", "value": "None"}, {"source": "t8672", "target": "t8673", "value": "None"}, {"source": "t8749", "target": "t8748", "value": "None"}, {"source": "t8748", "target": "t8750", "value": "None"}, {"source": "t8715", "target": "t8716", "value": "None"}, {"source": "t6282", "target": "t6283", "value": "None"}, {"source": "t6282", "target": "d25", "value": "None"}, {"source": "t6271", "target": "t6272", "value": "None"}, {"source": "t6174", "target": "t6175", "value": "None"}, {"source": "t6261", "target": "t6260", "value": "None"}, {"source": "t6260", "target": "t6262", "value": "None"}, {"source": "t6184", "target": "t6185", "value": "None"}, {"source": "t6198", "target": "t6199", "value": "None"}, {"source": "t6237", "target": "t6238", "value": "None"}, {"source": "t6241", "target": "t6242", "value": "None"}, {"source": "t6227", "target": "t6228", "value": "None"}, {"source": "t8730", "target": "t8733", "value": "None"}, {"source": "t8726", "target": "t8733", "value": "None"}, {"source": "t8760", "target": "t8764", "value": "None"}, {"source": "t8687", "target": "t8688", "value": "None"}, {"source": "t8673", "target": "t8674", "value": "None"}, {"source": "t8673", "target": "d25", "value": "None"}, {"source": "t8750", "target": "t8744", "value": "None"}, {"source": "t8750", "target": "t8753", "value": "None"}, {"source": "t8750", "target": "d25", "value": "None"}, {"source": "t8716", "target": "t8717", "value": "None"}, {"source": "t6272", "target": "t6276", "value": "None"}, {"source": "t6262", "target": "t6265", "value": "None"}, {"source": "t6262", "target": "t6256", "value": "None"}, {"source": "t6262", "target": "d25", "value": "None"}, {"source": "t6185", "target": "t6186", "value": "None"}, {"source": "t6185", "target": "d25", "value": "None"}, {"source": "t6199", "target": "t6200", "value": "None"}, {"source": "t6238", "target": "t6245", "value": "None"}, {"source": "t6242", "target": "t6245", "value": "None"}, {"source": "t6228", "target": "t6229", "value": "None"}, {"source": "t8674", "target": "t8675", "value": "None"}, {"source": "t8717", "target": "t8719", "value": "None"}, {"source": "t6186", "target": "t6187", "value": "None"}, {"source": "t6229", "target": "t6231", "value": "None"}, {"source": "t8675", "target": "t8676", "value": "None"}, {"source": "t6187", "target": "t6188", "value": "None"}, {"source": "t8676", "target": "t8677", "value": "None"}, {"source": "t8676", "target": "d271", "value": "None"}, {"source": "t8676", "target": "d375", "value": "None"}, {"source": "t8676", "target": "d396", "value": "None"}, {"source": "t6188", "target": "t6189", "value": "None"}, {"source": "t6188", "target": "d396", "value": "None"}, {"source": "t6188", "target": "d271", "value": "None"}, {"source": "t6188", "target": "d375", "value": "None"}, {"source": "t8677", "target": "t8678", "value": "None"}, {"source": "t6189", "target": "t6190", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Tuberculosis", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Tuberculosis"}}, {"category": "treatment", "id": "t8765", "name": "professionals delivering tuberculosis services", "draggable": "true", "value": {"name": "professionals delivering tuberculosis services", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:professionals delivering tuberculosis services", "drug": {}}}, {"category": "treatment", "id": "t8651", "name": "person with suspected tuberculosis", "draggable": "true", "value": {"name": "person with suspected tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with suspected tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8720", "name": "person with suspected or confirmed infectious tuberculosis", "draggable": "true", "value": {"name": "person with suspected or confirmed infectious tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with suspected or confirmed infectious tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8734", "name": "person with tuberculosis or at risk of tuberculosis", "draggable": "true", "value": {"name": "person with tuberculosis or at risk of tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with tuberculosis or at risk of tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8754", "name": "professionals delivering tuberculosis services", "draggable": "true", "value": {"name": "professionals delivering tuberculosis services", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:professionals delivering tuberculosis services", "drug": {}}}, {"category": "treatment", "id": "t8690", "name": "contact of someone with active tuberculosis", "draggable": "true", "value": {"name": "contact of someone with active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:contact of someone with active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8772", "name": "people at high risk of tuberculosis", "draggable": "true", "value": {"name": "people at high risk of tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people at high risk of tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8680", "name": "person with latent tuberculosis", "draggable": "true", "value": {"name": "person with latent tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with latent tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8701", "name": "people at high risk of tuberculosis", "draggable": "true", "value": {"name": "people at high risk of tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people at high risk of tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8664", "name": "person diagnosed with active tuberculosis", "draggable": "true", "value": {"name": "person diagnosed with active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person diagnosed with active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8743", "name": "service organisation", "draggable": "true", "value": {"name": "service organisation", "type": "cancer ralated", "time": "", "intention": "", "description": "title:service organisation", "drug": {}}}, {"category": "treatment", "id": "t8709", "name": "under served groups", "draggable": "true", "value": {"name": "under served groups", "type": "treatment related", "time": "", "intention": "", "description": "title:under-served groups", "drug": {}}}, {"category": "treatment", "id": "t6277", "name": "professionals delivering tuberculosis services", "draggable": "true", "value": {"name": "professionals delivering tuberculosis services", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:professionals delivering tuberculosis services", "drug": {}}}, {"category": "treatment", "id": "t6266", "name": "professionals delivering tuberculosis services", "draggable": "true", "value": {"name": "professionals delivering tuberculosis services", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:professionals delivering tuberculosis services", "drug": {}}}, {"category": "treatment", "id": "t6163", "name": "person with suspected tuberculosis", "draggable": "true", "value": {"name": "person with suspected tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with suspected tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6284", "name": "people at high risk of tuberculosis", "draggable": "true", "value": {"name": "people at high risk of tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people at high risk of tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6213", "name": "people at high risk of tuberculosis", "draggable": "true", "value": {"name": "people at high risk of tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people at high risk of tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6202", "name": "contact of someone with active tuberculosis", "draggable": "true", "value": {"name": "contact of someone with active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:contact of someone with active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6246", "name": "person with tuberculosis or at risk of tuberculosis", "draggable": "true", "value": {"name": "person with tuberculosis or at risk of tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with tuberculosis or at risk of tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6255", "name": "service organisation", "draggable": "true", "value": {"name": "service organisation", "type": "cancer ralated", "time": "", "intention": "", "description": "title:service organisation", "drug": {}}}, {"category": "treatment", "id": "t6176", "name": "person diagnosed with active tuberculosis", "draggable": "true", "value": {"name": "person diagnosed with active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person diagnosed with active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6192", "name": "person with latent tuberculosis", "draggable": "true", "value": {"name": "person with latent tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with latent tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6232", "name": "person with suspected or confirmed infectious tuberculosis", "draggable": "true", "value": {"name": "person with suspected or confirmed infectious tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with suspected or confirmed infectious tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6221", "name": "under served groups", "draggable": "true", "value": {"name": "under served groups", "type": "treatment related", "time": "", "intention": "", "description": "title:under-served groups", "drug": {}}}, {"category": "treatment", "id": "t8766", "name": "tuberculosis control boards", "draggable": "true", "value": {"name": "tuberculosis control boards", "type": "information and support", "time": "", "intention": "", "description": "title:tuberculosis control boardshead:Tuberculosis control boardsTB control boards should have clearly defined roles and responsibilities. Their roles and responsibilities could include: Establishing the links, partnerships and relationships between all aspects of the control board area within their remit (if necessary across usual geographical commissioning boundaries) Developing and supporting adoption and implementation of evidence-based model service specifications for the clinical and public health actions needed to control TB including: improving access and early diagnosis diagnostics, treatment and care services (see assessing for active TB, managing active TB and managing latent TB) contact investigations and contact tracing (see contact tracing and testing) cohort review (see service organisation) vaccination (see vaccination)  drug resistance tackling TB in under-served groups (see TB in under-served groups) surveillance, monitoring and quality assurance  workforce development and commissioning.TB control boards should (in collaboration with commissioners) consider the need for a TB network local coordinator, particularly if working across multiple clinical commissioning group areas.The coordinator should work in close collaboration with clinicians and all relevant multidisciplinary TB teams to develop the network and be responsible for: setting up the network and developing it based on needs, reporting back to the TB control board regularly establishing the links, partnerships and relationships across their local network (if necessary across usual geographical commissioning boundaries).See service organisation for information on the remit of control boards.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8653", "name": "referrals from emergency departments", "draggable": "true", "value": {"name": "referrals from emergency departments", "type": "treatment related", "time": "", "intention": "", "description": "title:referrals from emergency departmentshead:Referrals from emergency departmentsMultidisciplinary TB teams should consider accepting direct referrals from emergency departments.Commissioners and multidisciplinary teams should consider working with emergency departments to develop direct referral pathways for people with suspected active TB so that: the local multidisciplinary team is informed of all suspected cases of TB using the appropriate process referral is accepted from any appropriate healthcare professional for example, an on-call radiologist.Emergency department clinicians should ensure first-line diagnostic tests for TB are performed on anyone presenting with suspected TB (see diagnostic investigations for pulmonary TB).Emergency departments should consider carrying out audits of their direct referrals because of suspected active TB and the outcomes of diagnosis.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8656", "name": "self referrals", "draggable": "true", "value": {"name": "self referrals", "type": "information and support", "time": "", "intention": "", "description": "title:self-referralshead:Self-referralsMultidisciplinary TB teams should accept self-referrals to TB clinics by people who suspect they have TB or have recently been in contact with someone with TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8652", "name": "referrals from community settings", "draggable": "true", "value": {"name": "referrals from community settings", "type": "treatment related", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:referrals from community settingshead:Referrals from community settings Multidisciplinary TB teams should accept referrals from healthcare providers and allied organisations working in the community with under-served groups. This includes voluntary and statutory organisations (for example, mobile X-ray teams or community organisations or outreach workers working with vulnerable migrants).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8655", "name": "referrals from radiology departments", "draggable": "true", "value": {"name": "referrals from radiology departments", "type": "treatment related", "time": "", "intention": "", "description": "title:referrals from radiology departmentshead:Referrals from radiology departments Local hospitals, clinical commissioning groups and the local multidisciplinary team should consider developing a local pathway for people with imaging highly suggestive of active TB. The pathway should enable them to be referred by the radiology department by the next working day to multidisciplinary TB teams. Consider including the following in the pathway: Agreed standardised radiology codes to identify imaging investigations highly suggestive of active TB. Regular liaison between multidisciplinary TB teams and the radiology department (for example, weekly) to ensure all patients have been referred to the multidisciplinary team for triage using the agreed local mechanism or pathway.Report results of all pathology or other diagnostic results suggesting TB to the multidisciplinary TB team and clinicians who ask for them.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8654", "name": "referrals from healthcare settings", "draggable": "true", "value": {"name": "referrals from healthcare settings", "type": "treatment related", "time": "", "intention": "", "description": "title:referrals from healthcare settingshead:Referrals from healthcare settingsEnsure healthcare settings can promptly identify people with suspected infectious or confirmed pulmonary or laryngeal TB before or at presentation. Ensure people working in the settings follow the recommendations about testing and treatments. Healthcare professionals should consider urgent referral to TB clinics for people with suspected active TB. They should also ensure the results from first-line diagnostic tests (including a sputum smear and chest X-ray) are available before the person sees a specialist. (Note: this should not delay the referral.)SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8732", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t8731", "name": "criteria for carrying out contact tracing", "draggable": "true", "value": {"name": "criteria for carrying out contact tracing", "type": "information and support", "time": "", "intention": "", "description": "title:criteria for carrying out contact tracinghead:Criteria for carrying out contact tracingIf TB is diagnosed in a hospital inpatient, do a risk assessment. This should take into account: the degree of infectivity of the index case the length of time before the infectious patient was isolated whether other patients are unusually susceptible to infection the proximity of contact.Carry out contact tracing and testing only for patients for whom the risk is regarded as significant.Regard patients as at risk of infection if they spent more than 8 hours in the same bay as an inpatient with smear-positive TB who had a cough. Document the risk in the contact s clinical notes, for the attention of the contact s consultant. Give the contact  inform and advise  information, and inform their GP.If patients were exposed to a patient with smear-positive TB for long enough to be equivalent to close contacts (as determined by the risk assessment), or an exposed patient is known to be particularly susceptible to infection, manage their TB risk in the same way as close contacts.If an inpatient with smear-positive TB is found to have multidrug-resistant TB, or if exposed patients are HIV positive, trace contacts following the Interdepartmental Working Group on Tuberculosis guidelines.In cases of doubt when planning contact tracing after diagnosing smear-positive TB in an inpatient, seek further advice from the local or national Public Health England or Wales unit or people experienced in the field.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8721", "name": "minimise contact with other patients", "draggable": "true", "value": {"name": "minimise contact with other patients", "type": "information and support", "time": "", "intention": "", "description": "title:minimise contact with other patientshead:Minimise contact with other patientsPut people with suspected infectious or confirmed pulmonary or laryngeal TB who will remain in a hospital setting (including emergency, outpatients or inpatient care) in a single room. If this is not possible, keep the person s waiting times to a minimum. This may involve prioritising their care above that of other patients.Minimise the number and duration of visits a person with TB makes to an outpatient department while they are still infectious. To minimise the risk of infection, people with infectious TB should be seen at times or in places away from other patientsSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8742", "name": "service organisation", "draggable": "true", "value": {"name": "service organisation", "type": "cancer ralated", "time": "", "intention": "", "description": "title:service organisation", "drug": {}}}, {"category": "treatment", "id": "t8736", "name": "providing information", "draggable": "true", "value": {"name": "providing information", "type": "information and support", "time": "", "intention": "", "description": "title:providing informationhead:Providing informationNational organisations (for example, National Knowledge Service \u2013 Tuberculosis, TB Alert, Public Health England, Department of Health and NHS Choices) should work together to develop generic, quality-assured template materials with consistent up-to-date messages. These materials should be made freely available and designed so that they can be adapted to local needs.Multidisciplinary TB teams should use these templates for general awareness raising and targeted activities in under-served groups and other high-risk groups. Involve the target group in developing and piloting the materials.The content of any materials should: be up-to-date and attractively designed, including pictures and colour if possible be culturally appropriate, taking into account the language, actions, customs, beliefs and values of the group they are aimed at be tailored to the target population s needs include risks and benefits of treatment, and how to access services, advice and support dispel myths show that, by deciding to be tested and treated for TB, a person can be empowered to take responsibility for their own health use language that encourages the person to believe that they can change their behaviour (see what NICE says on behaviour change) be simple and succinct.Make the material available in a range of formats such as written, braille, text messages, electronic, audio (including podcasts), pictorial and video. Make them freely available in a variety of ways, for example, online, as print materials or on memory sticks.Disseminate materials in ways likely to reach target groups, for example, via culturally specific radio or TV stations, at shelters, and at community, commercial or religious venues that target groups attend regularly.Multidisciplinary TB teams and others working with at-risk groups should use high quality material to raise awareness of TB.Multidisciplinary TB teams and others working with the general public, and with under-served and other high-risk groups in particular, should include information on TB with other health-related messages and existing health promotion programmes tailored to the target group.Multidisciplinary TB teams should work in partnership with voluntary organisations and  community champions  to increase awareness of TB, in particular among under-served groups at risk of infection but also in the general population. If possible, peers who have experience of TB should contribute to awareness-raising activities and support people in treatment.See what NICE says on community engagement.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8735", "name": "high risk groups", "draggable": "true", "value": {"name": "high risk groups", "type": "treatment related", "time": "", "intention": "", "description": "title:high-risk groups", "drug": {}}}, {"category": "treatment", "id": "t8762", "name": "non nhs staff and staff of care homes", "draggable": "true", "value": {"name": "non nhs staff and staff of care homes", "type": "information and support", "time": "", "intention": "", "description": "title:non-nhs staff and staff of care homes", "drug": {}}}, {"category": "treatment", "id": "t8755", "name": "nhs staff", "draggable": "true", "value": {"name": "nhs staff", "type": "information and support", "time": "", "intention": "", "description": "title:nhs staff", "drug": {}}}, {"category": "treatment", "id": "t8698", "name": "incident and outbreak situations", "draggable": "true", "value": {"name": "incident and outbreak situations", "type": "information and support", "time": "", "intention": "", "description": "title:incident and outbreak situationshead:Incident and outbreak situationsIn an incident situation when large numbers of people may need to be screened, consider a single interferon-gamma release assay for people aged 18\u201365 years. For children and young people, follow recommendations for close contacts.Multidisciplinary TB teams should coordinate incident or outbreak contact investigations at places where the person with active TB spends significant amounts of time. Examples include workplaces, schools, colleges, universities, childcare settings. Identify people that the person with TB frequently spends substantial time with. Multidisciplinary TB teams should refer any incident in a congregate setting to the local Public Health England health protection team for risk assessment within 5 working days of suspicion of a potential incident.TB control boards working with local health protection teams should, through local arrangements, mobilise existing staff or have access to an incident team that will: undertake an incident risk assessment and provide advice support or undertake contact investigations provide information and communication support to the multidisciplinary TB team, the local director of public health, the setting in which the incident has occurred and the people affected including: written advice, printed or by email question and answer sessions telephone advice media engagement gather and collate data, and report on outcomes to measure the effectiveness of the investigation (for example, offering testing to all people identified at risk and monitoring uptake) report back to TB control boards at appropriate times. This includes when outcomes of initial investigation of people classified as close contacts are available. It also includes when a decision is made to broaden the investigation to the next stage using the concentric circle method for risk assessment.When incidents have been identified, multidisciplinary TB teams in discussion with local Public Health England health protection teams should consider providing support for strain-typing and other analysis to ascertain where transmission is occurring. (Examples of transmission sites may include workplaces, schools, colleges, universities, childcare settings.)SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8691", "name": "assess need for contact tracing", "draggable": "true", "value": {"name": "assess need for contact tracing", "type": "information and support", "time": "", "intention": "", "description": "title:assess need for contact tracinghead:Assess need for contact tracingOnce a person has been diagnosed with active TB, the diagnosing physician should inform relevant colleagues so that the need for contact tracing can be assessed without delay. Contact tracing should not be delayed until notification.In all types of contact investigation scenarios (active case-finding, incident or outbreak investigations) multidisciplinary TB teams should investigate all people who have been in contact with children who have pulmonary or extrapulmonary TB to identify the primary source of infection. If necessary, they should look beyond immediate close contacts to find the source.When an adult who works in childcare (including people who provide childcare informally) is diagnosed with smear-positive TB, manage as for close contacts.Offer  inform and advise  information to all contacts of people with smear-positive TB (see providing information).For information on contact tracing among under-served groups, see TB in under-served groups. For information on contact tracing in hospitals, see management and infection control in hospital.subhead:Cases on aircraftAfter diagnosis of TB in an aircraft traveller, do not routinely carry out contact tracing of fellow passengers.The notifying clinician should inform the relevant consultant in communicable disease control or health protection if: less than 3 months has elapsed since the flight and the flight was longer than 8 hours, and the index case is smear-positive, and either the index case has multidrug-resistant TB, or the index case coughed frequently during the flight.The consultant in communicable disease control or health protection should provide the airline with  inform and advise  information to send to passengers seated in the same part of the aircraft as the index case.If the TB index case is an aircraft crew member, contact tracing of passengers should not routinely take place.If the TB index case is an aircraft crew member, contact tracing of other members of staff is appropriate, in accordance with the usual principles for screening workplace colleagues.subhead:Cases in schoolsAfter diagnosis of TB in a school pupil or member of staff, the consultant in communicable disease control or health protection should be prepared to explain the prevention and control procedures to staff, parents and the press. Advice on managing these incidents and their public relations is available from the Public Health England health protection team and the local authority.If a school pupil is diagnosed with smear-positive TB, carry out a risk assessment of the need to test the rest of his or her class (if there is a single class group), or the rest of the year group who share classes, as part of contact tracing.If a teacher has smear-positive TB, assess the pupils in his or her classes during the preceding 3 months as part of contact tracing.Consider extending contact tracing in schools to include children and teachers involved in extracurricular activities, and non-teaching staff, on the basis of: the degree of infectivity of the index case the length of time the index case was in contact with others whether contacts are unusually susceptible to infection the proximity of contact.Treat secondary cases of smear-positive TB as index cases for contact tracing.If the index case of a pupil s TB infection is not found, and the child is not in a high-risk group for TB, contact tracing and screening (by either symptom enquiry or chest X-ray) should be considered for all relevant members of staff at the school.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8773", "name": "identify groups eligible for vaccination", "draggable": "true", "value": {"name": "identify groups eligible for vaccination", "type": "treatment related", "time": "", "intention": "", "description": "title:identify groups eligible for vaccinationhead:Identify groups eligible for vaccinationTo improve the uptake of BCG vaccination, identify eligible groups (in line with the Department of Health s Green Book) opportunistically through several routes, for example: new registrations in primary care and with antenatal services or other points of contact with secondary or tertiary care people entering education, including university links with statutory and voluntary groups working with new entrants and looked-after children and young people during contact investigations.For information on vaccination of new entrants from high-incidence countries, see TB in high-risk groups.For information on vaccinating NHS staff, see staff vaccination and screening.For information on vaccination in the context of contact tracing and testing, see contact tracing and testing.subhead:Patients at risk of being HIV positiveIf people identified for BCG vaccination through occupational health, contact tracing or new entrant screening are also considered to be at increased risk of being HIV positive, offer them HIV testing before BCG vaccination.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8681", "name": "develop a health and social care plan", "draggable": "true", "value": {"name": "develop a health and social care plan", "type": "information and support", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:develop a health and social care planhead:Develop a health and social care planThe TB case manager should work with the person diagnosed with TB to develop a health and social care plan, and support them to complete therapy successfully. The TB case manager should: offer a risk assessment to every person with TB, to identify their needs and whether they should have enhanced case management including directly observed therapy educate the person about TB and the treatment develop an individual care plan after discussion with the person gain the person s consent to the plan and agree a review date (for example, when moving from initiation to maintenance, or at each contact to ensure the person s needs are being met) the need for hepatitis B and C or HIV testing involve representatives from other allied professions and key workers from all organisations who work with the person, if appropriate explore appropriate ways that peers and voluntary organisations can provide support.TB case managers should ensure the health and social care plan (particularly if directly observed therapy is needed) identifies why a person may not attend for diagnostic testing or follow a treatment plan, and how they can be encouraged to do so. It should also include ways to address issues such as fear of stigmatisation, support needs or cultural beliefs, and may include information on: demographics (for example, age, nationality, place of birth, length of time in UK) all current prescribing regimens housing needs and living situation, including looked-after children substance misuse (drugs or alcohol) any contact with the criminal justice system HIV status other health conditions (physical or mental) communication factors (for example, language and literacy levels) ability to access treatment (mobility and transport needs) employment or entitlement to benefits legal or immigration status (including risk of removal or relocation within the UK) any enablers or incentives to overcome anything that is stopping diagnosis or treatment.The health and social care plan should:  state who will be observing treatment and where (if the person is having directly observed therapy this should be provided at a location that is convenient and accessible to them, for example, at a methadone clinic) include actions to take if contact with the person is lost (for example, keeping details of people who might be able to help re-establish contact) refer to, and be coordinated with, any other care plan already established for the person  define the support needed to address any unmet health and social care needs (for example, support to gain housing or other benefits, or to help them access other health or social care services) include a commitment from the person to complete their TB treatment be supported by frequent contact with any key workers who work with the person.See what NICE says on alcohol-use disorders, drug misuse management in over 16s and multimorbidity.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8689", "name": "medicines optimisation", "draggable": "true", "value": {"name": "medicines optimisation", "type": "treatment related", "time": "", "intention": "", "description": "title:medicines optimisation", "drug": {}}}, {"category": "treatment", "id": "t8702", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportMultidisciplinary TB teams should establish relationships with statutory, community and voluntary organisations that work with people at risk of TB to develop appropriate TB referral pathways. They should ensure these organisations know how to refer people to local TB services.Multidisciplinary TB teams should help professionals working in relevant statutory, community and voluntary organisations to raise awareness of TB among under-served groups and other high-risk groups. These professionals should be able to explain that treatment for TB is free and confidential for everyone (irrespective of eligibility for other NHS care). They should also be able to provide people with details of: how to recognise symptoms in adults and children how people get TB the benefits of diagnosis and treatment (including the fact that TB is treatable and curable) location and opening hours of testing services referral pathways, including self-referral the potential interaction of TB medication with other drugs, for example, oral contraceptives and opioids (especially methadone) and HIV treatment TB/HIV co-infection how to address the myths about TB infection and treatment (for example, to counter the belief that TB is hereditary) how to address the stigma associated with TB the risk of migrants from high-incidence countries developing active TB \u2013 even if they have already screened negative for it contact tracing.In non-healthcare settings catering for large numbers of people and populations at high risk of TB (such as detention settings, residential hostels and day centres): promote simple respiratory hygiene ensure awareness of symptoms of potentially infectious TB to enable prompt healthcare referral work with the local public health team and the local authority to ensure accommodation for people with TB ensure adequate ventilation.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8707", "name": "vaccination", "draggable": "true", "value": {"name": "vaccination", "type": "information and support", "time": "", "intention": "", "description": "title:vaccination", "drug": {}}}, {"category": "treatment", "id": "t8665", "name": "allocate a named case manager", "draggable": "true", "value": {"name": "allocate a named case manager", "type": "information and support", "time": "", "intention": "", "description": "title:allocate a named case managerhead:Allocate a named case managerAllocate a named TB case manager to everyone with active TB as soon as possible after diagnosis (and within 5 days). The clinical team should tell each person who their named TB case manager is and provide contact details.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8679", "name": "medicines optimisation", "draggable": "true", "value": {"name": "medicines optimisation", "type": "treatment related", "time": "", "intention": "", "description": "title:medicines optimisation", "drug": {}}}, {"category": "treatment", "id": "t8744", "name": "strategic oversight of tuberculosis services", "draggable": "true", "value": {"name": "strategic oversight of tuberculosis services", "type": "information and support", "time": "", "intention": "", "description": "title:strategic oversight of tuberculosis serviceshead:Strategic oversight of tuberculosis servicesPublic Health England, in partnership with NHS England, should take responsibility for national oversight of TB prevention and control activities. This includes setting up TB control boards.Public Health England and NHS England should consider working together to establish control boards in agreed geographical areas and employ appropriate staff.Public Health England, working with the Local Government Association and their special interest groups, should consider working with national housing organisations such as the Chartered Institute of Housing, Homeless Link, Sitra and the National Housing Federation to raise the profile of TB. This is to ensure people with TB are considered a priority for housing. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8752", "name": "staff vaccination and screening", "draggable": "true", "value": {"name": "staff vaccination and screening", "type": "information and support", "time": "", "intention": "", "description": "title:staff vaccination and screening", "drug": {}}}, {"category": "treatment", "id": "t8751", "name": "staffing and training", "draggable": "true", "value": {"name": "staffing and training", "type": "information and support", "time": "", "intention": "", "description": "title:staffing and training", "drug": {}}}, {"category": "treatment", "id": "t8710", "name": "assessing and managing tuberculosis", "draggable": "true", "value": {"name": "assessing and managing tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:assessing and managing tuberculosishead:Assessing and managing tuberculosisOffer people younger than 65 years from under-served groups a single interferon-gamma release assay.If the interferon-gamma release assay is positive, assess for active TB (see assessing for active tuberculosis); if this assessment is negative, offer them treatment for latent TB (see managing latent tuberculosis).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6278", "name": "tuberculosis control boards", "draggable": "true", "value": {"name": "tuberculosis control boards", "type": "information and support", "time": "", "intention": "", "description": "title:tuberculosis control boardshead:Tuberculosis control boardsTB control boards should have clearly defined roles and responsibilities. Their roles and responsibilities could include: Establishing the links, partnerships and relationships between all aspects of the control board area within their remit (if necessary across usual geographical commissioning boundaries) Developing and supporting adoption and implementation of evidence-based model service specifications for the clinical and public health actions needed to control TB including: improving access and early diagnosis diagnostics, treatment and care services (see assessing for active TB, managing active TB and managing latent TB) contact investigations and contact tracing (see contact tracing and testing) cohort review (see service organisation) vaccination (see vaccination)  drug resistance tackling TB in under-served groups (see TB in under-served groups) surveillance, monitoring and quality assurance  workforce development and commissioning.TB control boards should (in collaboration with commissioners) consider the need for a TB network local coordinator, particularly if working across multiple clinical commissioning group areas.The coordinator should work in close collaboration with clinicians and all relevant multidisciplinary TB teams to develop the network and be responsible for: setting up the network and developing it based on needs, reporting back to the TB control board regularly establishing the links, partnerships and relationships across their local network (if necessary across usual geographical commissioning boundaries).See service organisation for information on the remit of control boards.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6267", "name": "nhs staff", "draggable": "true", "value": {"name": "nhs staff", "type": "information and support", "time": "", "intention": "", "description": "title:nhs staff", "drug": {}}}, {"category": "treatment", "id": "t6274", "name": "non nhs staff and staff of care homes", "draggable": "true", "value": {"name": "non nhs staff and staff of care homes", "type": "information and support", "time": "", "intention": "", "description": "title:non-nhs staff and staff of care homes", "drug": {}}}, {"category": "treatment", "id": "t6168", "name": "self referrals", "draggable": "true", "value": {"name": "self referrals", "type": "information and support", "time": "", "intention": "", "description": "title:self-referralshead:Self-referralsMultidisciplinary TB teams should accept self-referrals to TB clinics by people who suspect they have TB or have recently been in contact with someone with TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6167", "name": "referrals from radiology departments", "draggable": "true", "value": {"name": "referrals from radiology departments", "type": "treatment related", "time": "", "intention": "", "description": "title:referrals from radiology departmentshead:Referrals from radiology departments Local hospitals, clinical commissioning groups and the local multidisciplinary team should consider developing a local pathway for people with imaging highly suggestive of active TB. The pathway should enable them to be referred by the radiology department by the next working day to multidisciplinary TB teams. Consider including the following in the pathway: Agreed standardised radiology codes to identify imaging investigations highly suggestive of active TB. Regular liaison between multidisciplinary TB teams and the radiology department (for example, weekly) to ensure all patients have been referred to the multidisciplinary team for triage using the agreed local mechanism or pathway.Report results of all pathology or other diagnostic results suggesting TB to the multidisciplinary TB team and clinicians who ask for them.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6166", "name": "referrals from healthcare settings", "draggable": "true", "value": {"name": "referrals from healthcare settings", "type": "treatment related", "time": "", "intention": "", "description": "title:referrals from healthcare settingshead:Referrals from healthcare settingsEnsure healthcare settings can promptly identify people with suspected infectious or confirmed pulmonary or laryngeal TB before or at presentation. Ensure people working in the settings follow the recommendations about testing and treatments. Healthcare professionals should consider urgent referral to TB clinics for people with suspected active TB. They should also ensure the results from first-line diagnostic tests (including a sputum smear and chest X-ray) are available before the person sees a specialist. (Note: this should not delay the referral.)SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6164", "name": "referrals from community settings", "draggable": "true", "value": {"name": "referrals from community settings", "type": "treatment related", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:referrals from community settingshead:Referrals from community settings Multidisciplinary TB teams should accept referrals from healthcare providers and allied organisations working in the community with under-served groups. This includes voluntary and statutory organisations (for example, mobile X-ray teams or community organisations or outreach workers working with vulnerable migrants).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6165", "name": "referrals from emergency departments", "draggable": "true", "value": {"name": "referrals from emergency departments", "type": "treatment related", "time": "", "intention": "", "description": "title:referrals from emergency departmentshead:Referrals from emergency departmentsMultidisciplinary TB teams should consider accepting direct referrals from emergency departments.Commissioners and multidisciplinary teams should consider working with emergency departments to develop direct referral pathways for people with suspected active TB so that: the local multidisciplinary team is informed of all suspected cases of TB using the appropriate process referral is accepted from any appropriate healthcare professional for example, an on-call radiologist.Emergency department clinicians should ensure first-line diagnostic tests for TB are performed on anyone presenting with suspected TB (see diagnostic investigations for pulmonary TB).Emergency departments should consider carrying out audits of their direct referrals because of suspected active TB and the outcomes of diagnosis.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6285", "name": "identify groups eligible for vaccination", "draggable": "true", "value": {"name": "identify groups eligible for vaccination", "type": "treatment related", "time": "", "intention": "", "description": "title:identify groups eligible for vaccinationhead:Identify groups eligible for vaccinationTo improve the uptake of BCG vaccination, identify eligible groups (in line with the Department of Health s Green Book) opportunistically through several routes, for example: new registrations in primary care and with antenatal services or other points of contact with secondary or tertiary care people entering education, including university links with statutory and voluntary groups working with new entrants and looked-after children and young people during contact investigations.For information on vaccination of new entrants from high-incidence countries, see TB in high-risk groups.For information on vaccinating NHS staff, see staff vaccination and screening.For information on vaccination in the context of contact tracing and testing, see contact tracing and testing.subhead:Patients at risk of being HIV positiveIf people identified for BCG vaccination through occupational health, contact tracing or new entrant screening are also considered to be at increased risk of being HIV positive, offer them HIV testing before BCG vaccination.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6214", "name": "information and support", "draggable": "true", "value": {"name": "information and support", "type": "information and support", "time": "", "intention": "", "description": "title:information and supporthead:Information and supportMultidisciplinary TB teams should establish relationships with statutory, community and voluntary organisations that work with people at risk of TB to develop appropriate TB referral pathways. They should ensure these organisations know how to refer people to local TB services.Multidisciplinary TB teams should help professionals working in relevant statutory, community and voluntary organisations to raise awareness of TB among under-served groups and other high-risk groups. These professionals should be able to explain that treatment for TB is free and confidential for everyone (irrespective of eligibility for other NHS care). They should also be able to provide people with details of: how to recognise symptoms in adults and children how people get TB the benefits of diagnosis and treatment (including the fact that TB is treatable and curable) location and opening hours of testing services referral pathways, including self-referral the potential interaction of TB medication with other drugs, for example, oral contraceptives and opioids (especially methadone) and HIV treatment TB/HIV co-infection how to address the myths about TB infection and treatment (for example, to counter the belief that TB is hereditary) how to address the stigma associated with TB the risk of migrants from high-incidence countries developing active TB \u2013 even if they have already screened negative for it contact tracing.In non-healthcare settings catering for large numbers of people and populations at high risk of TB (such as detention settings, residential hostels and day centres): promote simple respiratory hygiene ensure awareness of symptoms of potentially infectious TB to enable prompt healthcare referral work with the local public health team and the local authority to ensure accommodation for people with TB ensure adequate ventilation.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6219", "name": "vaccination", "draggable": "true", "value": {"name": "vaccination", "type": "information and support", "time": "", "intention": "", "description": "title:vaccination", "drug": {}}}, {"category": "treatment", "id": "t6210", "name": "incident and outbreak situations", "draggable": "true", "value": {"name": "incident and outbreak situations", "type": "information and support", "time": "", "intention": "", "description": "title:incident and outbreak situationshead:Incident and outbreak situationsIn an incident situation when large numbers of people may need to be screened, consider a single interferon-gamma release assay for people aged 18\u201365 years. For children and young people, follow recommendations for close contacts.Multidisciplinary TB teams should coordinate incident or outbreak contact investigations at places where the person with active TB spends significant amounts of time. Examples include workplaces, schools, colleges, universities, childcare settings. Identify people that the person with TB frequently spends substantial time with. Multidisciplinary TB teams should refer any incident in a congregate setting to the local Public Health England health protection team for risk assessment within 5 working days of suspicion of a potential incident.TB control boards working with local health protection teams should, through local arrangements, mobilise existing staff or have access to an incident team that will: undertake an incident risk assessment and provide advice support or undertake contact investigations provide information and communication support to the multidisciplinary TB team, the local director of public health, the setting in which the incident has occurred and the people affected including: written advice, printed or by email question and answer sessions telephone advice media engagement gather and collate data, and report on outcomes to measure the effectiveness of the investigation (for example, offering testing to all people identified at risk and monitoring uptake) report back to TB control boards at appropriate times. This includes when outcomes of initial investigation of people classified as close contacts are available. It also includes when a decision is made to broaden the investigation to the next stage using the concentric circle method for risk assessment.When incidents have been identified, multidisciplinary TB teams in discussion with local Public Health England health protection teams should consider providing support for strain-typing and other analysis to ascertain where transmission is occurring. (Examples of transmission sites may include workplaces, schools, colleges, universities, childcare settings.)SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6203", "name": "assess need for contact tracing", "draggable": "true", "value": {"name": "assess need for contact tracing", "type": "information and support", "time": "", "intention": "", "description": "title:assess need for contact tracinghead:Assess need for contact tracingOnce a person has been diagnosed with active TB, the diagnosing physician should inform relevant colleagues so that the need for contact tracing can be assessed without delay. Contact tracing should not be delayed until notification.In all types of contact investigation scenarios (active case-finding, incident or outbreak investigations) multidisciplinary TB teams should investigate all people who have been in contact with children who have pulmonary or extrapulmonary TB to identify the primary source of infection. If necessary, they should look beyond immediate close contacts to find the source.When an adult who works in childcare (including people who provide childcare informally) is diagnosed with smear-positive TB, manage as for close contacts.Offer  inform and advise  information to all contacts of people with smear-positive TB (see providing information).For information on contact tracing among under-served groups, see TB in under-served groups. For information on contact tracing in hospitals, see management and infection control in hospital.subhead:Cases on aircraftAfter diagnosis of TB in an aircraft traveller, do not routinely carry out contact tracing of fellow passengers.The notifying clinician should inform the relevant consultant in communicable disease control or health protection if: less than 3 months has elapsed since the flight and the flight was longer than 8 hours, and the index case is smear-positive, and either the index case has multidrug-resistant TB, or the index case coughed frequently during the flight.The consultant in communicable disease control or health protection should provide the airline with  inform and advise  information to send to passengers seated in the same part of the aircraft as the index case.If the TB index case is an aircraft crew member, contact tracing of passengers should not routinely take place.If the TB index case is an aircraft crew member, contact tracing of other members of staff is appropriate, in accordance with the usual principles for screening workplace colleagues.subhead:Cases in schoolsAfter diagnosis of TB in a school pupil or member of staff, the consultant in communicable disease control or health protection should be prepared to explain the prevention and control procedures to staff, parents and the press. Advice on managing these incidents and their public relations is available from the Public Health England health protection team and the local authority.If a school pupil is diagnosed with smear-positive TB, carry out a risk assessment of the need to test the rest of his or her class (if there is a single class group), or the rest of the year group who share classes, as part of contact tracing.If a teacher has smear-positive TB, assess the pupils in his or her classes during the preceding 3 months as part of contact tracing.Consider extending contact tracing in schools to include children and teachers involved in extracurricular activities, and non-teaching staff, on the basis of: the degree of infectivity of the index case the length of time the index case was in contact with others whether contacts are unusually susceptible to infection the proximity of contact.Treat secondary cases of smear-positive TB as index cases for contact tracing.If the index case of a pupil s TB infection is not found, and the child is not in a high-risk group for TB, contact tracing and screening (by either symptom enquiry or chest X-ray) should be considered for all relevant members of staff at the school.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6254", "name": "service organisation", "draggable": "true", "value": {"name": "service organisation", "type": "cancer ralated", "time": "", "intention": "", "description": "title:service organisation", "drug": {}}}, {"category": "treatment", "id": "t6248", "name": "providing information", "draggable": "true", "value": {"name": "providing information", "type": "information and support", "time": "", "intention": "", "description": "title:providing informationhead:Providing informationNational organisations (for example, National Knowledge Service \u2013 Tuberculosis, TB Alert, Public Health England, Department of Health and NHS Choices) should work together to develop generic, quality-assured template materials with consistent up-to-date messages. These materials should be made freely available and designed so that they can be adapted to local needs.Multidisciplinary TB teams should use these templates for general awareness raising and targeted activities in under-served groups and other high-risk groups. Involve the target group in developing and piloting the materials.The content of any materials should: be up-to-date and attractively designed, including pictures and colour if possible be culturally appropriate, taking into account the language, actions, customs, beliefs and values of the group they are aimed at be tailored to the target population s needs include risks and benefits of treatment, and how to access services, advice and support dispel myths show that, by deciding to be tested and treated for TB, a person can be empowered to take responsibility for their own health use language that encourages the person to believe that they can change their behaviour (see what NICE says on behaviour change) be simple and succinct.Make the material available in a range of formats such as written, braille, text messages, electronic, audio (including podcasts), pictorial and video. Make them freely available in a variety of ways, for example, online, as print materials or on memory sticks.Disseminate materials in ways likely to reach target groups, for example, via culturally specific radio or TV stations, at shelters, and at community, commercial or religious venues that target groups attend regularly.Multidisciplinary TB teams and others working with at-risk groups should use high quality material to raise awareness of TB.Multidisciplinary TB teams and others working with the general public, and with under-served and other high-risk groups in particular, should include information on TB with other health-related messages and existing health promotion programmes tailored to the target group.Multidisciplinary TB teams should work in partnership with voluntary organisations and  community champions  to increase awareness of TB, in particular among under-served groups at risk of infection but also in the general population. If possible, peers who have experience of TB should contribute to awareness-raising activities and support people in treatment.See what NICE says on community engagement.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6247", "name": "high risk groups", "draggable": "true", "value": {"name": "high risk groups", "type": "treatment related", "time": "", "intention": "", "description": "title:high-risk groups", "drug": {}}}, {"category": "treatment", "id": "t6263", "name": "staffing and training", "draggable": "true", "value": {"name": "staffing and training", "type": "information and support", "time": "", "intention": "", "description": "title:staffing and training", "drug": {}}}, {"category": "treatment", "id": "t6256", "name": "strategic oversight of tuberculosis services", "draggable": "true", "value": {"name": "strategic oversight of tuberculosis services", "type": "information and support", "time": "", "intention": "", "description": "title:strategic oversight of tuberculosis serviceshead:Strategic oversight of tuberculosis servicesPublic Health England, in partnership with NHS England, should take responsibility for national oversight of TB prevention and control activities. This includes setting up TB control boards.Public Health England and NHS England should consider working together to establish control boards in agreed geographical areas and employ appropriate staff.Public Health England, working with the Local Government Association and their special interest groups, should consider working with national housing organisations such as the Chartered Institute of Housing, Homeless Link, Sitra and the National Housing Federation to raise the profile of TB. This is to ensure people with TB are considered a priority for housing. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6264", "name": "staff vaccination and screening", "draggable": "true", "value": {"name": "staff vaccination and screening", "type": "information and support", "time": "", "intention": "", "description": "title:staff vaccination and screening", "drug": {}}}, {"category": "treatment", "id": "t6191", "name": "medicines optimisation", "draggable": "true", "value": {"name": "medicines optimisation", "type": "treatment related", "time": "", "intention": "", "description": "title:medicines optimisation", "drug": {}}}, {"category": "treatment", "id": "t6177", "name": "allocate a named case manager", "draggable": "true", "value": {"name": "allocate a named case manager", "type": "information and support", "time": "", "intention": "", "description": "title:allocate a named case managerhead:Allocate a named case managerAllocate a named TB case manager to everyone with active TB as soon as possible after diagnosis (and within 5 days). The clinical team should tell each person who their named TB case manager is and provide contact details.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6201", "name": "medicines optimisation", "draggable": "true", "value": {"name": "medicines optimisation", "type": "treatment related", "time": "", "intention": "", "description": "title:medicines optimisation", "drug": {}}}, {"category": "treatment", "id": "t6193", "name": "develop a health and social care plan", "draggable": "true", "value": {"name": "develop a health and social care plan", "type": "information and support", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:develop a health and social care planhead:Develop a health and social care planThe TB case manager should work with the person diagnosed with TB to develop a health and social care plan, and support them to complete therapy successfully. The TB case manager should: offer a risk assessment to every person with TB, to identify their needs and whether they should have enhanced case management including directly observed therapy educate the person about TB and the treatment develop an individual care plan after discussion with the person gain the person s consent to the plan and agree a review date (for example, when moving from initiation to maintenance, or at each contact to ensure the person s needs are being met) the need for hepatitis B and C or HIV testing involve representatives from other allied professions and key workers from all organisations who work with the person, if appropriate explore appropriate ways that peers and voluntary organisations can provide support.TB case managers should ensure the health and social care plan (particularly if directly observed therapy is needed) identifies why a person may not attend for diagnostic testing or follow a treatment plan, and how they can be encouraged to do so. It should also include ways to address issues such as fear of stigmatisation, support needs or cultural beliefs, and may include information on: demographics (for example, age, nationality, place of birth, length of time in UK) all current prescribing regimens housing needs and living situation, including looked-after children substance misuse (drugs or alcohol) any contact with the criminal justice system HIV status other health conditions (physical or mental) communication factors (for example, language and literacy levels) ability to access treatment (mobility and transport needs) employment or entitlement to benefits legal or immigration status (including risk of removal or relocation within the UK) any enablers or incentives to overcome anything that is stopping diagnosis or treatment.The health and social care plan should:  state who will be observing treatment and where (if the person is having directly observed therapy this should be provided at a location that is convenient and accessible to them, for example, at a methadone clinic) include actions to take if contact with the person is lost (for example, keeping details of people who might be able to help re-establish contact) refer to, and be coordinated with, any other care plan already established for the person  define the support needed to address any unmet health and social care needs (for example, support to gain housing or other benefits, or to help them access other health or social care services) include a commitment from the person to complete their TB treatment be supported by frequent contact with any key workers who work with the person.See what NICE says on alcohol-use disorders, drug misuse management in over 16s and multimorbidity.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6244", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t6243", "name": "criteria for carrying out contact tracing", "draggable": "true", "value": {"name": "criteria for carrying out contact tracing", "type": "information and support", "time": "", "intention": "", "description": "title:criteria for carrying out contact tracinghead:Criteria for carrying out contact tracingIf TB is diagnosed in a hospital inpatient, do a risk assessment. This should take into account: the degree of infectivity of the index case the length of time before the infectious patient was isolated whether other patients are unusually susceptible to infection the proximity of contact.Carry out contact tracing and testing only for patients for whom the risk is regarded as significant.Regard patients as at risk of infection if they spent more than 8 hours in the same bay as an inpatient with smear-positive TB who had a cough. Document the risk in the contact s clinical notes, for the attention of the contact s consultant. Give the contact  inform and advise  information, and inform their GP.If patients were exposed to a patient with smear-positive TB for long enough to be equivalent to close contacts (as determined by the risk assessment), or an exposed patient is known to be particularly susceptible to infection, manage their TB risk in the same way as close contacts.If an inpatient with smear-positive TB is found to have multidrug-resistant TB, or if exposed patients are HIV positive, trace contacts following the Interdepartmental Working Group on Tuberculosis guidelines.In cases of doubt when planning contact tracing after diagnosing smear-positive TB in an inpatient, seek further advice from the local or national Public Health England or Wales unit or people experienced in the field.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6233", "name": "minimise contact with other patients", "draggable": "true", "value": {"name": "minimise contact with other patients", "type": "information and support", "time": "", "intention": "", "description": "title:minimise contact with other patientshead:Minimise contact with other patientsPut people with suspected infectious or confirmed pulmonary or laryngeal TB who will remain in a hospital setting (including emergency, outpatients or inpatient care) in a single room. If this is not possible, keep the person s waiting times to a minimum. This may involve prioritising their care above that of other patients.Minimise the number and duration of visits a person with TB makes to an outpatient department while they are still infectious. To minimise the risk of infection, people with infectious TB should be seen at times or in places away from other patientsSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6222", "name": "assessing and managing tuberculosis", "draggable": "true", "value": {"name": "assessing and managing tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:assessing and managing tuberculosishead:Assessing and managing tuberculosisOffer people younger than 65 years from under-served groups a single interferon-gamma release assay.If the interferon-gamma release assay is positive, assess for active TB (see assessing for active tuberculosis); if this assessment is negative, offer them treatment for latent TB (see managing latent tuberculosis).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8767", "name": "multidisciplinary teams", "draggable": "true", "value": {"name": "multidisciplinary teams", "type": "information and support", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:multidisciplinary teamshead:Multidisciplinary teamsCommissioners should ensure multidisciplinary TB teams: Have the skills and resources to manage the care of people with active TB who are not from under-served groups. Include at least 1TB case manager with responsibility for planning and coordinating the care of under-served people and those with active TB who receive enhanced case management. Have the resources to manage latent TB care in under-served groups and the wider population. (One whole-time equivalent case manager is recommended per 40 latent TB cases needing enhanced case management and per 80 latent TB cases for standard case management). Include a range of clinical specialties in the multidisciplinary TB team, including paediatrics, infection control and respiratory medicine. Have regular attendance at these multidisciplinary team and cohort review meetings for all team members included as a programmed activity as part of their work planning. Have the skills and resources necessary to manage the care of people with complex social and clinical needs (either directly or via an established route). This includes the ability to provide prompt access (or if necessary, referral) to skilled outreach and advocacy workers who can draw on the services of allied practitioners. The aim is to address people s housing, asylum, immigration, welfare, substance dependency and other health and social care needs. (The allied practitioner support should include both a specified housing officer and a social worker.) Can provide rapid access TB clinics for all cases, including under-served groups. Consider providing administration support to TB nurses and case managers so they have capacity for clinical and case management work. This should include giving TB nurses access to computer hardware and software. Have the resources to provide a continuous service throughout the year, ensuring the TB service accounts for the following to manage continuity of care: planned absence (for example, professional development, mandatory training, annual, maternity or paternity leave) unplanned absence (such as sickness absence). Can provide prompt access to a professional who has training and experience in assessing and protecting children and vulnerable adults at risk of abuse or neglect. Have access to funds through local government and clinical commissioning groups that can be used flexibly to improve adherence to treatment among under-served groups. For example, funds could be used to provide transport to clinics, to provide support or enablers for treatment, or for paying outreach workers or community services to support directly observed therapy. Funds may also be used to provide accommodation during treatment. Have the resources to provide ongoing TB awareness-raising activities for professional, community and voluntary (including advocacy) groups that work with populations at high risk of TB. These resources should be financed by local government or clinical commissioning groups.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8657", "name": "triage and start investigations", "draggable": "true", "value": {"name": "triage and start investigations", "type": "treatment related", "time": "", "intention": "", "description": "title:triage and start investigationshead:Triage and start investigationsMultidisciplinary TB teams should have pathways to triage referrals, start investigations and collect clinical information before the person is seen by a physician. While triaging, multidisciplinary TB teams should ensure everyone is given information about TB as part of the process (see providing information). This should include who the person should contact if they have any questions and how to access advice or information from support groups, national charities such as TB Alert and other sources such as local government (for example, public health or social care teams).Multidisciplinary TB teams should ensure people who have a smear-positive result or imaging features highly suggestive of smear-positive TB (for example, evidence of cavitation on chest X-ray) are assessed the next working day. This is so that case management and infection control procedures start promptly.The multidisciplinary TB team should assess people who are not smear-positive but have imaging that suggests pulmonary or laryngeal TB as soon as possible. This should be no later than 5 working days after a referral.Multidisciplinary TB teams should, where necessary, be able to provide or arrange outreach services to ensure sputum samples or other assessments such as contact investigations can be arranged within the community.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.4AssessmentSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8722", "name": "policy on hospital admission", "draggable": "true", "value": {"name": "policy on hospital admission", "type": "information and support", "time": "", "intention": "", "description": "title:policy on hospital admissionhead:Policy on hospital admissionUnless there is a clear clinical or public health need, such as homelessness, people with suspected infectious TB or confirmed pulmonary TB should not be admitted to hospital for diagnostic tests or for care.In hospital settings, risk assess people with suspected infectious TB or confirmed pulmonary TB for multidrug-resistant TB (see also managing active TB). Care for people deemed to be at low risk in a single room, as a minimum. For people deemed to be at high risk: provide care in a negative-pressure room and have specimens sent for rapid diagnostic tests, such as nucleic acid amplification tests.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8737", "name": "assessing for latent tuberculosis", "draggable": "true", "value": {"name": "assessing for latent tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:assessing for latent tuberculosishead:Assessing for latent tuberculosisSee tuberculosis in high-risk groups for details of testing for latent tuberculosis in high-risk groups.See contact tracing and testing for details of testing for latent tuberculosis in close contacts of people diagnosed with active tuberculosis. This includes specific guidance for testing in neonates, infants (over 4 weeks and under 2 years), children and young people. For guidance on cases in schools see assess need for contact tracing.For guidance on incident and outbreak situations see contact tracing and testing. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8738", "name": "assessing for active tuberculosis", "draggable": "true", "value": {"name": "assessing for active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:assessing for active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8763", "name": "vaccination for non nhs staff and staff of care homes", "draggable": "true", "value": {"name": "vaccination for non nhs staff and staff of care homes", "type": "information and support", "time": "", "intention": "", "description": "title:vaccination for non-nhs staff and staff of care homeshead:Vaccination for non-NHS staff and staff of care homesOffer BCG vaccination to previously unvaccinated, Mantoux-negative people aged 35 years or younger in the following groups at increased risk of exposure to TB, in accordance with the Department of Health s Green Book: veterinary and other staff such as abattoir workers who handle animal species known to be susceptible to TB, such as simians prison staff working directly with prisoners staff of care homes for older people staff of hostels for people who are homeless and facilities accommodating refugees and asylum seekers people going to live or work with local people for more than 3 months in a high-incidence country.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8761", "name": "staff with no contact with patients or clinical specimens", "draggable": "true", "value": {"name": "staff with no contact with patients or clinical specimens", "type": "information and support", "time": "", "intention": "", "description": "title:staff with no contact with patients or clinical specimenshead:Staff with no contact with patients or clinical specimensEmployees new to the NHS who will not have contact with patients or clinical specimens should not start work if they have signs or symptoms of TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8756", "name": "vaccination for nhs staff", "draggable": "true", "value": {"name": "vaccination for nhs staff", "type": "information and support", "time": "", "intention": "", "description": "title:vaccination for nhs staffhead:Vaccination for NHS staffOffer BCG vaccination to healthcare workers and other NHS employees who have contact with patients or clinical specimens, irrespective of age, who: are previously unvaccinated (that is, without adequate documentation or a BCG scar), and are Mantoux-negative.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8692", "name": "close contacts", "draggable": "true", "value": {"name": "close contacts", "type": "information and support", "time": "", "intention": "", "description": "title:close contactshead:Close contactsOffer screening to the close contacts of any person with pulmonary or laryngeal TB.Assess symptomatic close contacts for active TB (see assessing for active TB).In asymptomatic close contacts younger than 65 years, consider standard testing for latent TB, followed by consideration of BCG vaccination (see vaccination) or treatment for latent TB infection (see managing latent TB) once active TB has been ruled out for people who: are previously unvaccinated, and are contacts of a person with smear-positive pulmonary or laryngeal TB, and are Mantoux-negative.Only consider using interferon-gamma release assays alone in children and young people if Mantoux testing is not available or is impractical. This includes for example, situations in which large numbers need to be tested.Refer children younger than 2 years and in close contact with people with smear-negative pulmonary or laryngeal TB to a specialist to determine what testing strategy for latent TB should be done. This should be a paediatrician with experience and training in TB, or a general paediatrician with advice from a specialist clinician.For information on close contacts who are immunocompromised, see TB in high-risk groups. See also staff vaccination and screening.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8699", "name": "social contacts", "draggable": "true", "value": {"name": "social contacts", "type": "information and support", "time": "", "intention": "", "description": "title:social contactshead:Social contactsDo not routinely assess social contacts of people with TB, who will include most workplace contacts.Assess the need for tracing social contacts of people with pulmonary or laryngeal TB if: the index case is judged to be particularly infectious (for example, evidenced by transmission to close contacts), or any casual contacts are known to possess features that put them at high risk of going on to develop active TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8774", "name": "discuss risks and benefits of vaccination", "draggable": "true", "value": {"name": "discuss risks and benefits of vaccination", "type": "information and support", "time": "", "intention": "", "description": "title:discuss risks and benefits of vaccinationhead:Discuss risks and benefits of vaccinationWhen BCG vaccination is being recommended, discuss the benefits and risks of vaccination or remaining unvaccinated with the person (or, if a child, with the parents), so that they can make an informed decision. Tailor this discussion to the person, use appropriate language, and take into account cultural sensitivities and stigma.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8682", "name": "risk factors for developing active tuberculosis", "draggable": "true", "value": {"name": "risk factors for developing active tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:risk factors for developing active tuberculosishead:Risk factors for developing active tuberculosisBe aware that certain groups of people with latent TB are at increased risk of going on to develop active TB, including people who: are HIV-positive are younger than 5 years have excessive alcohol intake are injecting drug users have had solid organ transplantation have a haematological malignancy are having chemotherapy have had a jejunoileal bypass have diabetes have chronic renal failure or receive haemodialysis have had a gastrectomy are having treatment with anti-tumour necrosis factor-alpha or other biologic agents have silicosis.People in the groups listed above who do not have treatment for latent TB, as specified, for any reason should be advised of the risks and symptoms of TB (on the basis of an individual risk assessment), usually in a standard letter of the type referred to as  Inform and advise  information (see providing information).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8706", "name": "contacts of people with active tuberculosis", "draggable": "true", "value": {"name": "contacts of people with active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:contacts of people with active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8703", "name": "new entrants from high incidence countries", "draggable": "true", "value": {"name": "new entrants from high incidence countries", "type": "treatment related", "time": "", "intention": "", "description": "title:new entrants from high-incidence countrieshead:New entrants from high-incidence countriesAssess and manage TB in new entrants from high-incidence countries who present to healthcare services as follows: assess risk of HIV, including HIV prevalence rates in the country of origin, and take this into account when deciding whether to give a BCG vaccination offer testing for latent TB assess for active TB if the test for latent TB is positive (see assessing for active tuberculosis) offer treatment to people aged 65 years or younger in whom active TB has been excluded but who have a positive Mantoux test or a positive interferon-gamma release assay for latent TB infection (see managing latent tuberculosis) consider offering BCG for unvaccinated people who are Mantoux- or interferon-gamma release assay-negative (see vaccination) give  inform and advise  information to people who do not have active TB and are not being offered BCG or treatment for latent TB infection (see providing information).Offer Mantoux testing as the initial diagnostic test for latent TB infection in people who have recently arrived from a high-incidence country who present to healthcare services. If the Mantoux test is positive (5 mm or larger, regardless of BCG history): assess for active TB (see assessing for active tuberculosis), and if this assessment is negative, offer them treatment for latent TB infection (see managing latent tuberculosis).If Mantoux testing is unavailable, offer an interferon-gamma release assay.Offer BCG vaccination to new entrants who are Mantoux-negative who: are from high-incidence countries, and are previously unvaccinated (that is, without adequate documentation or a BCG scar), and are aged: younger than 16 years, or 16-35 years  from sub-Saharan Africa or a country with a TB incidence of 500 per 100,000 or more.See also vulnerable migrants.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1Latent tuberculosis testing for people from high-incidence countriesSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8705", "name": "under served groups", "draggable": "true", "value": {"name": "under served groups", "type": "treatment related", "time": "", "intention": "", "description": "title:under-served groups", "drug": {}}}, {"category": "treatment", "id": "t8704", "name": "people who are immunocompromised", "draggable": "true", "value": {"name": "people who are immunocompromised", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people who are immunocompromisedhead:People who are immunocompromisedsubhead:ChildrenIf latent TB is suspected in children and young people who are anticipated to be or are currently immunocompromised (for example, if they are from a high-incidence country or are close contacts of people with suspected infectious or confirmed pulmonary or laryngeal TB), refer to a TB specialist.subhead:AdultsIn adults who are anticipated to be or are currently immunocompromised, do a risk assessment to establish whether testing should be offered, taking into account their: risk of progression to active TB based on how severely they are immunocompromised and for how long they have been immunocompromised risk factors for TB infection, such as country of birth or recent contact with an index case with suspected infectious or confirmed pulmonary or laryngeal TB.For adults who are severely immunocompromised, such as those with HIV and CD4 counts of fewer than 200 cells/mm3, or after solid organ or allogeneic stem cell transplant, offer an interferon-gamma release assay and concurrent Mantoux test.  If either test is positive (for Mantoux, this is an induration of 5 mm or larger, regardless of BCG history), assess for active TB (see assessing for active tuberculosis). If this assessment is negative, offer them treatment for latent TB infection (see managing latent tuberculosis).For other adults who are immunocompromised, consider an interferon-gamma release assay alone or an interferon-gamma release assay with a concurrent Mantoux test.  If either test is positive (for Mantoux, this is an induration of 5 mm or larger, regardless of BCG history), assess for active TB (see assessing for active tuberculosis). If this assessment is negative, offer them treatment for latent TB infection (see managing latent tuberculosis).Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.2Latent tuberculosis testing for adults with HIVSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8666", "name": "develop a health and social care plan", "draggable": "true", "value": {"name": "develop a health and social care plan", "type": "information and support", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:develop a health and social care planhead:Develop a health and social care planThe TB case manager should work with the person diagnosed with TB to develop a health and social care plan, and support them to complete therapy successfully. The TB case manager should: offer a risk assessment to every person with TB, to identify their needs and whether they should have enhanced case management including directly observed therapy educate the person about TB and the treatment develop an individual care plan after discussion with the person gain the person s consent to the plan and agree a review date (for example, when moving from initiation to maintenance, or at each contact to ensure the person s needs are being met) coordinate discharge planning, especially for people on directly observed therapy involve representatives from other allied professions and key workers from all organisations who work with the person, if appropriate explore appropriate ways that peers and voluntary organisations can provide support.TB case managers should ensure the health and social care plan (particularly if directly observed therapy is needed) identifies why a person may not attend for diagnostic testing or follow a treatment plan, and how they can be encouraged to do so. It should also include ways to address issues such as fear of stigmatisation, support needs or cultural beliefs, and may include information on: demographics (for example, age, nationality, place of birth, length of time in UK) all current prescribing regimens housing needs and living situation, including looked-after children substance misuse (drugs or alcohol) any contact with the criminal justice system HIV status other health conditions (physical or mental) communication factors (for example, language and literacy levels) ability to access treatment (mobility and transport needs) employment or entitlement to benefits legal or immigration status (including risk of removal or relocation within the UK) any enablers or incentives to overcome anything that is stopping diagnosis or treatment.The health and social care plan should:  state who will be observing treatment and where (if the person is having directly observed therapy this should be provided at a location that is convenient and accessible to them, for example, at a methadone clinic) include actions to take if contact with the person is lost (for example, keeping details of people who might be able to help re-establish contact) refer to, and be coordinated with, any other care plan already established for the person  define the support needed to address any unmet health and social care needs (for example, support to gain housing or other benefits, or to help them access other health or social care services) include a commitment from the person to complete their TB treatment be supported by frequent contact with any key workers who work with the person.See what NICE says on alcohol-use disorders, drug misuse management in over 16s and multimorbidity.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8745", "name": "population needs assessment", "draggable": "true", "value": {"name": "population needs assessment", "type": "information and support", "time": "", "intention": "", "description": "title:population needs assessmenthead:Population needs assessment Directors of public health, in discussion with local health protection teams, should ensure that TB is part of the joint strategic needs assessment.Directors of public health should provide commissioners of TB prevention and control programmes and TB control boards with local needs assessment information annually using data provided by Public Health England.Commissioners of TB prevention and control programmes should ensure services reflect the needs of their area, identified by needs assessment. Health and wellbeing boards should ensure that local TB services have been commissioned based on local needs identified through needs assessment.Directors of public health and TB control boards should use cohort review and other methods to collect data on the following, to inform local needs assessment:  Number of annual notified TB cases (see Public Health England s enhanced TB surveillance data and annual  suite of indicators ). Size, composition (for example, age and ethnicity) and distribution of local at-risk groups. Indices of social deprivation. Local statutory and non-statutory services working with these groups.  Organisation of local TB services, including the composition and capacity of the local multidisciplinary TB team (see the results of local audit) and location of services. This may also include data to support evaluating the need for integrated TB/HIV services including joint clinics.  Numbers needing enhanced case management. Numbers receiving directly observed therapy from the start of, or at any point during, treatment (see Public Health England s enhanced TB surveillance data).  Evidence of recent transmission (for example, using DNA fingerprinting or surrogate markers such as number of cases in children under 5 years (see Public Health England s national TB strain typing service).  Completeness and yield of contact investigations. This includes: proportion of sputum-smear-positive cases with 0, 5 or more contacts identified; proportion of identified contacts clinically assessed; and proportion of contacts with latent TB infection who successfully complete treatment. Active case-finding initiatives, incident contact investigations and identification of latent TB in high-risk groups.  Treatment outcomes for everyone grouped according to social risk factors and by the use of directly observed therapy (including rates of loss to follow-up and treatment interruption \u2013 see Public Health England s enhanced TB surveillance data).  Local education and awareness-raising programmes for under-served groups, professionals and practitioners working with them.  Views and experiences of people with TB, carers and the services working with them.Local needs assessments should also be equity proofed to assess the potential effect of planning, commissioning and policy decisions on health inequalities (see NICE local government briefing on health inequalities and population health.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8711", "name": "consider mobile x ray to identify active tuberculosis", "draggable": "true", "value": {"name": "consider mobile x ray to identify active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:consider mobile x-ray to identify active tuberculosishead:Consider mobile X-ray to identify active tuberculosisMultidisciplinary TB teams in discussion with local Public Health England health protection teams should consider using digital mobile X-ray for active case-finding in settings identified by looking at social networks as places where under-served people at risk congregate. They should also provide the necessary support so that multidisciplinary TB teams can use strain-typing and social network analysis to ascertain where transmission is occurring in the community. (Examples of transmission sites may include pubs, crack houses, hostels and day centres.) They should focus on active case-finding in the settings identified.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6279", "name": "multidisciplinary teams", "draggable": "true", "value": {"name": "multidisciplinary teams", "type": "information and support", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:multidisciplinary teamshead:Multidisciplinary teamsCommissioners should ensure multidisciplinary TB teams: Have the skills and resources to manage the care of people with active TB who are not from under-served groups. Include at least 1TB case manager with responsibility for planning and coordinating the care of under-served people and those with active TB who receive enhanced case management. Have the resources to manage latent TB care in under-served groups and the wider population. (One whole-time equivalent case manager is recommended per 40 latent TB cases needing enhanced case management and per 80 latent TB cases for standard case management). Include a range of clinical specialties in the multidisciplinary TB team, including paediatrics, infection control and respiratory medicine. Have regular attendance at these multidisciplinary team and cohort review meetings for all team members included as a programmed activity as part of their work planning. Have the skills and resources necessary to manage the care of people with complex social and clinical needs (either directly or via an established route). This includes the ability to provide prompt access (or if necessary, referral) to skilled outreach and advocacy workers who can draw on the services of allied practitioners. The aim is to address people s housing, asylum, immigration, welfare, substance dependency and other health and social care needs. (The allied practitioner support should include both a specified housing officer and a social worker.) Can provide rapid access TB clinics for all cases, including under-served groups. Consider providing administration support to TB nurses and case managers so they have capacity for clinical and case management work. This should include giving TB nurses access to computer hardware and software. Have the resources to provide a continuous service throughout the year, ensuring the TB service accounts for the following to manage continuity of care: planned absence (for example, professional development, mandatory training, annual, maternity or paternity leave) unplanned absence (such as sickness absence). Can provide prompt access to a professional who has training and experience in assessing and protecting children and vulnerable adults at risk of abuse or neglect. Have access to funds through local government and clinical commissioning groups that can be used flexibly to improve adherence to treatment among under-served groups. For example, funds could be used to provide transport to clinics, to provide support or enablers for treatment, or for paying outreach workers or community services to support directly observed therapy. Funds may also be used to provide accommodation during treatment. Have the resources to provide ongoing TB awareness-raising activities for professional, community and voluntary (including advocacy) groups that work with populations at high risk of TB. These resources should be financed by local government or clinical commissioning groups.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6268", "name": "vaccination for nhs staff", "draggable": "true", "value": {"name": "vaccination for nhs staff", "type": "information and support", "time": "", "intention": "", "description": "title:vaccination for nhs staffhead:Vaccination for NHS staffOffer BCG vaccination to healthcare workers and other NHS employees who have contact with patients or clinical specimens, irrespective of age, who: are previously unvaccinated (that is, without adequate documentation or a BCG scar), and are Mantoux-negative.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6273", "name": "staff with no contact with patients or clinical specimens", "draggable": "true", "value": {"name": "staff with no contact with patients or clinical specimens", "type": "information and support", "time": "", "intention": "", "description": "title:staff with no contact with patients or clinical specimenshead:Staff with no contact with patients or clinical specimensEmployees new to the NHS who will not have contact with patients or clinical specimens should not start work if they have signs or symptoms of TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6275", "name": "vaccination for non nhs staff and staff of care homes", "draggable": "true", "value": {"name": "vaccination for non nhs staff and staff of care homes", "type": "information and support", "time": "", "intention": "", "description": "title:vaccination for non-nhs staff and staff of care homeshead:Vaccination for non-NHS staff and staff of care homesOffer BCG vaccination to previously unvaccinated, Mantoux-negative people aged 35 years or younger in the following groups at increased risk of exposure to TB, in accordance with the Department of Health s Green Book: veterinary and other staff such as abattoir workers who handle animal species known to be susceptible to TB, such as simians prison staff working directly with prisoners staff of care homes for older people staff of hostels for people who are homeless and facilities accommodating refugees and asylum seekers people going to live or work with local people for more than 3 months in a high-incidence country.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6169", "name": "triage and start investigations", "draggable": "true", "value": {"name": "triage and start investigations", "type": "treatment related", "time": "", "intention": "", "description": "title:triage and start investigationshead:Triage and start investigationsMultidisciplinary TB teams should have pathways to triage referrals, start investigations and collect clinical information before the person is seen by a physician. While triaging, multidisciplinary TB teams should ensure everyone is given information about TB as part of the process (see providing information). This should include who the person should contact if they have any questions and how to access advice or information from support groups, national charities such as TB Alert and other sources such as local government (for example, public health or social care teams).Multidisciplinary TB teams should ensure people who have a smear-positive result or imaging features highly suggestive of smear-positive TB (for example, evidence of cavitation on chest X-ray) are assessed the next working day. This is so that case management and infection control procedures start promptly.The multidisciplinary TB team should assess people who are not smear-positive but have imaging that suggests pulmonary or laryngeal TB as soon as possible. This should be no later than 5 working days after a referral.Multidisciplinary TB teams should, where necessary, be able to provide or arrange outreach services to ensure sputum samples or other assessments such as contact investigations can be arranged within the community.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.4AssessmentSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6286", "name": "discuss risks and benefits of vaccination", "draggable": "true", "value": {"name": "discuss risks and benefits of vaccination", "type": "information and support", "time": "", "intention": "", "description": "title:discuss risks and benefits of vaccinationhead:Discuss risks and benefits of vaccinationWhen BCG vaccination is being recommended, discuss the benefits and risks of vaccination or remaining unvaccinated with the person (or, if a child, with the parents), so that they can make an informed decision. Tailor this discussion to the person, use appropriate language, and take into account cultural sensitivities and stigma.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6215", "name": "new entrants from high incidence countries", "draggable": "true", "value": {"name": "new entrants from high incidence countries", "type": "treatment related", "time": "", "intention": "", "description": "title:new entrants from high-incidence countrieshead:New entrants from high-incidence countriesAssess and manage TB in new entrants from high-incidence countries who present to healthcare services as follows: assess risk of HIV, including HIV prevalence rates in the country of origin, and take this into account when deciding whether to give a BCG vaccination offer testing for latent TB assess for active TB if the test for latent TB is positive (see assessing for active tuberculosis) offer treatment to people aged 65 years or younger in whom active TB has been excluded but who have a positive Mantoux test or a positive interferon-gamma release assay for latent TB infection (see managing latent tuberculosis) consider offering BCG for unvaccinated people who are Mantoux- or interferon-gamma release assay-negative (see vaccination) give  inform and advise  information to people who do not have active TB and are not being offered BCG or treatment for latent TB infection (see providing information).Offer Mantoux testing as the initial diagnostic test for latent TB infection in people who have recently arrived from a high-incidence country who present to healthcare services. If the Mantoux test is positive (5 mm or larger, regardless of BCG history): assess for active TB (see assessing for active tuberculosis), and if this assessment is negative, offer them treatment for latent TB infection (see managing latent tuberculosis).If Mantoux testing is unavailable, offer an interferon-gamma release assay.Offer BCG vaccination to new entrants who are Mantoux-negative who: are from high-incidence countries, and are previously unvaccinated (that is, without adequate documentation or a BCG scar), and are aged: younger than 16 years, or 16-35 years  from sub-Saharan Africa or a country with a TB incidence of 500 per 100,000 or more.See also vulnerable migrants.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.1Latent tuberculosis testing for people from high-incidence countriesSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6216", "name": "people who are immunocompromised", "draggable": "true", "value": {"name": "people who are immunocompromised", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people who are immunocompromisedhead:People who are immunocompromisedsubhead:ChildrenIf latent TB is suspected in children and young people who are anticipated to be or are currently immunocompromised (for example, if they are from a high-incidence country or are close contacts of people with suspected infectious or confirmed pulmonary or laryngeal TB), refer to a TB specialist.subhead:AdultsIn adults who are anticipated to be or are currently immunocompromised, do a risk assessment to establish whether testing should be offered, taking into account their: risk of progression to active TB based on how severely they are immunocompromised and for how long they have been immunocompromised risk factors for TB infection, such as country of birth or recent contact with an index case with suspected infectious or confirmed pulmonary or laryngeal TB.For adults who are severely immunocompromised, such as those with HIV and CD4 counts of fewer than 200 cells/mm3, or after solid organ or allogeneic stem cell transplant, offer an interferon-gamma release assay and concurrent Mantoux test.  If either test is positive (for Mantoux, this is an induration of 5 mm or larger, regardless of BCG history), assess for active TB (see assessing for active tuberculosis). If this assessment is negative, offer them treatment for latent TB infection (see managing latent tuberculosis).For other adults who are immunocompromised, consider an interferon-gamma release assay alone or an interferon-gamma release assay with a concurrent Mantoux test.  If either test is positive (for Mantoux, this is an induration of 5 mm or larger, regardless of BCG history), assess for active TB (see assessing for active tuberculosis). If this assessment is negative, offer them treatment for latent TB infection (see managing latent tuberculosis).Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.2Latent tuberculosis testing for adults with HIVSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6217", "name": "under served groups", "draggable": "true", "value": {"name": "under served groups", "type": "treatment related", "time": "", "intention": "", "description": "title:under-served groups", "drug": {}}}, {"category": "treatment", "id": "t6218", "name": "contacts of people with active tuberculosis", "draggable": "true", "value": {"name": "contacts of people with active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:contacts of people with active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6211", "name": "social contacts", "draggable": "true", "value": {"name": "social contacts", "type": "information and support", "time": "", "intention": "", "description": "title:social contactshead:Social contactsDo not routinely assess social contacts of people with TB, who will include most workplace contacts.Assess the need for tracing social contacts of people with pulmonary or laryngeal TB if: the index case is judged to be particularly infectious (for example, evidenced by transmission to close contacts), or any casual contacts are known to possess features that put them at high risk of going on to develop active TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6204", "name": "close contacts", "draggable": "true", "value": {"name": "close contacts", "type": "information and support", "time": "", "intention": "", "description": "title:close contactshead:Close contactsOffer screening to the close contacts of any person with pulmonary or laryngeal TB.Assess symptomatic close contacts for active TB (see assessing for active TB).In asymptomatic close contacts younger than 65 years, consider standard testing for latent TB, followed by consideration of BCG vaccination (see vaccination) or treatment for latent TB infection (see managing latent TB) once active TB has been ruled out for people who: are previously unvaccinated, and are contacts of a person with smear-positive pulmonary or laryngeal TB, and are Mantoux-negative.Only consider using interferon-gamma release assays alone in children and young people if Mantoux testing is not available or is impractical. This includes for example, situations in which large numbers need to be tested.Refer children younger than 2 years and in close contact with people with smear-negative pulmonary or laryngeal TB to a specialist to determine what testing strategy for latent TB should be done. This should be a paediatrician with experience and training in TB, or a general paediatrician with advice from a specialist clinician.For information on close contacts who are immunocompromised, see TB in high-risk groups. See also staff vaccination and screening.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6250", "name": "assessing for active tuberculosis", "draggable": "true", "value": {"name": "assessing for active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:assessing for active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6249", "name": "assessing for latent tuberculosis", "draggable": "true", "value": {"name": "assessing for latent tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:assessing for latent tuberculosishead:Assessing for latent tuberculosisSee tuberculosis in high-risk groups for details of testing for latent tuberculosis in high-risk groups.See contact tracing and testing for details of testing for latent tuberculosis in close contacts of people diagnosed with active tuberculosis. This includes specific guidance for testing in neonates, infants (over 4 weeks and under 2 years), children and young people. For guidance on cases in schools see assess need for contact tracing.For guidance on incident and outbreak situations see contact tracing and testing. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6257", "name": "population needs assessment", "draggable": "true", "value": {"name": "population needs assessment", "type": "information and support", "time": "", "intention": "", "description": "title:population needs assessmenthead:Population needs assessment Directors of public health, in discussion with local health protection teams, should ensure that TB is part of the joint strategic needs assessment.Directors of public health should provide commissioners of TB prevention and control programmes and TB control boards with local needs assessment information annually using data provided by Public Health England.Commissioners of TB prevention and control programmes should ensure services reflect the needs of their area, identified by needs assessment. Health and wellbeing boards should ensure that local TB services have been commissioned based on local needs identified through needs assessment.Directors of public health and TB control boards should use cohort review and other methods to collect data on the following, to inform local needs assessment:  Number of annual notified TB cases (see Public Health England s enhanced TB surveillance data and annual  suite of indicators ). Size, composition (for example, age and ethnicity) and distribution of local at-risk groups. Indices of social deprivation. Local statutory and non-statutory services working with these groups.  Organisation of local TB services, including the composition and capacity of the local multidisciplinary TB team (see the results of local audit) and location of services. This may also include data to support evaluating the need for integrated TB/HIV services including joint clinics.  Numbers needing enhanced case management. Numbers receiving directly observed therapy from the start of, or at any point during, treatment (see Public Health England s enhanced TB surveillance data).  Evidence of recent transmission (for example, using DNA fingerprinting or surrogate markers such as number of cases in children under 5 years (see Public Health England s national TB strain typing service).  Completeness and yield of contact investigations. This includes: proportion of sputum-smear-positive cases with 0, 5 or more contacts identified; proportion of identified contacts clinically assessed; and proportion of contacts with latent TB infection who successfully complete treatment. Active case-finding initiatives, incident contact investigations and identification of latent TB in high-risk groups.  Treatment outcomes for everyone grouped according to social risk factors and by the use of directly observed therapy (including rates of loss to follow-up and treatment interruption \u2013 see Public Health England s enhanced TB surveillance data).  Local education and awareness-raising programmes for under-served groups, professionals and practitioners working with them.  Views and experiences of people with TB, carers and the services working with them.Local needs assessments should also be equity proofed to assess the potential effect of planning, commissioning and policy decisions on health inequalities (see NICE local government briefing on health inequalities and population health.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6178", "name": "develop a health and social care plan", "draggable": "true", "value": {"name": "develop a health and social care plan", "type": "information and support", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:develop a health and social care planhead:Develop a health and social care planThe TB case manager should work with the person diagnosed with TB to develop a health and social care plan, and support them to complete therapy successfully. The TB case manager should: offer a risk assessment to every person with TB, to identify their needs and whether they should have enhanced case management including directly observed therapy educate the person about TB and the treatment develop an individual care plan after discussion with the person gain the person s consent to the plan and agree a review date (for example, when moving from initiation to maintenance, or at each contact to ensure the person s needs are being met) coordinate discharge planning, especially for people on directly observed therapy involve representatives from other allied professions and key workers from all organisations who work with the person, if appropriate explore appropriate ways that peers and voluntary organisations can provide support.TB case managers should ensure the health and social care plan (particularly if directly observed therapy is needed) identifies why a person may not attend for diagnostic testing or follow a treatment plan, and how they can be encouraged to do so. It should also include ways to address issues such as fear of stigmatisation, support needs or cultural beliefs, and may include information on: demographics (for example, age, nationality, place of birth, length of time in UK) all current prescribing regimens housing needs and living situation, including looked-after children substance misuse (drugs or alcohol) any contact with the criminal justice system HIV status other health conditions (physical or mental) communication factors (for example, language and literacy levels) ability to access treatment (mobility and transport needs) employment or entitlement to benefits legal or immigration status (including risk of removal or relocation within the UK) any enablers or incentives to overcome anything that is stopping diagnosis or treatment.The health and social care plan should:  state who will be observing treatment and where (if the person is having directly observed therapy this should be provided at a location that is convenient and accessible to them, for example, at a methadone clinic) include actions to take if contact with the person is lost (for example, keeping details of people who might be able to help re-establish contact) refer to, and be coordinated with, any other care plan already established for the person  define the support needed to address any unmet health and social care needs (for example, support to gain housing or other benefits, or to help them access other health or social care services) include a commitment from the person to complete their TB treatment be supported by frequent contact with any key workers who work with the person.See what NICE says on alcohol-use disorders, drug misuse management in over 16s and multimorbidity.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6194", "name": "risk factors for developing active tuberculosis", "draggable": "true", "value": {"name": "risk factors for developing active tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:risk factors for developing active tuberculosishead:Risk factors for developing active tuberculosisBe aware that certain groups of people with latent TB are at increased risk of going on to develop active TB, including people who: are HIV-positive are younger than 5 years have excessive alcohol intake are injecting drug users have had solid organ transplantation have a haematological malignancy are having chemotherapy have had a jejunoileal bypass have diabetes have chronic renal failure or receive haemodialysis have had a gastrectomy are having treatment with anti-tumour necrosis factor-alpha or other biologic agents have silicosis.People in the groups listed above who do not have treatment for latent TB, as specified, for any reason should be advised of the risks and symptoms of TB (on the basis of an individual risk assessment), usually in a standard letter of the type referred to as  Inform and advise  information (see providing information).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6234", "name": "policy on hospital admission", "draggable": "true", "value": {"name": "policy on hospital admission", "type": "information and support", "time": "", "intention": "", "description": "title:policy on hospital admissionhead:Policy on hospital admissionUnless there is a clear clinical or public health need, such as homelessness, people with suspected infectious TB or confirmed pulmonary TB should not be admitted to hospital for diagnostic tests or for care.In hospital settings, risk assess people with suspected infectious TB or confirmed pulmonary TB for multidrug-resistant TB (see also managing active TB). Care for people deemed to be at low risk in a single room, as a minimum. For people deemed to be at high risk: provide care in a negative-pressure room and have specimens sent for rapid diagnostic tests, such as nucleic acid amplification tests.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6223", "name": "consider mobile x ray to identify active tuberculosis", "draggable": "true", "value": {"name": "consider mobile x ray to identify active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:consider mobile x-ray to identify active tuberculosishead:Consider mobile X-ray to identify active tuberculosisMultidisciplinary TB teams in discussion with local Public Health England health protection teams should consider using digital mobile X-ray for active case-finding in settings identified by looking at social networks as places where under-served people at risk congregate. They should also provide the necessary support so that multidisciplinary TB teams can use strain-typing and social network analysis to ascertain where transmission is occurring in the community. (Examples of transmission sites may include pubs, crack houses, hostels and day centres.) They should focus on active case-finding in the settings identified.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8768", "name": "emergency department staff", "draggable": "true", "value": {"name": "emergency department staff", "type": "information and support", "time": "", "intention": "", "description": "title:emergency department staffhead:Emergency department staff Multidisciplinary TB teams should consider training emergency department staff in: using approaches that do not stigmatise people with TB giving people with TB appropriate advice (see providing information and management and infection control in hospital.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8661", "name": "management and infection control in hospital", "draggable": "true", "value": {"name": "management and infection control in hospital", "type": "treatment related", "time": "", "intention": "", "description": "title:management and infection control in hospital", "drug": {}}}, {"category": "treatment", "id": "t8658", "name": "when to take cultures and start treatment", "draggable": "true", "value": {"name": "when to take cultures and start treatment", "type": "treatment related", "time": "", "intention": "", "description": "title:when to take cultures and start treatmenthead:When to take cultures and start treatmentIf TB is a possibility, microbiology staff should consider carrying out TB culture on samples, even if it is not requested. If there are clinical signs and symptoms consistent with a diagnosis of TB, start treatment without waiting for culture results.Consider completing the standard recommended regimen, even if subsequent culture results are negative.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8727", "name": "person with multidrug resistant tuberculosis", "draggable": "true", "value": {"name": "person with multidrug resistant tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with multidrug-resistant tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8723", "name": "person with active tuberculosis", "draggable": "true", "value": {"name": "person with active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8739", "name": "managing latent tuberculosis", "draggable": "true", "value": {"name": "managing latent tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:managing latent tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8740", "name": "managing active tuberculosis", "draggable": "true", "value": {"name": "managing active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:managing active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8764", "name": "back to service organisation", "draggable": "true", "value": {"name": "back to service organisation", "type": "cancer ralated", "time": "", "intention": "", "description": "title:back to service organisation", "drug": {}}}, {"category": "treatment", "id": "t8757", "name": "screening for new staff", "draggable": "true", "value": {"name": "screening for new staff", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:screening for new staffhead:Screening for new staffEmployees new to the NHS who will be working with patients or clinical specimens should not start work until they have completed a TB screen or health check, or documentary evidence is provided of such screening having taken place within the preceding 12 months.Health checks for employees new to the NHS who will have contact with patients or clinical materials should include: assessment of personal or family history of TB asking about symptoms and signs, possibly by questionnaire documentary evidence of TB skin (or interferon-gamma release assay) testing within the past 5 years and/or BCG scar check by an occupational health professional, not relying on the applicant s personal assessment.Employees who will be working with patients or clinical specimens and who are Mantoux- or interferon-gamma release assay-negative should have an individual risk assessment for HIV infection before BCG vaccination is given.Offer BCG vaccination to employees of any age who are new to the NHS and are from countries of high TB incidence, or who have had contact with patients in settings with a high TB prevalence, and, who are Mantoux-negative.If a new employee from the UK or other low-incidence setting, who has not had a BCG vaccination, has a positive Mantoux test and a positive interferon-gamma release assay, they should have a medical assessment and a chest X-ray. They should be referred to a TB clinic to determine whether they need TB treatment if the chest X-ray is abnormal, or to determine whether they need treatment of latent TB infection if the chest X-ray is normal.If a prospective or current healthcare worker who is Mantoux-negative declines BCG vaccination, explain the risks and supplement the oral explanation with written advice. If the person still declines BCG vaccination, he or she should not work where there is a risk of exposure to TB. The employer will need to consider each case individually, taking account of employment and health and safety obligations.Screen clinical students, agency and locum staff and contract ancillary workers who have contact with patients or clinical materials for TB to the same standard as new employees in healthcare environments, according to the recommendations set out above. Seek documentary evidence of screening to this standard from locum agencies and contractors who carry out their own screening.NHS trusts arranging care for NHS patients in non-NHS settings should ensure that healthcare workers who have contact with patients or clinical materials in these settings have been screened for TB to the same standard as new employees in NHS settings.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8694", "name": "infant", "draggable": "true", "value": {"name": "infant", "type": "information and support", "time": "", "intention": "", "description": "title:infanthead:InfantIf a child aged between 4 weeks and 2 years has been in close contact with people with smear-positive pulmonary or laryngeal TB who have not had at least 2 weeks of anti-TB treatment: Assess for active TB (see assessing for active TB). Start treatment for latent TB (see managing latent TB) and carry out a Mantoux test. If the Mantoux test is inconclusive, refer the child to a TB specialist. If the Mantoux test is positive (5 mm or larger, regardless of BCG history), reassess for active TB; if this assessment is negative, complete treatment for latent TB. If the Mantoux test is negative, continue treatment for latent TB, reassess for active TB after 6 weeks and repeat the Mantoux test: if the Mantoux test is negative, consider an interferon-gamma release assay if the interferon-gamma release assay is negative, treatment for latent TB may be stopped; give a BCG vaccination (see vaccination) if the child has not already had one  if either test is positive, reassess for active TB; if this assessment is negative, complete treatment for latent TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8696", "name": "adult", "draggable": "true", "value": {"name": "adult", "type": "information and support", "time": "", "intention": "", "description": "title:adulthead:AdultOffer Mantoux testing to diagnose latent TB in adults aged 18 to 65 who are close contacts of a person with pulmonary or laryngeal TB. If the Mantoux test is inconclusive, refer the person to a TB specialist.  If the Mantoux test is positive (an induration of 5 mm or larger, regardless of BCG history), assess for active TB (see assessing for active TB). If the Mantoux test is positive but a diagnosis of active TB is excluded, consider an interferon gamma release assay if more evidence of infection is needed to decide on treatment. This could be, for example, if the person needs enhanced case management or if there could be adverse events from treatment. If the Mantoux is positive, and if an IGRA was done and that is also positive, offer them treatment for latent TB infection (see managing latent TB).  In asymptomatic close contacts older than 65 years, consider a chest X-ray (if there are no contraindications), possibly leading to further investigation for active TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8693", "name": "neonate", "draggable": "true", "value": {"name": "neonate", "type": "information and support", "time": "", "intention": "isoniazid\nisoniazid is used to treat and to prevent tuberculosis (tb). you may need to take other tb medicines in combination with isoniazid.\nisoniazid may also be used for purposes not listed in this medication guide.", "description": "title:neonatehead:Neonate If a neonate has been in close contact with people with smear-positive pulmonary or laryngeal TB who have not had at least 2 weeks of anti-TB treatment: Assess for active TB (see assessing for active TB). Start isoniazid (with pyridoxine). Carry out Mantoux test after 6 weeks of treatment. If the Matoux test is inconclusive, refer the child to a TB specialist. If the Mantoux test is positive (5 mm or larger, regardless of BCG history), reassess for active TB (see assessing for active TB); if this assessment is negative, continue isoniazid (with pyridoxine) for a total of 6 months. If the Mantoux test is negative, reassess for active TB and consider an interferon-gamma release assay: if the interferon-gamma release assay is negative then stop isoniazid (and pyridoxine) and give a BCG vaccination (see vaccination) if the interferon-gamma release assay is positive, reassess for active TB; if this assessment for active TB is negative, continue isoniazid (with pyridoxine) for a total of 6 months.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8695", "name": "child or young person", "draggable": "true", "value": {"name": "child or young person", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:child or young personhead:Child or young personIf a child or young person aged between 2 and 17 years has been in close contact with people with pulmonary or laryngeal TB: Offer Mantoux testing. If the Mantoux test is inconclusive, refer the child or young person to a TB specialist. If the Mantoux test is positive (5 mm or larger, regardless of BCG history), assess for active TB (see assessing for active TB); if this assessment is negative, offer them treatment for latent TB (see managing latent TB). If the initial Mantoux test is negative, offer an interferon-gamma release assay after 6 weeks and repeat the Mantoux test.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8775", "name": "interventions to encourage uptake of vaccinations", "draggable": "true", "value": {"name": "interventions to encourage uptake of vaccinations", "type": "information and support", "time": "", "intention": "", "description": "title:interventions to encourage uptake of vaccinationshead:Interventions to encourage uptake of vaccinationsDeliver the following interventions in primary care settings to improve uptake of BCG vaccination in people from eligible groups (as outlined in the Department of Health s Green Book): education and support for practice staff, including: raising awareness of relevant guidelines and case definition for at-risk groups promoting BCG and TB testing in eligible groups incorporating reminders for staff (prompts about eligibility for BCG) on practice computers (for example, embedded in medical records) consider financial incentives for practices for identifying eligible groups for BCG and TB testing reminders ( immunisations due ) and recall ( immunisations overdue ) for people who are eligible for vaccination or for parents of infants and children who are eligible, as outlined in the Green Book. (This could include written reminders, telephone calls from a member of staff or a computerised auto dialler, text messages or a combination of these approaches.)Use home visits to give information and advice to people who are disadvantaged on the importance of immunisation. This should be delivered by trained lay health workers, community-based healthcare staff or nurses.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8683", "name": "test for hiv and hepatitis prior to starting treatment for latent tuberculosis", "draggable": "true", "value": {"name": "test for hiv and hepatitis prior to starting treatment for latent tuberculosis", "type": "information and support", "time": "", "intention": "", "description": "title:test for hiv and hepatitis prior to starting treatment for latent tuberculosishead:Test for HIV and hepatitis prior to starting treatment for latent tuberculosisOffer testing for HIV before starting treatment for latent TB. See what NICE says on HIV testing and prevention.Offer adults testing, and consider testing children and young people, for hepatitis B and C before starting treatment for latent TB. See what NICE says on hepatitis B and C testing and chronic hepatitis B.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8708", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t8667", "name": "standard treatment", "draggable": "true", "value": {"name": "standard treatment", "type": "treatment related", "time": "", "intention": "ethambutol\nethambutol is used to treat tuberculosis (tb), and is usually given together with at least one other tuberculosis medicine.\nethambutol may also be used for purposes not listed in this medication guide.", "description": "title:standard treatmenthead:Standard treatmentOnce a diagnosis of active TB is made: the clinician responsible for care should refer the person with TB to a clinician with training in, and experience of, the specialised care of people with TB the TB service should include specialised nurses and health visitors active TB in children should be managed by a TB specialist (either a paediatrician with experience and training in TB or a general paediatrician with advice from a specialised clinician), and by paediatric trained nursing staff, where possible.If these arrangements are not possible, seek advice from more specialised colleagues throughout the treatment period.For people with active TB without CNS involvement, offer: isoniazid (with pyridoxine), rifampicin, pyrazinamide and ethambutol for 2 months, then isoniazid (with pyridoxine) and rifampicin for a further 4 months.Modify the treatment regimen according to drug susceptibility testing.For people with active TB of the CNS, offer: isoniazid (with pyridoxine), rifampicin, pyrazinamide and ethambutol for 2 months, then isoniazid (with pyridoxine) and rifampicin for a further 10 months.Modify the treatment regimen according to drug susceptibility testing.Test people (using a CT or MRI scan) with active spinal TB who have neurological signs or symptoms for CNS involvement. Manage direct spinal cord involvement (for example, a spinal cord tuberculoma) as TB of the CNS.For people with active spinal TB without CNS involvement, do not extend treatment beyond 6 months for residual effects (for example, persistent bending of the spine or vertebral loss).Test people with disseminated TB (including miliary TB) who have neurological signs or symptoms for CNS involvement. If there is evidence of CNS involvement, treat as for TB of the CNS.Treat active peripheral lymph node TB in people who have had an affected gland surgically removed with the standard recommended regimen.For people with active TB of the lymph nodes, do not routinely extend treatment beyond 6 months for newly enlarged lymph nodes or sinus formation, or for residual enlargement of the lymph nodes or sinuses.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8670", "name": "adjunctive corticosteroids", "draggable": "true", "value": {"name": "adjunctive corticosteroids", "type": "treatment related", "time": "", "intention": "dexamethasone\ndexamethasone is used to treat many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.\ndexamethasone may also be used for purposes not listed in this medication guide.\nshould dexamethasone sodim phosphate be used to treat upper respiratory tract infection?", "description": "title:adjunctive corticosteroidshead:Adjunctive corticosteroids subhead:Central nervous system tuberculosisAt the start of an anti-TB treatment regimen, offer people with active TB of the CNS dexamethasone or prednisolone, initially at a high dose with gradual withdrawal over 4\u20138 weeks. See example of suitable corticosteroid regimen for adults.At the start of an anti-TB treatment regimen, offer children and young people with active TB of the CNS dexamethasone or prednisolone. This should initially be at a high dose with gradual withdrawal over 4\u20138 weeks in line with the British National Formulary for Children.subhead:Pericardial tuberculosisAt the start of an anti-TB treatment regimen, offer adults with active pericardial TB oral prednisolone at a starting dose of 60 mg/day, gradually withdrawing it 2\u20133 weeks after starting treatment.At the start of an anti-TB treatment regimen, offer children and young people with active pericardial TB oral prednisolone in line with the British National Formulary for Children. Gradually withdraw prednisolone 2\u20133 weeks after starting treatment.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8669", "name": "multidrug resistant tuberculosis", "draggable": "true", "value": {"name": "multidrug resistant tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:multidrug-resistant tuberculosishead:Multidrug-resistant tuberculosisFor people with clinically suspected TB, a TB specialist should request rapid diagnostic nucleic acid amplification tests for rifampicin resistance on primary specimens if a risk assessment for multidrug resistance identifies any of the following risk factors: history of previous TB drug treatment, particularly if there was known to be poor adherence to that treatment contact with a known case of multidrug-resistant TB birth or residence in a country in which the World Health Organisation reports that a high proportion (5% or more) of new TB cases are multidrug-resistant.Start infection control measures (see also management and infection control in hospital).If the rapid diagnostic nucleic acid amplification test for rifampicin resistance is positive: continue infection control measures until pulmonary or laryngeal disease has been excluded  manage treatment along with a multidisciplinary team with experience of managing multidrug-resistant TB (see service organisation) offer a treatment regimen involving at least 6 drugs to which the mycobacterium is likely to be sensitive test for resistance to second-line drugs. If the rapid diagnostic nucleic acid amplification test for the M. tuberculosis complex is positive but rifampicin resistance is not detected, treat as drug-susceptible TB with the standard regimen. If the rapid diagnostic nucleic acid amplification test for the M. tuberculosis complex is negative in a person at high risk of multidrug-resistant TB: obtain further specimens for nucleic acid amplification testing and culture, if possible use rapid rifampicin resistance detection on cultures that become positive for the M. tuberculosis complex consider waiting for the results of further tests before starting treatment if the person is well if urgent treatment is needed, consider managing as multidrug-resistant TB until sensitivity results are available.When definitive phenotypic susceptibility results are available, modify treatment as needed.Consider more intensive clinical follow-up for people with multidrug-resistant TB. This includes people having directly observed therapy throughout treatment because of the complexity of treatment and risk of adverse events.Discuss the options for organising care for people with multidrug-resistant TB with clinicians who specialise in this. Seek the person s views and take them into account, and consider shared care.Consider surgery as a therapeutic intervention in people with potentially resectable multidrug-resistant disease if: optimal medical therapy under direct observation has not worked, or medical therapy is likely to fail because of extensively drug-resistant TB.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.3Rapid diagnosis of pulmonary tuberculosisSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8668", "name": "drug resistant tuberculosis", "draggable": "true", "value": {"name": "drug resistant tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:drug-resistant tuberculosishead:Drug-resistant tuberculosisConsider the treatment regimen for people with TB that is resistant to 1 drug for people with drug-resistant TB without CNS involvement.For people with drug-resistant TB and CNS involvement, involve a TB specialist with experience in managing drug-resistant TB in decisions about the most appropriate regimen and the duration of treatment.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8746", "name": "remit of control boards", "draggable": "true", "value": {"name": "remit of control boards", "type": "information and support", "time": "", "intention": "", "description": "title:remit of control boardshead:Remit of control boardsTB control boards should be responsible for developing a TB prevention and control programme based on the national strategy and evidence-based models.TB control boards should plan, oversee, support and monitor local TB control, including clinical and public health services and workforce planning.TB control boards should assess services in their area, identify gaps in provision and develop plans to meet these, including: undertaking a workforce review to support local or regional commissioning of TB services to meet the needs of their population  supporting development of appropriate services and pathways to improve access and early diagnosis  negotiating arrangements to cover the cost of additional services to address specific gaps in current TB control arrangements.TB control boards should consider integrating TB and HIV services,  joint clinics and training opportunities.TB control boards should ensure cohort review is undertaken at least quarterly, and the results are fed back to local clinical and TB networks. These should be agreed by accountable bodies such as clinical commissioning groups, trust management, regional Public Health England and centre directors and local authority directors of public health as agreed, all of whom should make sure appropriate action is taken.TB control boards should enable full and consistent use of national guidelines including: ensuring the needs of all people with TB, particularly under-served groups, are addressed  ensuring contact tracing arrangements are appropriate to the needs of the population (see contact tracing and testing)  assuring themselves that TB control in low-incidence areas is established and delivered appropriately  assuring themselves that multidrug-resistant TB is managed appropriately (see managing active TB) and mechanisms are in place to ensure: there is sufficient clinical expertise available to manage cases  regional multidrug-resistant TB networks take account of expert advice.TB control boards should develop links and partnerships and establish agreed relationships and lines of accountability between TB control boards and local clinical and TB networks. This includes engaging with other key stakeholders to ensure universal coverage of TB control efforts.TB control boards should collaborate with their local and regional partners. They should agree and establish regular monitoring, surveillance and reporting arrangements with all partners to support needs assessment and regular audit and evaluation.TB control boards should ensure there is sufficient capacity available to them to manage a sudden increase in demand such as:  TB contact investigations (such as incidents in congregate settings) large scale active case-finding initiatives in under-served groups in the community outbreaks in a variety of settings or sites where transmission risk may be high, including but not limited to schools, workplaces, hostels and prisons.To set up, monitor and evaluate a TB control programme, TB control boards should: agree plans within their partnerships to assess local services against the service specifications develop plans and quality standards to secure improvements establish quality assurance mechanisms and regular audits including but not limited to cohort review for all aspects of the TB control board partnership plans.See also staffing and training.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8712", "name": "contact tracing", "draggable": "true", "value": {"name": "contact tracing", "type": "information and support", "time": "", "intention": "", "description": "title:contact tracinghead:Contact tracingMultidisciplinary TB teams should follow NICE recommendations on contact tracing (see contact tracing and testing). They should coordinate contact investigations at places where the person with TB spends significant amounts of time. Examples could include pubs, crack houses, parks and community centres. The aim is to help identify people who have been living with them and people they frequently socialise with.Multidisciplinary TB teams dealing with under-served groups should work alongside health and social care professionals known to them to help trace relevant contacts. They should also work in partnership with voluntary, community and statutory organisations to conduct outreach contact investigations.Multidisciplinary TB teams should, if available and appropriate, encourage peer educators or TB programme support workers to help with contact investigations involving under-served people who have complex social networks.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6280", "name": "emergency department staff", "draggable": "true", "value": {"name": "emergency department staff", "type": "information and support", "time": "", "intention": "", "description": "title:emergency department staffhead:Emergency department staff Multidisciplinary TB teams should consider training emergency department staff in: using approaches that do not stigmatise people with TB giving people with TB appropriate advice (see providing information and management and infection control in hospital.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6269", "name": "screening for new staff", "draggable": "true", "value": {"name": "screening for new staff", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:screening for new staffhead:Screening for new staffEmployees new to the NHS who will be working with patients or clinical specimens should not start work until they have completed a TB screen or health check, or documentary evidence is provided of such screening having taken place within the preceding 12 months.Health checks for employees new to the NHS who will have contact with patients or clinical materials should include: assessment of personal or family history of TB asking about symptoms and signs, possibly by questionnaire documentary evidence of TB skin (or interferon-gamma release assay) testing within the past 5 years and/or BCG scar check by an occupational health professional, not relying on the applicant s personal assessment.Employees who will be working with patients or clinical specimens and who are Mantoux- or interferon-gamma release assay-negative should have an individual risk assessment for HIV infection before BCG vaccination is given.Offer BCG vaccination to employees of any age who are new to the NHS and are from countries of high TB incidence, or who have had contact with patients in settings with a high TB prevalence, and, who are Mantoux-negative.If a new employee from the UK or other low-incidence setting, who has not had a BCG vaccination, has a positive Mantoux test and a positive interferon-gamma release assay, they should have a medical assessment and a chest X-ray. They should be referred to a TB clinic to determine whether they need TB treatment if the chest X-ray is abnormal, or to determine whether they need treatment of latent TB infection if the chest X-ray is normal.If a prospective or current healthcare worker who is Mantoux-negative declines BCG vaccination, explain the risks and supplement the oral explanation with written advice. If the person still declines BCG vaccination, he or she should not work where there is a risk of exposure to TB. The employer will need to consider each case individually, taking account of employment and health and safety obligations.Screen clinical students, agency and locum staff and contract ancillary workers who have contact with patients or clinical materials for TB to the same standard as new employees in healthcare environments, according to the recommendations set out above. Seek documentary evidence of screening to this standard from locum agencies and contractors who carry out their own screening.NHS trusts arranging care for NHS patients in non-NHS settings should ensure that healthcare workers who have contact with patients or clinical materials in these settings have been screened for TB to the same standard as new employees in NHS settings.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6276", "name": "back to service organisation", "draggable": "true", "value": {"name": "back to service organisation", "type": "cancer ralated", "time": "", "intention": "", "description": "title:back to service organisation", "drug": {}}}, {"category": "treatment", "id": "t6170", "name": "when to take cultures and start treatment", "draggable": "true", "value": {"name": "when to take cultures and start treatment", "type": "treatment related", "time": "", "intention": "", "description": "title:when to take cultures and start treatmenthead:When to take cultures and start treatmentIf TB is a possibility, microbiology staff should consider carrying out TB culture on samples, even if it is not requested. If there are clinical signs and symptoms consistent with a diagnosis of TB, start treatment without waiting for culture results.Consider completing the standard recommended regimen, even if subsequent culture results are negative.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6173", "name": "management and infection control in hospital", "draggable": "true", "value": {"name": "management and infection control in hospital", "type": "treatment related", "time": "", "intention": "", "description": "title:management and infection control in hospital", "drug": {}}}, {"category": "treatment", "id": "t6287", "name": "interventions to encourage uptake of vaccinations", "draggable": "true", "value": {"name": "interventions to encourage uptake of vaccinations", "type": "information and support", "time": "", "intention": "", "description": "title:interventions to encourage uptake of vaccinationshead:Interventions to encourage uptake of vaccinationsDeliver the following interventions in primary care settings to improve uptake of BCG vaccination in people from eligible groups (as outlined in the Department of Health s Green Book): education and support for practice staff, including: raising awareness of relevant guidelines and case definition for at-risk groups promoting BCG and TB testing in eligible groups incorporating reminders for staff (prompts about eligibility for BCG) on practice computers (for example, embedded in medical records) consider financial incentives for practices for identifying eligible groups for BCG and TB testing reminders ( immunisations due ) and recall ( immunisations overdue ) for people who are eligible for vaccination or for parents of infants and children who are eligible, as outlined in the Green Book. (This could include written reminders, telephone calls from a member of staff or a computerised auto dialler, text messages or a combination of these approaches.)Use home visits to give information and advice to people who are disadvantaged on the importance of immunisation. This should be delivered by trained lay health workers, community-based healthcare staff or nurses.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6220", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t6207", "name": "child or young person", "draggable": "true", "value": {"name": "child or young person", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:child or young personhead:Child or young personIf a child or young person aged between 2 and 17 years has been in close contact with people with pulmonary or laryngeal TB: Offer Mantoux testing. If the Mantoux test is inconclusive, refer the child or young person to a TB specialist. If the Mantoux test is positive (5 mm or larger, regardless of BCG history), assess for active TB (see assessing for active TB); if this assessment is negative, offer them treatment for latent TB (see managing latent TB). If the initial Mantoux test is negative, offer an interferon-gamma release assay after 6 weeks and repeat the Mantoux test.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6206", "name": "infant", "draggable": "true", "value": {"name": "infant", "type": "information and support", "time": "", "intention": "", "description": "title:infanthead:InfantIf a child aged between 4 weeks and 2 years has been in close contact with people with smear-positive pulmonary or laryngeal TB who have not had at least 2 weeks of anti-TB treatment: Assess for active TB (see assessing for active TB). Start treatment for latent TB (see managing latent TB) and carry out a Mantoux test. If the Mantoux test is inconclusive, refer the child to a TB specialist. If the Mantoux test is positive (5 mm or larger, regardless of BCG history), reassess for active TB; if this assessment is negative, complete treatment for latent TB. If the Mantoux test is negative, continue treatment for latent TB, reassess for active TB after 6 weeks and repeat the Mantoux test: if the Mantoux test is negative, consider an interferon-gamma release assay if the interferon-gamma release assay is negative, treatment for latent TB may be stopped; give a BCG vaccination (see vaccination) if the child has not already had one  if either test is positive, reassess for active TB; if this assessment is negative, complete treatment for latent TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6208", "name": "adult", "draggable": "true", "value": {"name": "adult", "type": "information and support", "time": "", "intention": "", "description": "title:adulthead:AdultOffer Mantoux testing to diagnose latent TB in adults aged 18 to 65 who are close contacts of a person with pulmonary or laryngeal TB. If the Mantoux test is inconclusive, refer the person to a TB specialist.  If the Mantoux test is positive (an induration of 5 mm or larger, regardless of BCG history), assess for active TB (see assessing for active TB). If the Mantoux test is positive but a diagnosis of active TB is excluded, consider an interferon gamma release assay if more evidence of infection is needed to decide on treatment. This could be, for example, if the person needs enhanced case management or if there could be adverse events from treatment. If the Mantoux is positive, and if an IGRA was done and that is also positive, offer them treatment for latent TB infection (see managing latent TB).  In asymptomatic close contacts older than 65 years, consider a chest X-ray (if there are no contraindications), possibly leading to further investigation for active TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6205", "name": "neonate", "draggable": "true", "value": {"name": "neonate", "type": "information and support", "time": "", "intention": "isoniazid\nisoniazid is used to treat and to prevent tuberculosis (tb). you may need to take other tb medicines in combination with isoniazid.\nisoniazid may also be used for purposes not listed in this medication guide.", "description": "title:neonatehead:Neonate If a neonate has been in close contact with people with smear-positive pulmonary or laryngeal TB who have not had at least 2 weeks of anti-TB treatment: Assess for active TB (see assessing for active TB). Start isoniazid (with pyridoxine). Carry out Mantoux test after 6 weeks of treatment. If the Matoux test is inconclusive, refer the child to a TB specialist. If the Mantoux test is positive (5 mm or larger, regardless of BCG history), reassess for active TB (see assessing for active TB); if this assessment is negative, continue isoniazid (with pyridoxine) for a total of 6 months. If the Mantoux test is negative, reassess for active TB and consider an interferon-gamma release assay: if the interferon-gamma release assay is negative then stop isoniazid (and pyridoxine) and give a BCG vaccination (see vaccination) if the interferon-gamma release assay is positive, reassess for active TB; if this assessment for active TB is negative, continue isoniazid (with pyridoxine) for a total of 6 months.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6252", "name": "managing active tuberculosis", "draggable": "true", "value": {"name": "managing active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:managing active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6251", "name": "managing latent tuberculosis", "draggable": "true", "value": {"name": "managing latent tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:managing latent tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6258", "name": "remit of control boards", "draggable": "true", "value": {"name": "remit of control boards", "type": "information and support", "time": "", "intention": "", "description": "title:remit of control boardshead:Remit of control boardsTB control boards should be responsible for developing a TB prevention and control programme based on the national strategy and evidence-based models.TB control boards should plan, oversee, support and monitor local TB control, including clinical and public health services and workforce planning.TB control boards should assess services in their area, identify gaps in provision and develop plans to meet these, including: undertaking a workforce review to support local or regional commissioning of TB services to meet the needs of their population  supporting development of appropriate services and pathways to improve access and early diagnosis  negotiating arrangements to cover the cost of additional services to address specific gaps in current TB control arrangements.TB control boards should consider integrating TB and HIV services,  joint clinics and training opportunities.TB control boards should ensure cohort review is undertaken at least quarterly, and the results are fed back to local clinical and TB networks. These should be agreed by accountable bodies such as clinical commissioning groups, trust management, regional Public Health England and centre directors and local authority directors of public health as agreed, all of whom should make sure appropriate action is taken.TB control boards should enable full and consistent use of national guidelines including: ensuring the needs of all people with TB, particularly under-served groups, are addressed  ensuring contact tracing arrangements are appropriate to the needs of the population (see contact tracing and testing)  assuring themselves that TB control in low-incidence areas is established and delivered appropriately  assuring themselves that multidrug-resistant TB is managed appropriately (see managing active TB) and mechanisms are in place to ensure: there is sufficient clinical expertise available to manage cases  regional multidrug-resistant TB networks take account of expert advice.TB control boards should develop links and partnerships and establish agreed relationships and lines of accountability between TB control boards and local clinical and TB networks. This includes engaging with other key stakeholders to ensure universal coverage of TB control efforts.TB control boards should collaborate with their local and regional partners. They should agree and establish regular monitoring, surveillance and reporting arrangements with all partners to support needs assessment and regular audit and evaluation.TB control boards should ensure there is sufficient capacity available to them to manage a sudden increase in demand such as:  TB contact investigations (such as incidents in congregate settings) large scale active case-finding initiatives in under-served groups in the community outbreaks in a variety of settings or sites where transmission risk may be high, including but not limited to schools, workplaces, hostels and prisons.To set up, monitor and evaluate a TB control programme, TB control boards should: agree plans within their partnerships to assess local services against the service specifications develop plans and quality standards to secure improvements establish quality assurance mechanisms and regular audits including but not limited to cohort review for all aspects of the TB control board partnership plans.See also staffing and training.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6181", "name": "multidrug resistant tuberculosis", "draggable": "true", "value": {"name": "multidrug resistant tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:multidrug-resistant tuberculosishead:Multidrug-resistant tuberculosisFor people with clinically suspected TB, a TB specialist should request rapid diagnostic nucleic acid amplification tests for rifampicin resistance on primary specimens if a risk assessment for multidrug resistance identifies any of the following risk factors: history of previous TB drug treatment, particularly if there was known to be poor adherence to that treatment contact with a known case of multidrug-resistant TB birth or residence in a country in which the World Health Organisation reports that a high proportion (5% or more) of new TB cases are multidrug-resistant.Start infection control measures (see also management and infection control in hospital).If the rapid diagnostic nucleic acid amplification test for rifampicin resistance is positive: continue infection control measures until pulmonary or laryngeal disease has been excluded  manage treatment along with a multidisciplinary team with experience of managing multidrug-resistant TB (see service organisation) offer a treatment regimen involving at least 6 drugs to which the mycobacterium is likely to be sensitive test for resistance to second-line drugs. If the rapid diagnostic nucleic acid amplification test for the M. tuberculosis complex is positive but rifampicin resistance is not detected, treat as drug-susceptible TB with the standard regimen. If the rapid diagnostic nucleic acid amplification test for the M. tuberculosis complex is negative in a person at high risk of multidrug-resistant TB: obtain further specimens for nucleic acid amplification testing and culture, if possible use rapid rifampicin resistance detection on cultures that become positive for the M. tuberculosis complex consider waiting for the results of further tests before starting treatment if the person is well if urgent treatment is needed, consider managing as multidrug-resistant TB until sensitivity results are available.When definitive phenotypic susceptibility results are available, modify treatment as needed.Consider more intensive clinical follow-up for people with multidrug-resistant TB. This includes people having directly observed therapy throughout treatment because of the complexity of treatment and risk of adverse events.Discuss the options for organising care for people with multidrug-resistant TB with clinicians who specialise in this. Seek the person s views and take them into account, and consider shared care.Consider surgery as a therapeutic intervention in people with potentially resectable multidrug-resistant disease if: optimal medical therapy under direct observation has not worked, or medical therapy is likely to fail because of extensively drug-resistant TB.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.3Rapid diagnosis of pulmonary tuberculosisSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6179", "name": "standard treatment", "draggable": "true", "value": {"name": "standard treatment", "type": "treatment related", "time": "", "intention": "ethambutol\nethambutol is used to treat tuberculosis (tb), and is usually given together with at least one other tuberculosis medicine.\nethambutol may also be used for purposes not listed in this medication guide.", "description": "title:standard treatmenthead:Standard treatmentOnce a diagnosis of active TB is made: the clinician responsible for care should refer the person with TB to a clinician with training in, and experience of, the specialised care of people with TB the TB service should include specialised nurses and health visitors active TB in children should be managed by a TB specialist (either a paediatrician with experience and training in TB or a general paediatrician with advice from a specialised clinician), and by paediatric trained nursing staff, where possible.If these arrangements are not possible, seek advice from more specialised colleagues throughout the treatment period.For people with active TB without CNS involvement, offer: isoniazid (with pyridoxine), rifampicin, pyrazinamide and ethambutol for 2 months, then isoniazid (with pyridoxine) and rifampicin for a further 4 months.Modify the treatment regimen according to drug susceptibility testing.For people with active TB of the CNS, offer: isoniazid (with pyridoxine), rifampicin, pyrazinamide and ethambutol for 2 months, then isoniazid (with pyridoxine) and rifampicin for a further 10 months.Modify the treatment regimen according to drug susceptibility testing.Test people (using a CT or MRI scan) with active spinal TB who have neurological signs or symptoms for CNS involvement. Manage direct spinal cord involvement (for example, a spinal cord tuberculoma) as TB of the CNS.For people with active spinal TB without CNS involvement, do not extend treatment beyond 6 months for residual effects (for example, persistent bending of the spine or vertebral loss).Test people with disseminated TB (including miliary TB) who have neurological signs or symptoms for CNS involvement. If there is evidence of CNS involvement, treat as for TB of the CNS.Treat active peripheral lymph node TB in people who have had an affected gland surgically removed with the standard recommended regimen.For people with active TB of the lymph nodes, do not routinely extend treatment beyond 6 months for newly enlarged lymph nodes or sinus formation, or for residual enlargement of the lymph nodes or sinuses.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6182", "name": "adjunctive corticosteroids", "draggable": "true", "value": {"name": "adjunctive corticosteroids", "type": "treatment related", "time": "", "intention": "dexamethasone\ndexamethasone is used to treat many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.\ndexamethasone may also be used for purposes not listed in this medication guide.\nshould dexamethasone sodim phosphate be used to treat upper respiratory tract infection?", "description": "title:adjunctive corticosteroidshead:Adjunctive corticosteroids subhead:Central nervous system tuberculosisAt the start of an anti-TB treatment regimen, offer people with active TB of the CNS dexamethasone or prednisolone, initially at a high dose with gradual withdrawal over 4\u20138 weeks. See example of suitable corticosteroid regimen for adults.At the start of an anti-TB treatment regimen, offer children and young people with active TB of the CNS dexamethasone or prednisolone. This should initially be at a high dose with gradual withdrawal over 4\u20138 weeks in line with the British National Formulary for Children.subhead:Pericardial tuberculosisAt the start of an anti-TB treatment regimen, offer adults with active pericardial TB oral prednisolone at a starting dose of 60 mg/day, gradually withdrawing it 2\u20133 weeks after starting treatment.At the start of an anti-TB treatment regimen, offer children and young people with active pericardial TB oral prednisolone in line with the British National Formulary for Children. Gradually withdraw prednisolone 2\u20133 weeks after starting treatment.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6180", "name": "drug resistant tuberculosis", "draggable": "true", "value": {"name": "drug resistant tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:drug-resistant tuberculosishead:Drug-resistant tuberculosisConsider the treatment regimen for people with TB that is resistant to 1 drug for people with drug-resistant TB without CNS involvement.For people with drug-resistant TB and CNS involvement, involve a TB specialist with experience in managing drug-resistant TB in decisions about the most appropriate regimen and the duration of treatment.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6195", "name": "test for hiv and hepatitis prior to starting treatment for latent tuberculosis", "draggable": "true", "value": {"name": "test for hiv and hepatitis prior to starting treatment for latent tuberculosis", "type": "information and support", "time": "", "intention": "", "description": "title:test for hiv and hepatitis prior to starting treatment for latent tuberculosishead:Test for HIV and hepatitis prior to starting treatment for latent tuberculosisOffer testing for HIV before starting treatment for latent TB. See what NICE says on HIV testing and prevention.Offer adults testing, and consider testing children and young people, for hepatitis B and C before starting treatment for latent TB. See what NICE says on hepatitis B and C testing and chronic hepatitis B.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6235", "name": "person with active tuberculosis", "draggable": "true", "value": {"name": "person with active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6239", "name": "person with multidrug resistant tuberculosis", "draggable": "true", "value": {"name": "person with multidrug resistant tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person with multidrug-resistant tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6224", "name": "contact tracing", "draggable": "true", "value": {"name": "contact tracing", "type": "information and support", "time": "", "intention": "", "description": "title:contact tracinghead:Contact tracingMultidisciplinary TB teams should follow NICE recommendations on contact tracing (see contact tracing and testing). They should coordinate contact investigations at places where the person with TB spends significant amounts of time. Examples could include pubs, crack houses, parks and community centres. The aim is to help identify people who have been living with them and people they frequently socialise with.Multidisciplinary TB teams dealing with under-served groups should work alongside health and social care professionals known to them to help trace relevant contacts. They should also work in partnership with voluntary, community and statutory organisations to conduct outreach contact investigations.Multidisciplinary TB teams should, if available and appropriate, encourage peer educators or TB programme support workers to help with contact investigations involving under-served people who have complex social networks.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8769", "name": "non clinical support staff", "draggable": "true", "value": {"name": "non clinical support staff", "type": "information and support", "time": "", "intention": "", "description": "title:non-clinical support staffhead:Non-clinical support staffTB control boards and local TB services should consider employing trained, non-clinically qualified professionals to work alongside clinical teams to agreed protocols, and to contribute to a variety of activities. Examples of this may include awareness raising and supporting people to attend appointments (including other health and social care appointments). They could also help with collecting samples, contact tracing, case management including directly observed therapy and cohort review, or any other aspect of the service if: they are trained to deliver the intervention or processes effectively they are supported, mentored and supervised by a named case manager, such as a TB nurse they have the skills to monitor, evaluate and report on their work practices and outcomes to maintain a process of ongoing evaluation and service improvement in relation to cohort review (see service organisation).TB control boards should ensure that people working in the TB service have the right knowledge, engagement, advocacy and communication skills to meet the needs (for example, language, cultural or other requirements) of all the groups they may work with.Commissioners should consider taking into account different needs across traditional geographical and organisational boundaries. Put agreements in place so that staff can work across these boundaries, covering the whole service or TB control board area if appropriate.Commissioners and TB control boards should ensure they put in place appropriate governance (including clear lines of accountability and extension of scope of practice) and data sharing practices and agreements. This includes ensuring they are part of service level agreements between NHS and non-NHS services, for example, the third sector or local government and appropriate training has been completed.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8659", "name": "extrapulmonary tuberculosis", "draggable": "true", "value": {"name": "extrapulmonary tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:extrapulmonary tuberculosishead:Extrapulmonary tuberculosisDiscuss the advantages and disadvantages of both biopsy and needle aspiration with the patient, with the aim of obtaining adequate material for diagnosis.Do not place part or all of any of the samples in formalin (or other fixative agent) when sending for TB culture.Think about a diagnosis of extrapulmonary TB even if rapid diagnostic tests in, for example, cerebrospinal fluid, pleural fluid or ascitic fluid are negative.Offer all patients presenting with extrapulmonary TB a chest X-ray and, if possible, culture of a spontaneously-produced respiratory sample to exclude or confirm coexisting pulmonary TB. Also, consider site-specific tests as described below to exclude or confirm additional sites of TB.Refer to an expert for sites not listed here, including TB of the eye and other rare sites of disease.subhead:Bone and joint tuberculosisUse the site-specific investigations for bone and joint TB to diagnose and assess bone and joint TB.subhead:Central nervous system tuberculosisUse the site-specific investigations for central nervous system TB to diagnose and assess CNS TB.Offer a CT or MRI scan to people in whom CNS involvement is suspected. Offer treatment for TB meningitis if clinical signs and other laboratory findings are consistent with the diagnosis, even if a rapid diagnostic test is negative.subhead:Disseminated tuberculosisUse the site-specific investigations for disseminated TB to diagnose and assess disseminated TB. subhead:Gastrointestinal tuberculosisUse the site-specific investigations for gastrointestinal TB to diagnose and assess gastrointestinal TB.subhead:Genitourinary tuberculosisUse the site-specific investigations for genitourinary TB to diagnose and assess genitourinary TB.subhead:Localised tuberculous abscessUse the site-specific investigations for localised tuberculous abscess to diagnose and assess TB in a localised, tuberculous abscess at a site other than a lymph node.subhead:Lymph node tuberculosisUse the site-specific investigations for lymph node TB to diagnose and assess lymph node TB (including intrathoracic mediastinal adenopathy).subhead:Pericardial tuberculosisUse the site-specific investigations for pericardial TB to diagnose and assess pericardial TB.subhead:Pleural tuberculosisUse the site-specific investigations for pleural TB to diagnose and assess pleural TB.subhead:Skin tuberculosisUse the site-specific investigations for skin TB to diagnose and assess skin TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8660", "name": "pulmonary tuberculosis", "draggable": "true", "value": {"name": "pulmonary tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:pulmonary tuberculosishead:Pulmonary tuberculosisTake a chest X-ray; do further diagnostic investigations (as detailed below and summarised in diagnostic investigations for pulmonary TB) if chest X-ray appearances suggest TB.Send multiple respiratory samples (3 deep cough sputum samples, preferably including 1 early morning sample) for TB microscopy and culture. This should be before starting treatment if possible or, failing that, within 7 days of starting treatment in people with life-threatening disease. Obtain spontaneously-produced, deep cough sputum samples if possible, otherwise use: 3 gastric lavages or 3 inductions of sputum in children and young people, or induction of sputum or bronchoscopy and lavage in adults (see also criteria for hospital admission. Laboratory practices should be in accordance with the UK Standards for Microbiology Investigations.Send samples for TB culture from autopsy samples if pulmonary or laryngeal TB is a possibility.subhead:Children and young peopleIn children aged 15 years or younger with suspected pulmonary TB, offer rapid diagnostic nucleic acid amplification tests for the M. tuberculosis complex (M.  tuberculosis, M.  bovis, M.  africanum). Usually only 1 nucleic acid amplification test is needed per specimen type (for example, spontaneous sputum, induced sputum or gastric lavage; see diagnostic investigations for pulmonary TB.)In young people aged 16\u201318 years use the same criteria as in adults to decide whether to request rapid diagnostic nucleic acid amplification tests.Either a paediatrician with experience and training in TB or a general paediatrician with advice from a specialised clinician should investigate and manage TB in children and young people.An expert in paediatric TB may request an interferon gamma-release assay and tuberculin skin tests. Interpret these together with other diagnostic tools (such as history taking, clinical examination and imaging).subhead:AdultsRequest rapid diagnostic nucleic acid amplification tests for the M. tuberculosis complex (M. tuberculosis, M.  bovis, M.  africanum) on primary specimens (see diagnostic investigations for pulmonary TB) if there is clinical suspicion of TB disease, and: the person has HIV, or rapid information about mycobacterial species would alter the person s care, or the need for a large contact tracing initiative is being explored.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.3Rapid diagnosis of pulmonary tuberculosisSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8728", "name": "criteria for admission or transfer", "draggable": "true", "value": {"name": "criteria for admission or transfer", "type": "treatment related", "time": "", "intention": "", "description": "title:criteria for admission or transferhead:Criteria for admission or transfer If people with suspected or known infectious multidrug-resistant TB are admitted to hospital, admit them to a negative-pressure room. If none is available locally, transfer them to a hospital that has these facilities and a clinician experienced in managing complex drug-resistant cases. Carry out care in a negative-pressure room for people with: suspected multidrug-resistant TB, until non-resistance is confirmed confirmed multidrug-resistant TB, until they have 3 negative smears at weekly intervals and ideally have a negative culture.Ensure negative-pressure rooms used for infection control in multidrug-resistant TB meet the standards of the Interdepartmental Working Group on Tuberculosis, and are clearly identified for staff, for example by a standard sign. Keep such signs up to date.As soon as possible, explore options to reduce the psychosocial impact of prolonged isolation. For example, through providing free access to internet, telephone and television, and accompanied walks in the open air.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8724", "name": "criteria for admission", "draggable": "true", "value": {"name": "criteria for admission", "type": "treatment related", "time": "", "intention": "", "description": "title:criteria for admissionhead:Criteria for admissionDo not admit people with suspected infectious TB or confirmed pulmonary TB to a ward containing people who are immunocompromised, such as transplant recipients, people with HIV and those on anti-tumour necrosis factor alpha or other biologics, unless they can be cared for in a negative-pressure room on the same ward.Care for people with a continuing clinical or public health need for admission with pulmonary TB in a single room (as a minimum) until they have completed 2 weeks of the standard treatment regimen (see managing active TB) if they: are unlikely to be rifampicin resistant (that is, do not have risk factors for multidrug-resistant TB), or have negative rifampicin resistance on nucleic acid amplification tests or culture.Consider de-escalating isolation after 2 weeks of treatment, taking into account the risks and benefits, if: the person is showing tolerance to the prescribed treatment there is agreement to adhere to treatment there is resolution of cough there is definite clinical improvement on treatment; for example, remaining afebrile for a week there are not immunocompromised people, such as transplant recipients, people with HIV and those on anti-tumour necrosis factor alpha or other biologics, in the same accommodation the person s initial smear grade was not high; for example, 2 or less there is not extensive pulmonary involvement, including cavitation there is no laryngeal TB.In people who may have TB, only carry out aerosol-generating procedures such as bronchoscopy, sputum induction or nebuliser treatment in an appropriately engineered and ventilated area (ideally a negative-pressure room).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8741", "name": "contact tracing and testing", "draggable": "true", "value": {"name": "contact tracing and testing", "type": "information and support", "time": "", "intention": "", "description": "title:contact tracing and testing", "drug": {}}}, {"category": "treatment", "id": "t8758", "name": "testing for latent tuberculosis for new staff", "draggable": "true", "value": {"name": "testing for latent tuberculosis for new staff", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:testing for latent tuberculosis for new staffhead:Testing for latent tuberculosis in new staffOffer a Mantoux test to new NHS employees who will be in contact with patients or clinical materials, if the employees: are not new entrants from high-incidence countries and have not had BCG vaccination (for example, they are without a BCG scar, other documentation or a reliable history).If the Mantoux test is positive, offer an interferon-gamma release assay. If this is positive, assess them for active TB (see assessing for active TB): if this assessment is negative, offer them treatment for latent TB (see managing latent TB). Offer a Mantoux test to new NHS employees who are from a high-incidence country.  If the Mantoux test is positive (5 mm or larger, regardless of BCG history), assess for active TB (see assessing for active TB): if this assessment is negative, offer them treatment for latent TB infection (see managing latent TB). If Mantoux testing is unavailable, offer an interferon-gamma release assay.Offer an interferon-gamma release assay to new NHS employees who have had contact with patients in settings where TB is highly prevalent.  If the interferon-gamma release assay is positive, assess for active TB (see assessing for active TB) and If this assessment is negative, offer them treatment for latent TB infection (see managing latent TB).Healthcare workers who are immunocompromised should be screened in the same way as other people who are immunocompromised (see high-risk groups).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8697", "name": "when to offer bcg vaccination", "draggable": "true", "value": {"name": "when to offer bcg vaccination", "type": "information and support", "time": "", "intention": "", "description": "title:when to offer bcg vaccinationhead:When to offer BCG vaccinationOffer BCG vaccination to Mantoux-negative contacts of people with pulmonary and laryngeal TB (see vaccination) if they: have not been vaccinated previously (that is, there is no adequate documentation or a BCG scar), and are aged 35 years or younger, or are aged 36 years and older and a healthcare or laboratory worker who has contact with patients or clinical materials.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8776", "name": "vaccination for neonates", "draggable": "true", "value": {"name": "vaccination for neonates", "type": "information and support", "time": "", "intention": "", "description": "title:vaccination for neonateshead:Vaccination for neonatesIdentify babies eligible for vaccination (in line with the Green Book) before birth, ideally through antenatal services.Discuss neonatal BCG vaccination for any baby at increased risk of TB with the parents or legal guardian.Preferably vaccinate babies at increased risk of TB before discharge from hospital or before handover from midwifery to primary care. Otherwise, vaccinate as soon as possible afterwards, for example, at the 6-week postnatal check.Incorporate computer reminders into maternity service (obstetrics) IT systems for staff, to identify and offer BCG vaccination to babies eligible for vaccination.Provide education and training for postnatal ward staff, midwives, health visitors and other clinicians on identifying babies eligible for vaccination, local service information and providing BCG vaccination, including: case definition for at-risk groups to be offered vaccination information about the local BCG vaccination policy that can be given verbally, in writing or in any other appropriate format (see providing information) to parents and carers at the routine examination of the baby before discharge local service information about BCG vaccination, such as pre-discharge availability of neonatal vaccination, local BCG clinics and referral for BCG vaccination if this is not available in maternity services administration of BCG vaccination and contraindications.Primary care providers with a high incidence of TB should consider vaccinating all neonates soon after birth.In areas with a low incidence of TB (see Public Health England s TB rate bands published in its annual report), primary care organisations should offer BCG vaccination to selected neonates who: were born in an area with a high incidence of TB, or have 1 or more parents or grandparents who were born in a high-incidence country, or have a family history of TB in the past 5 years.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8777", "name": "vaccination for infants and older children", "draggable": "true", "value": {"name": "vaccination for infants and older children", "type": "information and support", "time": "", "intention": "", "description": "title:vaccination for infants and older childrenhead:Vaccination for infants and older childrenRoutine BCG vaccination is not recommended for children aged 10\u201314 years. Healthcare professionals should opportunistically identify unvaccinated children older than 4 weeks and younger than 16 years at increased risk of TB who would have qualified for neonatal BCG and provide Mantoux testingAt the time of publication (January 2016) the BNF states: The Mantoux test is recommended for tuberculin skin testing, but no licensed preparation is currently available.  and BCG vaccination (if Mantoux-negative). This opportunistic vaccination should be in line with the Department of Health s Green Book.Mantoux testing should not be done routinely before BCG vaccination in children younger than 6 years unless they have a history of residence or prolonged stay (more than 1 month) in a country with a high incidence of TB.See what NICE says on immunisations for under 19s. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8684", "name": "treatment for latent tuberculosis", "draggable": "true", "value": {"name": "treatment for latent tuberculosis", "type": "disease name and patient related", "time": "", "intention": "isoniazid\nisoniazid is used to treat and to prevent tuberculosis (tb). you may need to take other tb medicines in combination with isoniazid.\nisoniazid may also be used for purposes not listed in this medication guide.", "description": "title:treatment for latent tuberculosishead:Treatment for latent tuberculosisFor people, including those with HIV, aged younger than 65 years with evidence of latent TB who have been in close contact with people who have suspected infectious or confirmed active pulmonary or laryngeal drug-sensitive TB offer either of the following drug treatments: 3 months of isoniazid (with pyridoxine) and rifampicin, or 6 months of isoniazid (with pyridoxine).Base the choice of regimen on the person s clinical circumstances. Offer: 3 months of isoniazid (with pyridoxine) and rifampicin to people younger than 35 years if hepatotoxicity is a concern after an assessment of both liver function (including transaminase levels) and risk factors 6 months of isoniazid (with pyridoxine) if interactions with rifamycins are a concern, for example, in people with HIV or who have had a transplant.Clearly explain the risks and potential benefits of each treatment regimen. In discussion with the person, select a suitable regimen if they wish to proceed with preventive treatment.For adults between the ages of 35 and 65 years, offer drug treatments only if hepatotoxicity is not a concern.Ensure people having treatment for latent TB who also have social risk factors, such as misusing alcohol or drugs or being homeless, are linked to support services. They should also have an assessment of social needs and stability, including potential barriers to adherence or treatment completion.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8685", "name": "managing tuberculosis and liver disease", "draggable": "true", "value": {"name": "managing tuberculosis and liver disease", "type": "treatment related", "time": "", "intention": "", "description": "title:managing tuberculosis and liver diseasehead:Managing tuberculosis and liver diseaseIf a person also has severe liver disease, for example, Child-Pugh level B or C, work with a specialist multidisciplinary team with experience of managing TB and liver disease.Manage treatment with caution, ensuring careful monitoring of liver function, in: people with non-severe liver disease people with abnormal liver function (including abnormal transaminase levels) before starting treatment for latent TB  people who misuse alcohol or drugs.See what NICE says on liver conditions and alcohol-use disorders.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8671", "name": "dosing regimens", "draggable": "true", "value": {"name": "dosing regimens", "type": "treatment related", "time": "", "intention": "", "description": "title:dosing regimenshead:Dosing regimensUse fixed-dose combination tablets as part of any TB treatment regimen.Do not offer anti-TB treatment dosing regimens of fewer than 3 times per week.Offer a daily dosing schedule to people with active pulmonary TB.Consider a daily dosing schedule as first choice in people with active extrapulmonary TB.Consider 3 times weekly dosing for people with active TB only if:  risk assessment identifies a need for directly observed therapy and enhanced case management and daily directly observed therapy is not possible.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8747", "name": "commissioning arrangements", "draggable": "true", "value": {"name": "commissioning arrangements", "type": "treatment related", "time": "", "intention": "", "description": "title:commissioning arrangementshead:Commissioning arrangementsClinical commissioning groups and local authority public health teams working in partnership with Public Health England and NHS England should consider collaborative commissioning arrangements through TB control boards. This could, for example, include working with 1 or more clinical commissioning groups to cover a major metropolitan district, region or TB control board area taking into account:  local TB incidence local at-risk populations and their movements across different geographical areas existing service configurations for organisations involved in TB prevention and control the need to share services, such as mobile X-ray facilities and outreach incident teams across different geographical areas.TB control boards should develop TB prevention and control programmes working with commissioners, Public Health England and NHS England. The board should include clinical, commissioning (from clinical commissioning groups, local government and the voluntary sector) and public health leaders and people with TB or groups who advocate on their behalf from across the control board area. This may include identifying a lead clinical commissioning group, which should be led by an executive director of that commissioning group working with the board. Feedback mechanisms between local commissioning groups and the TB control board should be developed.An executive director of local commissioning groups, working with the local director of public health or another nominated public health consultant, should lead implementation of the programme in their locality. The lead should ensure a comprehensive prevention and control programme is commissioned to support the level of need and that they work with the control board regularly.Working together through TB control boards and local networks, commissioners, local government and Public Health England should ensure TB prevention and control programmes set up multidisciplinary TB teams to provide all TB services. They should ensure that local strategy and service commissioning focuses on an end-to-end pathway.Working together through TB control boards, commissioners and Public Health England should ensure the TB prevention and control programme is informed by relevant NICE guidance and developed in collaboration with clinical services. It should also be informed by the standard minimum data set collected through local needs assessment and service audit.Working together through TB control boards, commissioners and Public Health England should ensure the TB prevention and control programme targets all ages, including children, and covers all aspects of TB prevention and control, including but not limited to:  active case-finding (contact investigations and identifying latent TB in high-risk groups) awareness-raising activities standard and enhanced case management (including providing directly observed therapy and free treatment) finding people lost to follow-up and encouraging them back into treatment incident and outbreak control monitoring, evaluating and gathering surveillance and outcome data.Working together through TB control boards, commissioners, Public Health England and the voluntary sector should ensure TB prevention and control programmes take account of the need to work with other programmes targeting specific high-risk groups, such as under-served groups. Examples include programmes focused on the health of asylum seekers and refugees, under-served children, homelessness and housing, offenders and people who misuse substances.Commissioners should consider commissioning support and advice to all groups diagnosed with TB irrespective of whether they are under-served.Commissioners should ensure NHS England s safe staffing principles are applied when commissioning TB servicesThe staffing ratios used in Public Health England and NHS England s collaborative tuberculosis strategy for England (published in 2015) came from NICE s guideline on tuberculosis: identification and management in under-served groups (published in 2012). ,NICE s 2012 guideline on tuberculosis: identification and management in under-served groups recommended 1 WTE case manager per 40 incident cases needing standard management and 1 WTE case manager per 20 incident cases needing enhanced case management..SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8718", "name": "people in prisons or immigration removal centres", "draggable": "true", "value": {"name": "people in prisons or immigration removal centres", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people in prisons or immigration removal centres", "drug": {}}}, {"category": "treatment", "id": "t8714", "name": "people using homeless or substance misuse services", "draggable": "true", "value": {"name": "people using homeless or substance misuse services", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people using homeless or substance misuse services", "drug": {}}}, {"category": "treatment", "id": "t8713", "name": "vulnerable migrants", "draggable": "true", "value": {"name": "vulnerable migrants", "type": "treatment related", "time": "", "intention": "", "description": "title:vulnerable migrantshead:Vulnerable migrantsPrimary care services should support local, community-based and voluntary organisations that work with vulnerable migrants to ensure they: register with a primary care provider know how to use NHS services (emergency or primary care).Healthcare professionals, including primary care staff, responsible for testing new entrants should test all vulnerable migrants who have not previously been checked. This is regardless of when they arrived in England. People born in countries with an incidence of more than 150 per 100,000 per year should be made a priority for latent TB testing when they arrive here.TB control boards should ensure services take into account the barriers facing vulnerable migrants who may need treatment, and in particular the stigma they may face. Other issues include the location of services (both geographically and in terms of opening times) and people s language and cultural needs, in terms of the format of advice and the type of information given.See also new entrants from high-incidence countries.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6281", "name": "non clinical support staff", "draggable": "true", "value": {"name": "non clinical support staff", "type": "information and support", "time": "", "intention": "", "description": "title:non-clinical support staffhead:Non-clinical support staffTB control boards and local TB services should consider employing trained, non-clinically qualified professionals to work alongside clinical teams to agreed protocols, and to contribute to a variety of activities. Examples of this may include awareness raising and supporting people to attend appointments (including other health and social care appointments). They could also help with collecting samples, contact tracing, case management including directly observed therapy and cohort review, or any other aspect of the service if: they are trained to deliver the intervention or processes effectively they are supported, mentored and supervised by a named case manager, such as a TB nurse they have the skills to monitor, evaluate and report on their work practices and outcomes to maintain a process of ongoing evaluation and service improvement in relation to cohort review (see service organisation).TB control boards should ensure that people working in the TB service have the right knowledge, engagement, advocacy and communication skills to meet the needs (for example, language, cultural or other requirements) of all the groups they may work with.Commissioners should consider taking into account different needs across traditional geographical and organisational boundaries. Put agreements in place so that staff can work across these boundaries, covering the whole service or TB control board area if appropriate.Commissioners and TB control boards should ensure they put in place appropriate governance (including clear lines of accountability and extension of scope of practice) and data sharing practices and agreements. This includes ensuring they are part of service level agreements between NHS and non-NHS services, for example, the third sector or local government and appropriate training has been completed.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6270", "name": "testing for latent tuberculosis for new staff", "draggable": "true", "value": {"name": "testing for latent tuberculosis for new staff", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:testing for latent tuberculosis for new staffhead:Testing for latent tuberculosis in new staffOffer a Mantoux test to new NHS employees who will be in contact with patients or clinical materials, if the employees: are not new entrants from high-incidence countries and have not had BCG vaccination (for example, they are without a BCG scar, other documentation or a reliable history).If the Mantoux test is positive, offer an interferon-gamma release assay. If this is positive, assess them for active TB (see assessing for active TB): if this assessment is negative, offer them treatment for latent TB (see managing latent TB). Offer a Mantoux test to new NHS employees who are from a high-incidence country.  If the Mantoux test is positive (5 mm or larger, regardless of BCG history), assess for active TB (see assessing for active TB): if this assessment is negative, offer them treatment for latent TB infection (see managing latent TB). If Mantoux testing is unavailable, offer an interferon-gamma release assay.Offer an interferon-gamma release assay to new NHS employees who have had contact with patients in settings where TB is highly prevalent.  If the interferon-gamma release assay is positive, assess for active TB (see assessing for active TB) and If this assessment is negative, offer them treatment for latent TB infection (see managing latent TB).Healthcare workers who are immunocompromised should be screened in the same way as other people who are immunocompromised (see high-risk groups).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6172", "name": "pulmonary tuberculosis", "draggable": "true", "value": {"name": "pulmonary tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:pulmonary tuberculosishead:Pulmonary tuberculosisTake a chest X-ray; do further diagnostic investigations (as detailed below and summarised in diagnostic investigations for pulmonary TB) if chest X-ray appearances suggest TB.Send multiple respiratory samples (3 deep cough sputum samples, preferably including 1 early morning sample) for TB microscopy and culture. This should be before starting treatment if possible or, failing that, within 7 days of starting treatment in people with life-threatening disease. Obtain spontaneously-produced, deep cough sputum samples if possible, otherwise use: 3 gastric lavages or 3 inductions of sputum in children and young people, or induction of sputum or bronchoscopy and lavage in adults (see also criteria for hospital admission. Laboratory practices should be in accordance with the UK Standards for Microbiology Investigations.Send samples for TB culture from autopsy samples if pulmonary or laryngeal TB is a possibility.subhead:Children and young peopleIn children aged 15 years or younger with suspected pulmonary TB, offer rapid diagnostic nucleic acid amplification tests for the M. tuberculosis complex (M.  tuberculosis, M.  bovis, M.  africanum). Usually only 1 nucleic acid amplification test is needed per specimen type (for example, spontaneous sputum, induced sputum or gastric lavage; see diagnostic investigations for pulmonary TB.)In young people aged 16\u201318 years use the same criteria as in adults to decide whether to request rapid diagnostic nucleic acid amplification tests.Either a paediatrician with experience and training in TB or a general paediatrician with advice from a specialised clinician should investigate and manage TB in children and young people.An expert in paediatric TB may request an interferon gamma-release assay and tuberculin skin tests. Interpret these together with other diagnostic tools (such as history taking, clinical examination and imaging).subhead:AdultsRequest rapid diagnostic nucleic acid amplification tests for the M. tuberculosis complex (M. tuberculosis, M.  bovis, M.  africanum) on primary specimens (see diagnostic investigations for pulmonary TB) if there is clinical suspicion of TB disease, and: the person has HIV, or rapid information about mycobacterial species would alter the person s care, or the need for a large contact tracing initiative is being explored.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.3Rapid diagnosis of pulmonary tuberculosisSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6171", "name": "extrapulmonary tuberculosis", "draggable": "true", "value": {"name": "extrapulmonary tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:extrapulmonary tuberculosishead:Extrapulmonary tuberculosisDiscuss the advantages and disadvantages of both biopsy and needle aspiration with the patient, with the aim of obtaining adequate material for diagnosis.Do not place part or all of any of the samples in formalin (or other fixative agent) when sending for TB culture.Think about a diagnosis of extrapulmonary TB even if rapid diagnostic tests in, for example, cerebrospinal fluid, pleural fluid or ascitic fluid are negative.Offer all patients presenting with extrapulmonary TB a chest X-ray and, if possible, culture of a spontaneously-produced respiratory sample to exclude or confirm coexisting pulmonary TB. Also, consider site-specific tests as described below to exclude or confirm additional sites of TB.Refer to an expert for sites not listed here, including TB of the eye and other rare sites of disease.subhead:Bone and joint tuberculosisUse the site-specific investigations for bone and joint TB to diagnose and assess bone and joint TB.subhead:Central nervous system tuberculosisUse the site-specific investigations for central nervous system TB to diagnose and assess CNS TB.Offer a CT or MRI scan to people in whom CNS involvement is suspected. Offer treatment for TB meningitis if clinical signs and other laboratory findings are consistent with the diagnosis, even if a rapid diagnostic test is negative.subhead:Disseminated tuberculosisUse the site-specific investigations for disseminated TB to diagnose and assess disseminated TB. subhead:Gastrointestinal tuberculosisUse the site-specific investigations for gastrointestinal TB to diagnose and assess gastrointestinal TB.subhead:Genitourinary tuberculosisUse the site-specific investigations for genitourinary TB to diagnose and assess genitourinary TB.subhead:Localised tuberculous abscessUse the site-specific investigations for localised tuberculous abscess to diagnose and assess TB in a localised, tuberculous abscess at a site other than a lymph node.subhead:Lymph node tuberculosisUse the site-specific investigations for lymph node TB to diagnose and assess lymph node TB (including intrathoracic mediastinal adenopathy).subhead:Pericardial tuberculosisUse the site-specific investigations for pericardial TB to diagnose and assess pericardial TB.subhead:Pleural tuberculosisUse the site-specific investigations for pleural TB to diagnose and assess pleural TB.subhead:Skin tuberculosisUse the site-specific investigations for skin TB to diagnose and assess skin TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6288", "name": "vaccination for neonates", "draggable": "true", "value": {"name": "vaccination for neonates", "type": "information and support", "time": "", "intention": "", "description": "title:vaccination for neonateshead:Vaccination for neonatesIdentify babies eligible for vaccination (in line with the Green Book) before birth, ideally through antenatal services.Discuss neonatal BCG vaccination for any baby at increased risk of TB with the parents or legal guardian.Preferably vaccinate babies at increased risk of TB before discharge from hospital or before handover from midwifery to primary care. Otherwise, vaccinate as soon as possible afterwards, for example, at the 6-week postnatal check.Incorporate computer reminders into maternity service (obstetrics) IT systems for staff, to identify and offer BCG vaccination to babies eligible for vaccination.Provide education and training for postnatal ward staff, midwives, health visitors and other clinicians on identifying babies eligible for vaccination, local service information and providing BCG vaccination, including: case definition for at-risk groups to be offered vaccination information about the local BCG vaccination policy that can be given verbally, in writing or in any other appropriate format (see providing information) to parents and carers at the routine examination of the baby before discharge local service information about BCG vaccination, such as pre-discharge availability of neonatal vaccination, local BCG clinics and referral for BCG vaccination if this is not available in maternity services administration of BCG vaccination and contraindications.Primary care providers with a high incidence of TB should consider vaccinating all neonates soon after birth.In areas with a low incidence of TB (see Public Health England s TB rate bands published in its annual report), primary care organisations should offer BCG vaccination to selected neonates who: were born in an area with a high incidence of TB, or have 1 or more parents or grandparents who were born in a high-incidence country, or have a family history of TB in the past 5 years.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6289", "name": "vaccination for infants and older children", "draggable": "true", "value": {"name": "vaccination for infants and older children", "type": "information and support", "time": "", "intention": "", "description": "title:vaccination for infants and older childrenhead:Vaccination for infants and older childrenRoutine BCG vaccination is not recommended for children aged 10\u201314 years. Healthcare professionals should opportunistically identify unvaccinated children older than 4 weeks and younger than 16 years at increased risk of TB who would have qualified for neonatal BCG and provide Mantoux testingAt the time of publication (January 2016) the BNF states: The Mantoux test is recommended for tuberculin skin testing, but no licensed preparation is currently available.  and BCG vaccination (if Mantoux-negative). This opportunistic vaccination should be in line with the Department of Health s Green Book.Mantoux testing should not be done routinely before BCG vaccination in children younger than 6 years unless they have a history of residence or prolonged stay (more than 1 month) in a country with a high incidence of TB.See what NICE says on immunisations for under 19s. SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6209", "name": "when to offer bcg vaccination", "draggable": "true", "value": {"name": "when to offer bcg vaccination", "type": "information and support", "time": "", "intention": "", "description": "title:when to offer bcg vaccinationhead:When to offer BCG vaccinationOffer BCG vaccination to Mantoux-negative contacts of people with pulmonary and laryngeal TB (see vaccination) if they: have not been vaccinated previously (that is, there is no adequate documentation or a BCG scar), and are aged 35 years or younger, or are aged 36 years and older and a healthcare or laboratory worker who has contact with patients or clinical materials.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6253", "name": "contact tracing and testing", "draggable": "true", "value": {"name": "contact tracing and testing", "type": "information and support", "time": "", "intention": "", "description": "title:contact tracing and testing", "drug": {}}}, {"category": "treatment", "id": "t6259", "name": "commissioning arrangements", "draggable": "true", "value": {"name": "commissioning arrangements", "type": "treatment related", "time": "", "intention": "", "description": "title:commissioning arrangementshead:Commissioning arrangementsClinical commissioning groups and local authority public health teams working in partnership with Public Health England and NHS England should consider collaborative commissioning arrangements through TB control boards. This could, for example, include working with 1 or more clinical commissioning groups to cover a major metropolitan district, region or TB control board area taking into account:  local TB incidence local at-risk populations and their movements across different geographical areas existing service configurations for organisations involved in TB prevention and control the need to share services, such as mobile X-ray facilities and outreach incident teams across different geographical areas.TB control boards should develop TB prevention and control programmes working with commissioners, Public Health England and NHS England. The board should include clinical, commissioning (from clinical commissioning groups, local government and the voluntary sector) and public health leaders and people with TB or groups who advocate on their behalf from across the control board area. This may include identifying a lead clinical commissioning group, which should be led by an executive director of that commissioning group working with the board. Feedback mechanisms between local commissioning groups and the TB control board should be developed.An executive director of local commissioning groups, working with the local director of public health or another nominated public health consultant, should lead implementation of the programme in their locality. The lead should ensure a comprehensive prevention and control programme is commissioned to support the level of need and that they work with the control board regularly.Working together through TB control boards and local networks, commissioners, local government and Public Health England should ensure TB prevention and control programmes set up multidisciplinary TB teams to provide all TB services. They should ensure that local strategy and service commissioning focuses on an end-to-end pathway.Working together through TB control boards, commissioners and Public Health England should ensure the TB prevention and control programme is informed by relevant NICE guidance and developed in collaboration with clinical services. It should also be informed by the standard minimum data set collected through local needs assessment and service audit.Working together through TB control boards, commissioners and Public Health England should ensure the TB prevention and control programme targets all ages, including children, and covers all aspects of TB prevention and control, including but not limited to:  active case-finding (contact investigations and identifying latent TB in high-risk groups) awareness-raising activities standard and enhanced case management (including providing directly observed therapy and free treatment) finding people lost to follow-up and encouraging them back into treatment incident and outbreak control monitoring, evaluating and gathering surveillance and outcome data.Working together through TB control boards, commissioners, Public Health England and the voluntary sector should ensure TB prevention and control programmes take account of the need to work with other programmes targeting specific high-risk groups, such as under-served groups. Examples include programmes focused on the health of asylum seekers and refugees, under-served children, homelessness and housing, offenders and people who misuse substances.Commissioners should consider commissioning support and advice to all groups diagnosed with TB irrespective of whether they are under-served.Commissioners should ensure NHS England s safe staffing principles are applied when commissioning TB servicesThe staffing ratios used in Public Health England and NHS England s collaborative tuberculosis strategy for England (published in 2015) came from NICE s guideline on tuberculosis: identification and management in under-served groups (published in 2012). ,NICE s 2012 guideline on tuberculosis: identification and management in under-served groups recommended 1 WTE case manager per 40 incident cases needing standard management and 1 WTE case manager per 20 incident cases needing enhanced case management..SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6183", "name": "dosing regimens", "draggable": "true", "value": {"name": "dosing regimens", "type": "treatment related", "time": "", "intention": "", "description": "title:dosing regimenshead:Dosing regimensUse fixed-dose combination tablets as part of any TB treatment regimen.Do not offer anti-TB treatment dosing regimens of fewer than 3 times per week.Offer a daily dosing schedule to people with active pulmonary TB.Consider a daily dosing schedule as first choice in people with active extrapulmonary TB.Consider 3 times weekly dosing for people with active TB only if:  risk assessment identifies a need for directly observed therapy and enhanced case management and daily directly observed therapy is not possible.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6197", "name": "managing tuberculosis and liver disease", "draggable": "true", "value": {"name": "managing tuberculosis and liver disease", "type": "treatment related", "time": "", "intention": "", "description": "title:managing tuberculosis and liver diseasehead:Managing tuberculosis and liver diseaseIf a person also has severe liver disease, for example, Child-Pugh level B or C, work with a specialist multidisciplinary team with experience of managing TB and liver disease.Manage treatment with caution, ensuring careful monitoring of liver function, in: people with non-severe liver disease people with abnormal liver function (including abnormal transaminase levels) before starting treatment for latent TB  people who misuse alcohol or drugs.See what NICE says on liver conditions and alcohol-use disorders.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6196", "name": "treatment for latent tuberculosis", "draggable": "true", "value": {"name": "treatment for latent tuberculosis", "type": "disease name and patient related", "time": "", "intention": "isoniazid\nisoniazid is used to treat and to prevent tuberculosis (tb). you may need to take other tb medicines in combination with isoniazid.\nisoniazid may also be used for purposes not listed in this medication guide.", "description": "title:treatment for latent tuberculosishead:Treatment for latent tuberculosisFor people, including those with HIV, aged younger than 65 years with evidence of latent TB who have been in close contact with people who have suspected infectious or confirmed active pulmonary or laryngeal drug-sensitive TB offer either of the following drug treatments: 3 months of isoniazid (with pyridoxine) and rifampicin, or 6 months of isoniazid (with pyridoxine).Base the choice of regimen on the person s clinical circumstances. Offer: 3 months of isoniazid (with pyridoxine) and rifampicin to people younger than 35 years if hepatotoxicity is a concern after an assessment of both liver function (including transaminase levels) and risk factors 6 months of isoniazid (with pyridoxine) if interactions with rifamycins are a concern, for example, in people with HIV or who have had a transplant.Clearly explain the risks and potential benefits of each treatment regimen. In discussion with the person, select a suitable regimen if they wish to proceed with preventive treatment.For adults between the ages of 35 and 65 years, offer drug treatments only if hepatotoxicity is not a concern.Ensure people having treatment for latent TB who also have social risk factors, such as misusing alcohol or drugs or being homeless, are linked to support services. They should also have an assessment of social needs and stability, including potential barriers to adherence or treatment completion.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6236", "name": "criteria for admission", "draggable": "true", "value": {"name": "criteria for admission", "type": "treatment related", "time": "", "intention": "", "description": "title:criteria for admissionhead:Criteria for admissionDo not admit people with suspected infectious TB or confirmed pulmonary TB to a ward containing people who are immunocompromised, such as transplant recipients, people with HIV and those on anti-tumour necrosis factor alpha or other biologics, unless they can be cared for in a negative-pressure room on the same ward.Care for people with a continuing clinical or public health need for admission with pulmonary TB in a single room (as a minimum) until they have completed 2 weeks of the standard treatment regimen (see managing active TB) if they: are unlikely to be rifampicin resistant (that is, do not have risk factors for multidrug-resistant TB), or have negative rifampicin resistance on nucleic acid amplification tests or culture.Consider de-escalating isolation after 2 weeks of treatment, taking into account the risks and benefits, if: the person is showing tolerance to the prescribed treatment there is agreement to adhere to treatment there is resolution of cough there is definite clinical improvement on treatment; for example, remaining afebrile for a week there are not immunocompromised people, such as transplant recipients, people with HIV and those on anti-tumour necrosis factor alpha or other biologics, in the same accommodation the person s initial smear grade was not high; for example, 2 or less there is not extensive pulmonary involvement, including cavitation there is no laryngeal TB.In people who may have TB, only carry out aerosol-generating procedures such as bronchoscopy, sputum induction or nebuliser treatment in an appropriately engineered and ventilated area (ideally a negative-pressure room).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6240", "name": "criteria for admission or transfer", "draggable": "true", "value": {"name": "criteria for admission or transfer", "type": "treatment related", "time": "", "intention": "", "description": "title:criteria for admission or transferhead:Criteria for admission or transfer If people with suspected or known infectious multidrug-resistant TB are admitted to hospital, admit them to a negative-pressure room. If none is available locally, transfer them to a hospital that has these facilities and a clinician experienced in managing complex drug-resistant cases. Carry out care in a negative-pressure room for people with: suspected multidrug-resistant TB, until non-resistance is confirmed confirmed multidrug-resistant TB, until they have 3 negative smears at weekly intervals and ideally have a negative culture.Ensure negative-pressure rooms used for infection control in multidrug-resistant TB meet the standards of the Interdepartmental Working Group on Tuberculosis, and are clearly identified for staff, for example by a standard sign. Keep such signs up to date.As soon as possible, explore options to reduce the psychosocial impact of prolonged isolation. For example, through providing free access to internet, telephone and television, and accompanied walks in the open air.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6226", "name": "people using homeless or substance misuse services", "draggable": "true", "value": {"name": "people using homeless or substance misuse services", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people using homeless or substance misuse services", "drug": {}}}, {"category": "treatment", "id": "t6230", "name": "people in prisons or immigration removal centres", "draggable": "true", "value": {"name": "people in prisons or immigration removal centres", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:people in prisons or immigration removal centres", "drug": {}}}, {"category": "treatment", "id": "t6225", "name": "vulnerable migrants", "draggable": "true", "value": {"name": "vulnerable migrants", "type": "treatment related", "time": "", "intention": "", "description": "title:vulnerable migrantshead:Vulnerable migrantsPrimary care services should support local, community-based and voluntary organisations that work with vulnerable migrants to ensure they: register with a primary care provider know how to use NHS services (emergency or primary care).Healthcare professionals, including primary care staff, responsible for testing new entrants should test all vulnerable migrants who have not previously been checked. This is regardless of when they arrived in England. People born in countries with an incidence of more than 150 per 100,000 per year should be made a priority for latent TB testing when they arrive here.TB control boards should ensure services take into account the barriers facing vulnerable migrants who may need treatment, and in particular the stigma they may face. Other issues include the location of services (both geographically and in terms of opening times) and people s language and cultural needs, in terms of the format of advice and the type of information given.See also new entrants from high-incidence countries.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8770", "name": "ongoing education programme", "draggable": "true", "value": {"name": "ongoing education programme", "type": "information and support", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:ongoing education programmehead:Ongoing education programmeMultidisciplinary TB teams (in collaboration with Public Health England, primary care, the voluntary sector and Health Education England) should identify and support an ongoing TB education programme for local professionals in contact with the general public, and at-risk groups in particular. This includes, for example, staff in emergency departments, GPs and wider primary care staff, people who work in housing support services, staff who support migrants and those working in walk-in centres, hostels, substance misuse projects and prisons.Multidisciplinary TB teams should ensure the education programme increases other professionals  awareness of the possibility of TB and reduces the stigma associated with it. The programme should include detail on: causes of TB, how it is transmitted, and the signs and symptoms lifestyle factors that may mask symptoms local epidemiology, highlighting under-served groups, other high-risk groups and the fact that TB also occurs in people without risk factors principles of TB control: early diagnosis and active case-finding how to support treatment (including directly observed therapy) drug resistance awareness of drug interactions (including factors such as effect on contraception efficacy) contact investigations after diagnosing an active case the importance of adhering to treatment  treatment for TB is free for everyone (irrespective of eligibility for other NHS care) social and cultural barriers to accessing health services (for example, fear of stigma and staff attitudes) local referral pathways, including details of who to refer and how the role of allied professionals in awareness-raising, identifying cases and helping people complete treatment misinformation that causes fear about TB, including concerns about housing people with the condition the best ways to effectively communicate all the above topics with different groups.Statutory, community and voluntary organisations and advocates working with the general public, and under-served and high-risk groups in particular, should share information on TB education and awareness training with all frontline staff. (They should get information on this from the local multidisciplinary TB team.)If possible, statutory, community and voluntary organisations should ensure peers from under-served groups and anyone else with experience of TB contribute to, or lead, awareness-raising activities. (Peers who lead such activities will need training and support.)Consider training housing commissioners and frontline staff on TB and the need for housing support so that they understand that stable home life is a prerequisite to successful TB treatment.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8662", "name": "managing active tuberculosis", "draggable": "true", "value": {"name": "managing active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:managing active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8729", "name": "hygiene procedures for staff and visitors", "draggable": "true", "value": {"name": "hygiene procedures for staff and visitors", "type": "information and support", "time": "", "intention": "", "description": "title:hygiene procedures for staff and visitorshead:Hygiene procedures for staff and visitorsStaff and visitors should wear FFP3 masks during contact with a person with suspected or known multidrug-resistant TB while the person is thought to be infectious.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8725", "name": "hygiene procedures for patients and visitors", "draggable": "true", "value": {"name": "hygiene procedures for patients and visitors", "type": "information and support", "time": "", "intention": "", "description": "title:hygiene procedures for patients and visitorshead:Hygiene procedures for patients and visitorsExplain to inpatients with suspected infectious TB or confirmed pulmonary or laryngeal TB that they will need to wear a surgical mask in the hospital whenever they leave their room. Ask them to continue wearing it until they have had at least 2 weeks of treatment.Offer people advice on simple respiratory hygiene measures.Assess any visitors to a child with suspected active TB in hospital for symptoms of infectious TB, and keep them separate from other people until they have been excluded as a source of infection (see also contact tracing and testing).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8759", "name": "healthcare staff who are hiv positive", "draggable": "true", "value": {"name": "healthcare staff who are hiv positive", "type": "information and support", "time": "", "intention": "", "description": "title:healthcare staff who are hiv positivehead:Healthcare staff who are HIV positiveAssess the risk of TB for a new healthcare worker who knows he or she is HIV-positive at the time of recruitment as part of the occupational health checks.The employer, through the occupational health department, should be aware of the settings with increased risk of exposure to TB, and that these pose increased risks to HIV-positive healthcare workers.Healthcare workers who are found to be HIV-positive during employment should have medical and occupational assessments of TB risk, and may need to modify their work to reduce exposure.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8700", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t8778", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t8686", "name": "strategies to encourage treatment adherence", "draggable": "true", "value": {"name": "strategies to encourage treatment adherence", "type": "information and support", "time": "", "intention": "", "description": "title:strategies to encourage treatment adherencehead:Strategies to encourage treatment adherenceTo encourage people to follow their treatment plan, involve people in treatment decisions from the start. Emphasise the importance of following the treatment plan when agreeing the regimen.Multidisciplinary TB teams should implement strategies to encourage people to follow the treatment plan and prevent people stopping treatment early. These could include: reminder letters, printed information, telephone calls, texts and apps using an appropriate language health education counselling and patient-centred interviews tailored health education booklets from quality sources (see providing information) home visits random urine tests and other monitoring (for example, pill counts) access to free TB treatment for everyone (irrespective of eligibility for other NHS care) and information about help with paying for prescriptions social and psychological support (including cultural case management and broader social support) advice and support for parents and carers incentives and enablers to help people follow their treatment regimen.For guidance on treatment adherence in prisons or immigration removal centres, see procedures for treating TB in prisons or immigration removal centres and arrangements for treating prisoners and detainees after their release.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8672", "name": "people with comorbidities or coexisting conditions", "draggable": "true", "value": {"name": "people with comorbidities or coexisting conditions", "type": "information and support", "time": "", "intention": "", "description": "title:people with comorbidities or coexisting conditionshead:People with comorbidities or coexisting conditionsIf the person has a comorbidity or coexisting condition such as: HIV, or severe liver disease, for example, Child-Pugh level  B or  C, or stage  4 or  5 chronic kidney disease (a glomerular filtration rate of <30 ml/minute/1.73m2), or diabetes, or eye disease or impaired vision, or pregnancy or breastfeeding, or a history of alcohol or substance misusework with a specialist multidisciplinary team with experience of managing TB and the comorbidity or coexisting condition.For people with HIV and active TB without CNS involvement, do not routinely extend treatment beyond 6 months.For people with HIV and active TB with CNS involvement, do not routinely extend treatment beyond 12 months.Take into account drug-to-drug interactions when co-prescribing antiretroviral and anti-TB drugs.See what NICE says on alcohol-use disorders, drug misuse management in over 16s and antimicrobial stewardship.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8749", "name": "collaborative approaches to rural tuberculosis services", "draggable": "true", "value": {"name": "collaborative approaches to rural tuberculosis services", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:collaborative approaches to rural tuberculosis serviceshead:Collaborative approaches to rural tuberculosis servicesCommissioners in rural areas (working with TB control boards) should consider collaborative approaches to deliver and manage TB services. They could, for example, set up a network including areas with high and low incidence of TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8748", "name": "consider networks for multidrug resistant tuberculosis", "draggable": "true", "value": {"name": "consider networks for multidrug resistant tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:consider networks for multidrug-resistant tuberculosishead:Consider networks for multidrug-resistant tuberculosisTB control boards should consider setting up a regional multidisciplinary TB network to oversee management of multidrug-resistant TB. This could: Identify and designate regional expert centres. Ensure all healthcare professionals who suspect or treat a case of multidrug-resistant TB are informed about and have access to specialist advisory services for multidrug-resistant TB. This includes the designated expert centre in their regional network and may also include the national advisory service for multidrug-resistant TB (currently provided by the British Thoracic Society). Ensure all cases of multidrug-resistant TB are discussed at the regional multidisciplinary TB team meeting in the local clinical network. Formally consider and record the advice from the specialist advisory services for multidrug-resistant TB provided by the designated regional expert centre or the national advisory service for multidrug-resistant TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8715", "name": "when substance misuse services should test for latent tuberculosis", "draggable": "true", "value": {"name": "when substance misuse services should test for latent tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:when substance misuse services should test for latent tuberculosishead:When substance misuse services should test for latent tuberculosisSubstance misuse services with access to an interferon-gamma release assay should provide testing for people younger than 65 years who misuse substances if they: live in a high-incidence area are likely to be involved with substance misuse services or other support services on a regular basis (for example, for opioid substitution therapy), when support should be available for directly observed preventive therapy.Substance misuse services should incorporate interferon-gamma release assay testing with screening for hepatitis B and C, and HIV testing. They should refer people who misuse substances with positive interferon-gamma release assays to local multidisciplinary TB teams for further clinical investigations.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8719", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t6282", "name": "ongoing education programme", "draggable": "true", "value": {"name": "ongoing education programme", "type": "information and support", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:ongoing education programmehead:Ongoing education programmeMultidisciplinary TB teams (in collaboration with Public Health England, primary care, the voluntary sector and Health Education England) should identify and support an ongoing TB education programme for local professionals in contact with the general public, and at-risk groups in particular. This includes, for example, staff in emergency departments, GPs and wider primary care staff, people who work in housing support services, staff who support migrants and those working in walk-in centres, hostels, substance misuse projects and prisons.Multidisciplinary TB teams should ensure the education programme increases other professionals  awareness of the possibility of TB and reduces the stigma associated with it. The programme should include detail on: causes of TB, how it is transmitted, and the signs and symptoms lifestyle factors that may mask symptoms local epidemiology, highlighting under-served groups, other high-risk groups and the fact that TB also occurs in people without risk factors principles of TB control: early diagnosis and active case-finding how to support treatment (including directly observed therapy) drug resistance awareness of drug interactions (including factors such as effect on contraception efficacy) contact investigations after diagnosing an active case the importance of adhering to treatment  treatment for TB is free for everyone (irrespective of eligibility for other NHS care) social and cultural barriers to accessing health services (for example, fear of stigma and staff attitudes) local referral pathways, including details of who to refer and how the role of allied professionals in awareness-raising, identifying cases and helping people complete treatment misinformation that causes fear about TB, including concerns about housing people with the condition the best ways to effectively communicate all the above topics with different groups.Statutory, community and voluntary organisations and advocates working with the general public, and under-served and high-risk groups in particular, should share information on TB education and awareness training with all frontline staff. (They should get information on this from the local multidisciplinary TB team.)If possible, statutory, community and voluntary organisations should ensure peers from under-served groups and anyone else with experience of TB contribute to, or lead, awareness-raising activities. (Peers who lead such activities will need training and support.)Consider training housing commissioners and frontline staff on TB and the need for housing support so that they understand that stable home life is a prerequisite to successful TB treatment.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6271", "name": "healthcare staff who are hiv positive", "draggable": "true", "value": {"name": "healthcare staff who are hiv positive", "type": "information and support", "time": "", "intention": "", "description": "title:healthcare staff who are hiv positivehead:Healthcare staff who are HIV positiveAssess the risk of TB for a new healthcare worker who knows he or she is HIV-positive at the time of recruitment as part of the occupational health checks.The employer, through the occupational health department, should be aware of the settings with increased risk of exposure to TB, and that these pose increased risks to HIV-positive healthcare workers.Healthcare workers who are found to be HIV-positive during employment should have medical and occupational assessments of TB risk, and may need to modify their work to reduce exposure.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6174", "name": "managing active tuberculosis", "draggable": "true", "value": {"name": "managing active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:managing active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6290", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t6212", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t6261", "name": "collaborative approaches to rural tuberculosis services", "draggable": "true", "value": {"name": "collaborative approaches to rural tuberculosis services", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:collaborative approaches to rural tuberculosis serviceshead:Collaborative approaches to rural tuberculosis servicesCommissioners in rural areas (working with TB control boards) should consider collaborative approaches to deliver and manage TB services. They could, for example, set up a network including areas with high and low incidence of TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6260", "name": "consider networks for multidrug resistant tuberculosis", "draggable": "true", "value": {"name": "consider networks for multidrug resistant tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:consider networks for multidrug-resistant tuberculosishead:Consider networks for multidrug-resistant tuberculosisTB control boards should consider setting up a regional multidisciplinary TB network to oversee management of multidrug-resistant TB. This could: Identify and designate regional expert centres. Ensure all healthcare professionals who suspect or treat a case of multidrug-resistant TB are informed about and have access to specialist advisory services for multidrug-resistant TB. This includes the designated expert centre in their regional network and may also include the national advisory service for multidrug-resistant TB (currently provided by the British Thoracic Society). Ensure all cases of multidrug-resistant TB are discussed at the regional multidisciplinary TB team meeting in the local clinical network. Formally consider and record the advice from the specialist advisory services for multidrug-resistant TB provided by the designated regional expert centre or the national advisory service for multidrug-resistant TB.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6184", "name": "people with comorbidities or coexisting conditions", "draggable": "true", "value": {"name": "people with comorbidities or coexisting conditions", "type": "information and support", "time": "", "intention": "", "description": "title:people with comorbidities or coexisting conditionshead:People with comorbidities or coexisting conditionsIf the person has a comorbidity or coexisting condition such as: HIV, or severe liver disease, for example, Child-Pugh level  B or  C, or stage  4 or  5 chronic kidney disease (a glomerular filtration rate of <30 ml/minute/1.73m2), or diabetes, or eye disease or impaired vision, or pregnancy or breastfeeding, or a history of alcohol or substance misusework with a specialist multidisciplinary team with experience of managing TB and the comorbidity or coexisting condition.For people with HIV and active TB without CNS involvement, do not routinely extend treatment beyond 6 months.For people with HIV and active TB with CNS involvement, do not routinely extend treatment beyond 12 months.Take into account drug-to-drug interactions when co-prescribing antiretroviral and anti-TB drugs.See what NICE says on alcohol-use disorders, drug misuse management in over 16s and antimicrobial stewardship.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6198", "name": "strategies to encourage treatment adherence", "draggable": "true", "value": {"name": "strategies to encourage treatment adherence", "type": "information and support", "time": "", "intention": "", "description": "title:strategies to encourage treatment adherencehead:Strategies to encourage treatment adherenceTo encourage people to follow their treatment plan, involve people in treatment decisions from the start. Emphasise the importance of following the treatment plan when agreeing the regimen.Multidisciplinary TB teams should implement strategies to encourage people to follow the treatment plan and prevent people stopping treatment early. These could include: reminder letters, printed information, telephone calls, texts and apps using an appropriate language health education counselling and patient-centred interviews tailored health education booklets from quality sources (see providing information) home visits random urine tests and other monitoring (for example, pill counts) access to free TB treatment for everyone (irrespective of eligibility for other NHS care) and information about help with paying for prescriptions social and psychological support (including cultural case management and broader social support) advice and support for parents and carers incentives and enablers to help people follow their treatment regimen.For guidance on treatment adherence in prisons or immigration removal centres, see procedures for treating TB in prisons or immigration removal centres and arrangements for treating prisoners and detainees after their release.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6237", "name": "hygiene procedures for patients and visitors", "draggable": "true", "value": {"name": "hygiene procedures for patients and visitors", "type": "information and support", "time": "", "intention": "", "description": "title:hygiene procedures for patients and visitorshead:Hygiene procedures for patients and visitorsExplain to inpatients with suspected infectious TB or confirmed pulmonary or laryngeal TB that they will need to wear a surgical mask in the hospital whenever they leave their room. Ask them to continue wearing it until they have had at least 2 weeks of treatment.Offer people advice on simple respiratory hygiene measures.Assess any visitors to a child with suspected active TB in hospital for symptoms of infectious TB, and keep them separate from other people until they have been excluded as a source of infection (see also contact tracing and testing).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6241", "name": "hygiene procedures for staff and visitors", "draggable": "true", "value": {"name": "hygiene procedures for staff and visitors", "type": "information and support", "time": "", "intention": "", "description": "title:hygiene procedures for staff and visitorshead:Hygiene procedures for staff and visitorsStaff and visitors should wear FFP3 masks during contact with a person with suspected or known multidrug-resistant TB while the person is thought to be infectious.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6227", "name": "when substance misuse services should test for latent tuberculosis", "draggable": "true", "value": {"name": "when substance misuse services should test for latent tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:when substance misuse services should test for latent tuberculosishead:When substance misuse services should test for latent tuberculosisSubstance misuse services with access to an interferon-gamma release assay should provide testing for people younger than 65 years who misuse substances if they: live in a high-incidence area are likely to be involved with substance misuse services or other support services on a regular basis (for example, for opioid substitution therapy), when support should be available for directly observed preventive therapy.Substance misuse services should incorporate interferon-gamma release assay testing with screening for hepatitis B and C, and HIV testing. They should refer people who misuse substances with positive interferon-gamma release assays to local multidisciplinary TB teams for further clinical investigations.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6231", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t8771", "name": "back to service organisation", "draggable": "true", "value": {"name": "back to service organisation", "type": "cancer ralated", "time": "", "intention": "", "description": "title:back to service organisation", "drug": {}}}, {"category": "treatment", "id": "t8663", "name": "contact tracing and testing", "draggable": "true", "value": {"name": "contact tracing and testing", "type": "information and support", "time": "", "intention": "", "description": "title:contact tracing and testing", "drug": {}}}, {"category": "treatment", "id": "t8730", "name": "criteria for discharging patients with multidrug resistant tuberculosis", "draggable": "true", "value": {"name": "criteria for discharging patients with multidrug resistant tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:criteria for discharging patients with multidrug-resistant tuberculosishead:Criteria for discharging patients with multidrug-resistant tuberculosisConsider earlier discharge for people with confirmed multidrug-resistant TB, if there are suitable facilities for home isolation and the person will adhere to the care plan.For people with confirmed multidrug-resistant TB whose symptoms have improved and who are unable to produce sputum, discharge decisions should be taken by the multidisciplinary team and the health protection team.Before deciding to discharge a person with suspected or known multidrug-resistant TB from hospital, agree with the person and their carers secure arrangements for supervising and administering all anti-TB therapy.Discuss the decision to discharge a person with suspected or known multidrug-resistant TB with: the infection control team and the local microbiologist and the local TB service and the health protection team.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8726", "name": "criteria for discharge", "draggable": "true", "value": {"name": "criteria for discharge", "type": "treatment related", "time": "", "intention": "", "description": "title:criteria for dischargehead:Criteria for dischargeConsider discharging from hospital people: who do not have a continuing clinical or public health need for admission with pulmonary TB, and who are unlikely to be rifampicin resistant (that is, do not have risk factors for multidrug-resistant TB, or who have negative rifampicin resistance on nucleic acid amplification tests or culture.If discharged, the person should avoid congregate settings for the first 2 weeks of their treatment.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8760", "name": "ongoing health checks", "draggable": "true", "value": {"name": "ongoing health checks", "type": "information and support", "time": "", "intention": "", "description": "title:ongoing health checkshead:Ongoing health checksInclude reminders of the symptoms of TB, and the need for prompt reporting of such symptoms, with annual reminders about occupational health for staff who: are in regular contact with TB patients or clinical materials, or have worked in a high-risk clinical setting for 4 weeks or longer.Give one-off reminders after a TB incident on a ward.If no documentary evidence of previous screening is available, screen staff in contact with patients or clinical material who are transferring jobs within the NHS as for new employees.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8687", "name": "when to offer directly observed therapy", "draggable": "true", "value": {"name": "when to offer directly observed therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:when to offer directly observed therapyhead:When to offer directly observed therapyOffer directly observed therapy as part of enhanced case management in people who: do not adhere to treatment (or have not in the past) have a history of homelessness, drug or alcohol misuse are currently in prison, or have been in the past 5 years have a major psychiatric, memory or cognitive disorder are in denial of the TB diagnosis request directly observed therapy after discussion with the clinical team.In children whose parents are members of any of the above groups, offer directly observed therapy as part of enhanced case management and include advice and support for parents to assist with treatment completion.Re-evaluate the need for directly observed therapy throughout the course of TB treatment whenever the person s (or in the case of children, parents ) circumstances change.See what NICE says on alcohol-use disorders and drug misuse management in over 16s.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8673", "name": "addressing housing needs", "draggable": "true", "value": {"name": "addressing housing needs", "type": "information and support", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:addressing housing needshead:Addressing housing needsMultidisciplinary TB teams should assess the living circumstances of people with TB. Where there is a housing need they should work with allied agencies to ensure that all those who are entitled to state-funded accommodation receive it as early as possible during their treatment, for example, as a result of statutory homelessness review and identified need.Multidisciplinary TB teams should make people who would not otherwise be entitled to state-funded accommodation aware that they may lose this accommodation if they do not comply with treatment. They should ensure plans are made to continue housing people once their TB treatment is completed.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.6AccommodationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8750", "name": "conduct cohort reviews", "draggable": "true", "value": {"name": "conduct cohort reviews", "type": "disease name and patient related", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:conduct cohort reviewshead:Conduct cohort reviewsTB control boards and prevention and control programme leads should initiate, audit and evaluate cohort reviews in their commissioning area. Quarterly cohort review meetings should take place in the area covered by the programme. Combine these meetings with others if possible, or use technology to make it easier for clinicians and case managers to attend.TB case managers should present standardised information on each case, including: demographic information, HIV test results, pre-treatment and ongoing status (clinical, laboratory, radiology), adherence to treatment and the results of contact investigations.TB case managers and key allied professionals from the TB prevention and control programme should attend cohort review meetings. This should include the lead clinician (who may or may not be the case manager). Either a paediatrician with experience and training in the treatment of TB or a general paediatrician with advice from a specialised clinician should be present when cases of children with TB are presented.The chair of the cohort review should not work for any of the TB services included in the review. Examples of possible chairs include a public health consultant, a specialist physician or a senior TB nurse, preferably from a different geographical area. Alternatively the chair could be a representative from the local Public Health England health protection team or the TB control board.Multidisciplinary TB teams in conjunction with Public Health England units, should collate and present cohort review data on TB treatment and the outcome of contact investigations at the review meetings. In addition, progress towards national, regional and local service targets should be presented.TB control boards, directors of public health and local public health consultants should ensure outputs from the cohort review feed into the needs assessment for TB services. TB control board directors should attend the cohort review at least once a year.TB case managers should feed back promptly to multidisciplinary TB teams on issues identified as a result of cohort review. The results of the cohort review should be collated locally and agreed by the chair before being fed back to TB control boards, commissioners and health and wellbeing boards regularly and via needs assessment.People participating in a cohort review should review the results and evaluate local services (for example, auditing adverse outcomes, rates of culture confirmation, treatment completion rates or time to diagnosis).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8716", "name": "identifying active tuberculosis", "draggable": "true", "value": {"name": "identifying active tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:identifying active tuberculosishead:Identifying active tuberculosisIn areas of identified need (see population needs assessment), including major urban centres with a high incidence of TB, commissioners should: ensure there is a programme of active case-finding using mobile X-ray in places where homeless people and people who misuse substances congregate (this includes: homeless day centres, rolling shelters, hostels and temporary shelters established as part of cold weather initiatives and venues housing needle and syringe programmes) base the frequency of screening at any 1 location on population turnover where local demand does not warrant a mobile X-ray team, consider commissioning mobile X-ray capacity from another area.Multidisciplinary TB teams should consider using simple incentives, such as providing hot drinks and snacks, to encourage people to attend for testing.Commissioners of TB prevention and control programmes should consider offering people who are homeless and people who misuse substances other health interventions when they are screened for TB at a mobile X-ray unit. (Examples may include blood-borne virus screening, dentistry and podiatry services.)Multidisciplinary TB teams should work closely with mobile X-ray teams and frontline staff in hostels and day centres to promote TB screening and to ensure appropriate onward referrals and follow-up.Multidisciplinary TB teams should consider using peer educators to promote the uptake of TB screening in hostels and day centres.Multidisciplinary TB teams should provide routine data to TB control boards on: screening uptake, referrals and the number of active TB cases identified.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6283", "name": "back to service organisation", "draggable": "true", "value": {"name": "back to service organisation", "type": "cancer ralated", "time": "", "intention": "", "description": "title:back to service organisation", "drug": {}}}, {"category": "treatment", "id": "t6272", "name": "ongoing health checks", "draggable": "true", "value": {"name": "ongoing health checks", "type": "information and support", "time": "", "intention": "", "description": "title:ongoing health checkshead:Ongoing health checksInclude reminders of the symptoms of TB, and the need for prompt reporting of such symptoms, with annual reminders about occupational health for staff who: are in regular contact with TB patients or clinical materials, or have worked in a high-risk clinical setting for 4 weeks or longer.Give one-off reminders after a TB incident on a ward.If no documentary evidence of previous screening is available, screen staff in contact with patients or clinical material who are transferring jobs within the NHS as for new employees.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6175", "name": "contact tracing and testing", "draggable": "true", "value": {"name": "contact tracing and testing", "type": "information and support", "time": "", "intention": "", "description": "title:contact tracing and testing", "drug": {}}}, {"category": "treatment", "id": "t6262", "name": "conduct cohort reviews", "draggable": "true", "value": {"name": "conduct cohort reviews", "type": "disease name and patient related", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:conduct cohort reviewshead:Conduct cohort reviewsTB control boards and prevention and control programme leads should initiate, audit and evaluate cohort reviews in their commissioning area. Quarterly cohort review meetings should take place in the area covered by the programme. Combine these meetings with others if possible, or use technology to make it easier for clinicians and case managers to attend.TB case managers should present standardised information on each case, including: demographic information, HIV test results, pre-treatment and ongoing status (clinical, laboratory, radiology), adherence to treatment and the results of contact investigations.TB case managers and key allied professionals from the TB prevention and control programme should attend cohort review meetings. This should include the lead clinician (who may or may not be the case manager). Either a paediatrician with experience and training in the treatment of TB or a general paediatrician with advice from a specialised clinician should be present when cases of children with TB are presented.The chair of the cohort review should not work for any of the TB services included in the review. Examples of possible chairs include a public health consultant, a specialist physician or a senior TB nurse, preferably from a different geographical area. Alternatively the chair could be a representative from the local Public Health England health protection team or the TB control board.Multidisciplinary TB teams in conjunction with Public Health England units, should collate and present cohort review data on TB treatment and the outcome of contact investigations at the review meetings. In addition, progress towards national, regional and local service targets should be presented.TB control boards, directors of public health and local public health consultants should ensure outputs from the cohort review feed into the needs assessment for TB services. TB control board directors should attend the cohort review at least once a year.TB case managers should feed back promptly to multidisciplinary TB teams on issues identified as a result of cohort review. The results of the cohort review should be collated locally and agreed by the chair before being fed back to TB control boards, commissioners and health and wellbeing boards regularly and via needs assessment.People participating in a cohort review should review the results and evaluate local services (for example, auditing adverse outcomes, rates of culture confirmation, treatment completion rates or time to diagnosis).SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6185", "name": "addressing housing needs", "draggable": "true", "value": {"name": "addressing housing needs", "type": "information and support", "time": "", "intention": "alli\norlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. this medicine must be used together with a reduced-calorie diet. orlistat is for use only in adults.\norlistat may also be used for purposes not listed in this medication guide.", "description": "title:addressing housing needshead:Addressing housing needsMultidisciplinary TB teams should assess the living circumstances of people with TB. Where there is a housing need they should work with allied agencies to ensure that all those who are entitled to state-funded accommodation receive it as early as possible during their treatment, for example, as a result of statutory homelessness review and identified need.Multidisciplinary TB teams should make people who would not otherwise be entitled to state-funded accommodation aware that they may lose this accommodation if they do not comply with treatment. They should ensure plans are made to continue housing people once their TB treatment is completed.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.6AccommodationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6199", "name": "when to offer directly observed therapy", "draggable": "true", "value": {"name": "when to offer directly observed therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:when to offer directly observed therapyhead:When to offer directly observed therapyOffer directly observed therapy as part of enhanced case management in people who: do not adhere to treatment (or have not in the past) have a history of homelessness, drug or alcohol misuse are currently in prison, or have been in the past 5 years have a major psychiatric, memory or cognitive disorder are in denial of the TB diagnosis request directly observed therapy after discussion with the clinical team.In children whose parents are members of any of the above groups, offer directly observed therapy as part of enhanced case management and include advice and support for parents to assist with treatment completion.Re-evaluate the need for directly observed therapy throughout the course of TB treatment whenever the person s (or in the case of children, parents ) circumstances change.See what NICE says on alcohol-use disorders and drug misuse management in over 16s.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6238", "name": "criteria for discharge", "draggable": "true", "value": {"name": "criteria for discharge", "type": "treatment related", "time": "", "intention": "", "description": "title:criteria for dischargehead:Criteria for dischargeConsider discharging from hospital people: who do not have a continuing clinical or public health need for admission with pulmonary TB, and who are unlikely to be rifampicin resistant (that is, do not have risk factors for multidrug-resistant TB, or who have negative rifampicin resistance on nucleic acid amplification tests or culture.If discharged, the person should avoid congregate settings for the first 2 weeks of their treatment.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6242", "name": "criteria for discharging patients with multidrug resistant tuberculosis", "draggable": "true", "value": {"name": "criteria for discharging patients with multidrug resistant tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:criteria for discharging patients with multidrug-resistant tuberculosishead:Criteria for discharging patients with multidrug-resistant tuberculosisConsider earlier discharge for people with confirmed multidrug-resistant TB, if there are suitable facilities for home isolation and the person will adhere to the care plan.For people with confirmed multidrug-resistant TB whose symptoms have improved and who are unable to produce sputum, discharge decisions should be taken by the multidisciplinary team and the health protection team.Before deciding to discharge a person with suspected or known multidrug-resistant TB from hospital, agree with the person and their carers secure arrangements for supervising and administering all anti-TB therapy.Discuss the decision to discharge a person with suspected or known multidrug-resistant TB with: the infection control team and the local microbiologist and the local TB service and the health protection team.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6228", "name": "identifying active tuberculosis", "draggable": "true", "value": {"name": "identifying active tuberculosis", "type": "treatment related", "time": "", "intention": "", "description": "title:identifying active tuberculosishead:Identifying active tuberculosisIn areas of identified need (see population needs assessment), including major urban centres with a high incidence of TB, commissioners should: ensure there is a programme of active case-finding using mobile X-ray in places where homeless people and people who misuse substances congregate (this includes: homeless day centres, rolling shelters, hostels and temporary shelters established as part of cold weather initiatives and venues housing needle and syringe programmes) base the frequency of screening at any 1 location on population turnover where local demand does not warrant a mobile X-ray team, consider commissioning mobile X-ray capacity from another area.Multidisciplinary TB teams should consider using simple incentives, such as providing hot drinks and snacks, to encourage people to attend for testing.Commissioners of TB prevention and control programmes should consider offering people who are homeless and people who misuse substances other health interventions when they are screened for TB at a mobile X-ray unit. (Examples may include blood-borne virus screening, dentistry and podiatry services.)Multidisciplinary TB teams should work closely with mobile X-ray teams and frontline staff in hostels and day centres to promote TB screening and to ensure appropriate onward referrals and follow-up.Multidisciplinary TB teams should consider using peer educators to promote the uptake of TB screening in hostels and day centres.Multidisciplinary TB teams should provide routine data to TB control boards on: screening uptake, referrals and the number of active TB cases identified.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8733", "name": "back to diagnosing active tuberculosis", "draggable": "true", "value": {"name": "back to diagnosing active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:back to diagnosing active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t8688", "name": "follow up", "draggable": "true", "value": {"name": "follow up", "type": "treatment related", "time": "", "intention": "", "description": "title:follow-uphead:Follow-upFollow-up clinic visits should not be conducted routinely after treatment completion.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8674", "name": "strategies to encourage treatment adherence", "draggable": "true", "value": {"name": "strategies to encourage treatment adherence", "type": "information and support", "time": "", "intention": "", "description": "title:strategies to encourage treatment adherencehead:Strategies to encourage treatment adherenceTo encourage people to follow their treatment plan, involve people in treatment decisions from the start. Emphasise the importance of following the treatment plan when agreeing the regimen.Multidisciplinary TB teams should implement strategies to encourage people to follow the treatment plan and prevent people stopping treatment early. These could include: reminder letters, printed information, telephone calls, texts and apps using an appropriate language health education counselling and patient-centred interviews tailored health education booklets from quality sources (see providing information) home visits random urine tests and other monitoring (for example, pill counts) access to free TB treatment for everyone (irrespective of eligibility for other NHS care) and information about help with paying for prescriptions social and psychological support (including cultural case management and broader social support) advice and support for parents and carers incentives and enablers to help people follow their treatment regimen.For guidance on treatment adherence in prisons or immigration removal centres, see procedures for treating TB in prisons or immigration removal centres and arrangements for treating prisoners and detainees after their release.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8753", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t8717", "name": "addressing housing needs", "draggable": "true", "value": {"name": "addressing housing needs", "type": "information and support", "time": "", "intention": "", "description": "title:addressing housing needshead:Addressing housing needsMultidisciplinary TB teams, commissioners, local authority housing lead officers and other social landlords, providers of hostel accommodation, hospital discharge teams, Public Health England and the Local Government Association should work together to agree a process for identifying and providing accommodation for homeless people diagnosed with active pulmonary TB who are otherwise ineligible for state-funded accommodation. This includes people who are not sleeping rough but do not have access to housing or recourse to public funds. The process should detail the person s eligibility and ensure they are given accommodation for the duration of their TB treatment.Local government and clinical commissioning groups should fund accommodation for homeless people diagnosed with active TB who are otherwise ineligible for state-funded accommodation. Use health and public health resources, in line with the Care Act 2014.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.6AccommodationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6265", "name": "back to overview", "draggable": "true", "value": {"name": "back to overview", "type": "treatment related", "time": "", "intention": "", "description": "title:back to overview", "drug": {}}}, {"category": "treatment", "id": "t6186", "name": "strategies to encourage treatment adherence", "draggable": "true", "value": {"name": "strategies to encourage treatment adherence", "type": "information and support", "time": "", "intention": "", "description": "title:strategies to encourage treatment adherencehead:Strategies to encourage treatment adherenceTo encourage people to follow their treatment plan, involve people in treatment decisions from the start. Emphasise the importance of following the treatment plan when agreeing the regimen.Multidisciplinary TB teams should implement strategies to encourage people to follow the treatment plan and prevent people stopping treatment early. These could include: reminder letters, printed information, telephone calls, texts and apps using an appropriate language health education counselling and patient-centred interviews tailored health education booklets from quality sources (see providing information) home visits random urine tests and other monitoring (for example, pill counts) access to free TB treatment for everyone (irrespective of eligibility for other NHS care) and information about help with paying for prescriptions social and psychological support (including cultural case management and broader social support) advice and support for parents and carers incentives and enablers to help people follow their treatment regimen.For guidance on treatment adherence in prisons or immigration removal centres, see procedures for treating TB in prisons or immigration removal centres and arrangements for treating prisoners and detainees after their release.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6200", "name": "follow up", "draggable": "true", "value": {"name": "follow up", "type": "treatment related", "time": "", "intention": "", "description": "title:follow-uphead:Follow-upFollow-up clinic visits should not be conducted routinely after treatment completion.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6245", "name": "back to diagnosing active tuberculosis", "draggable": "true", "value": {"name": "back to diagnosing active tuberculosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:back to diagnosing active tuberculosis", "drug": {}}}, {"category": "treatment", "id": "t6229", "name": "addressing housing needs", "draggable": "true", "value": {"name": "addressing housing needs", "type": "information and support", "time": "", "intention": "", "description": "title:addressing housing needshead:Addressing housing needsMultidisciplinary TB teams, commissioners, local authority housing lead officers and other social landlords, providers of hostel accommodation, hospital discharge teams, Public Health England and the Local Government Association should work together to agree a process for identifying and providing accommodation for homeless people diagnosed with active pulmonary TB who are otherwise ineligible for state-funded accommodation. This includes people who are not sleeping rough but do not have access to housing or recourse to public funds. The process should detail the person s eligibility and ensure they are given accommodation for the duration of their TB treatment.Local government and clinical commissioning groups should fund accommodation for homeless people diagnosed with active TB who are otherwise ineligible for state-funded accommodation. Use health and public health resources, in line with the Care Act 2014.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.6AccommodationSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8675", "name": "when to offer directly observed therapy", "draggable": "true", "value": {"name": "when to offer directly observed therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:when to offer directly observed therapyhead:When to offer directly observed therapyOffer directly observed therapy as part of enhanced case management in people who: do not adhere to treatment (or have not in the past) have been treated previously for TB have a history of homelessness, drug or alcohol misuse are currently in prison, or have been in the past 5 years have a major psychiatric, memory or cognitive disorder are in denial of the TB diagnosis have multidrug-resistant TB request directly observed therapy after discussion with the clinical team are too ill to administer the treatment themselves.In children whose parents are members of any of the above groups, offer directly observed therapy as part of enhanced case management and include advice and support for parents to assist with treatment completion.Re-evaluate the need for directly observed therapy throughout the course of TB treatment whenever the person s (or in the case of children, parents ) circumstances change.See what NICE says on alcohol-use disorders and drug misuse management in over 16s.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.5Directly observed therapySourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6187", "name": "when to offer directly observed therapy", "draggable": "true", "value": {"name": "when to offer directly observed therapy", "type": "treatment related", "time": "", "intention": "", "description": "title:when to offer directly observed therapyhead:When to offer directly observed therapyOffer directly observed therapy as part of enhanced case management in people who: do not adhere to treatment (or have not in the past) have been treated previously for TB have a history of homelessness, drug or alcohol misuse are currently in prison, or have been in the past 5 years have a major psychiatric, memory or cognitive disorder are in denial of the TB diagnosis have multidrug-resistant TB request directly observed therapy after discussion with the clinical team are too ill to administer the treatment themselves.In children whose parents are members of any of the above groups, offer directly observed therapy as part of enhanced case management and include advice and support for parents to assist with treatment completion.Re-evaluate the need for directly observed therapy throughout the course of TB treatment whenever the person s (or in the case of children, parents ) circumstances change.See what NICE says on alcohol-use disorders and drug misuse management in over 16s.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.5Directly observed therapySourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8676", "name": "treatment interruption", "draggable": "true", "value": {"name": "treatment interruption", "type": "treatment related", "time": "", "intention": "ethambutol\nethambutol is used to treat tuberculosis (tb), and is usually given together with at least one other tuberculosis medicine.\nethambutol may also be used for purposes not listed in this medication guide.", "description": "title:treatment interruptionhead:Treatment interruptionIn people who have experienced a treatment interruption because of drug-induced hepatotoxicity: investigate other causes of acute liver reactions and wait until aspartate or alanine transaminase levels fall below twice the upper limit of normal, bilirubin levels return to the normal range and hepatotoxic symptoms have resolved, then sequentially reintroduce each of the anti-TB drugs at full dose over a period of no more than 10 days, starting with ethambutol and either isoniazid (with pyridoxine) or rifampicin.In people with severe or highly infectious TB who need to interrupt standard therapy because of a reaction, consider continuing treatment with: for hepatotoxicity, a combination of at least 2 anti-TB drugs of low hepatotoxicity (such as ethambutol and streptomycin, with or without a quinolone, such as levofloxacin or moxifloxacin) and monitor with a liver specialist for further reactions  for a cutaneous reaction, a combination of at least 2 anti-TB drugs with a low risk of cutaneous reactions (such as ethambutol and streptomycin) and monitor with a dermatologist for further reactions.If another reaction of a similar or greater severity occurs because of reintroducing a particular drug, do not give that drug in future regimens and consider extending the total regimen accordingly.See what NICE says on drug allergy.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6188", "name": "treatment interruption", "draggable": "true", "value": {"name": "treatment interruption", "type": "treatment related", "time": "", "intention": "ethambutol\nethambutol is used to treat tuberculosis (tb), and is usually given together with at least one other tuberculosis medicine.\nethambutol may also be used for purposes not listed in this medication guide.", "description": "title:treatment interruptionhead:Treatment interruptionIn people who have experienced a treatment interruption because of drug-induced hepatotoxicity: investigate other causes of acute liver reactions and wait until aspartate or alanine transaminase levels fall below twice the upper limit of normal, bilirubin levels return to the normal range and hepatotoxic symptoms have resolved, then sequentially reintroduce each of the anti-TB drugs at full dose over a period of no more than 10 days, starting with ethambutol and either isoniazid (with pyridoxine) or rifampicin.In people with severe or highly infectious TB who need to interrupt standard therapy because of a reaction, consider continuing treatment with: for hepatotoxicity, a combination of at least 2 anti-TB drugs of low hepatotoxicity (such as ethambutol and streptomycin, with or without a quinolone, such as levofloxacin or moxifloxacin) and monitor with a liver specialist for further reactions  for a cutaneous reaction, a combination of at least 2 anti-TB drugs with a low risk of cutaneous reactions (such as ethambutol and streptomycin) and monitor with a dermatologist for further reactions.If another reaction of a similar or greater severity occurs because of reintroducing a particular drug, do not give that drug in future regimens and consider extending the total regimen accordingly.See what NICE says on drug allergy.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8677", "name": "criteria for surgery", "draggable": "true", "value": {"name": "criteria for surgery", "type": "treatment related", "time": "", "intention": "", "description": "title:criteria for surgeryhead:Criteria for adjunctive surgery If surgery is indicated, the surgeon should fully explain what is involved to the person, either with or after consulting a TB specialist. Discuss the possible benefits and risks with the person and their family members or carers, as appropriate, so that they can make an informed decision.subhead:Central nervous system tuberculosisConsider referring people with TB of the CNS for surgery as a therapeutic intervention only if there is evidence of raised intracranial pressure.subhead:Spinal tuberculosisDo not routinely refer people with spinal TB for surgery to eradicate the disease.Consider referring people with spinal TB for surgery if there is spinal instability or evidence of spinal cord compression.See what NICE says on preoperative tests.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6189", "name": "criteria for surgery", "draggable": "true", "value": {"name": "criteria for surgery", "type": "treatment related", "time": "", "intention": "", "description": "title:criteria for surgeryhead:Criteria for adjunctive surgery If surgery is indicated, the surgeon should fully explain what is involved to the person, either with or after consulting a TB specialist. Discuss the possible benefits and risks with the person and their family members or carers, as appropriate, so that they can make an informed decision.subhead:Central nervous system tuberculosisConsider referring people with TB of the CNS for surgery as a therapeutic intervention only if there is evidence of raised intracranial pressure.subhead:Spinal tuberculosisDo not routinely refer people with spinal TB for surgery to eradicate the disease.Consider referring people with spinal TB for surgery if there is spinal instability or evidence of spinal cord compression.See what NICE says on preoperative tests.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t8678", "name": "follow up", "draggable": "true", "value": {"name": "follow up", "type": "treatment related", "time": "", "intention": "", "description": "title:follow-uphead:Follow-upFollow-up clinic visits should not be conducted routinely after treatment completion.Tell patients to watch for symptoms of relapse and how to contact the TB service rapidly through primary care or a TB clinic. Key workers should ensure that patients at increased risk of relapse are particularly well informed about symptoms.Patients who have had drug-resistant TB should be considered for follow-up for 12 months after completing treatment. Patients who have had multidrug-resistant TB should be considered for prolonged follow-up.Multidisciplinary TB teams should aim to find people with active TB who are lost to follow-up, or who stop using services before completing diagnostic investigations. They should report all those lost to follow-up to local Public Health England teams, GPs, the referring organisation and specialist outreach teams.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "treatment", "id": "t6190", "name": "follow up", "draggable": "true", "value": {"name": "follow up", "type": "treatment related", "time": "", "intention": "", "description": "title:follow-uphead:Follow-upFollow-up clinic visits should not be conducted routinely after treatment completion.Tell patients to watch for symptoms of relapse and how to contact the TB service rapidly through primary care or a TB clinic. Key workers should ensure that patients at increased risk of relapse are particularly well informed about symptoms.Patients who have had drug-resistant TB should be considered for follow-up for 12 months after completing treatment. Patients who have had multidrug-resistant TB should be considered for prolonged follow-up.Multidisciplinary TB teams should aim to find people with active TB who are lost to follow-up, or who stop using services before completing diagnostic investigations. They should report all those lost to follow-up to local Public Health England teams, GPs, the referring organisation and specialist outreach teams.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG33", "drug": {}}}, {"category": "drug", "id": "d25", "name": "alli", "draggable": "true", "value": {"name": "alli", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d181", "name": "commit", "draggable": "true", "value": {"name": "commit", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d375", "name": "isoniazid", "draggable": "true", "value": {"name": "isoniazid", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d271", "name": "ethambutol", "draggable": "true", "value": {"name": "ethambutol", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d213", "name": "dexamethasone", "draggable": "true", "value": {"name": "dexamethasone", "time": "None", "period": "None", "dosage": "None"}}, {"category": "drug", "id": "d396", "name": "levofloxacin", "draggable": "true", "value": {"name": "levofloxacin", "time": "None", "period": "None", "dosage": "None"}}]}